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Biological processes are often regulated by signal transduction pathway via 
transcription factor through protein-protein interactions (PPIs).  Aberrant activation of 
transcription factor deregulates the cell signaling pathway which contributes to disease 
progression. Cancer is well characterized as a result of over activation of transcription 
factor and/or loss of an essential protein-protein interaction. Therefore, transcription 
factor have become attractive molecular target for drug development.  
Protein-templated fragment ligations have been established as a powerful method 
for the assembly and detection of optimized protein ligands. Initially developed for 
reversible ligations, the method has been expanded to irreversible reactions enabling the 
formation of super-additive fragment combinations. In this thesis, protein-induced 
Mannich ligations are introduced and discovered as a biocatalytic reaction furnishing 
inhibitors of the transcription factor STAT5. STAT5 protein was employed to catalyze 
multicomponent reactions of a phosphate mimetic, formaldehyde, and 1H-tetrazoles 
yielding protein ligands with greatly increased binding affinity and ligand efficiency. 
Reactions are induced under physiological conditions selectively by native STAT5 but 
not by other proteins. Formation of ligation products and (auto-) inhibition of the reaction 
are quantified and the mechanism is investigated. 
 Inhibitors assembled by STAT5 were further validated using functional 
biochemical assay and were proven to block specifically the phosphorylation of this 
protein in a cellular model of acute myeloid leukemia (AML), DNA-binding of STAT5 
dimers, expression of downstream targets of the transcription factor, and the proliferation 
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of cancer cells in mice. In addition, STAT5 inhibitors also exert strong synergistic effect 
with tyrosine kinase inhibitor, PKC412 in targeting leukemic cells.  
Throughout our effort in establishing highly selective STAT5 inhibitor, a first 
class of inhibitors that assembled through protein induced Mannich ligation reported to 
date have been successfully identified. STAT5 assembled inhibitors have proven to 
exhibit favorable potency and selectivity profile against STAT5 and possess the potential 
to become candidate for combination therapy with tyrosine kinase inhibitor for pre-
clinical trials as STAT5 targeted therapeutic. Last but not least, these small molecules 
STAT5 inhibitors well served as a research tool to study the effect of knocking down of 


















Biologische Prozesse werden häufig über Signaltransduktionswege durch 
Transkriptionsfaktoren gesteuert und werden durch Protein-Protein-Interaktion (PPIs) 
vermittelt. Die abweichende Aktivierung eines Transkriptionsfaktors verändert den 
zellulären Signalweg, was zur Entwicklung oder zum Fortschreiten von Krankheiten 
beitragen kann. Krebs ist gut charakterisiert als das Ergebnis einer Überaktivierung von 
Transkriptionsfaktoren und/oder des Verlustes von essentiellen Protein-Protein-
Interaktionen. Daher sind Transkriptionsfaktoren ein attraktives molekulares Ziel für die 
Arzneimittelentwicklung  
Protein-templierte Fragment-Ligationen wurden als leistungsfähiges Verfahren 
zur Gewinnung und zur Erkennung von optimierten Protein-Liganden eingeführt. 
Ursprünglich entwickelt für reversible Ligationen wurde die Methode auf irreversible 
Reaktionen ausgeweitet und ermöglicht die Bildung von super-additiven 
Fragmentkombinationen. In dieser Arbeit werden protein-induzierte Mannich-Ligationen 
als eine biokatalytische Reaktion entdeckt, die Inhibitoren für den Transkriptionsfaktor 
STAT5 liefern. STAT5-Protein katalysiert Multikomponenten-Reaktionen eines 
Phosphat-Mimetikums, von Formaldehyd und von 1H-Tetrazolen, die Proteinliganden 
mit stark erhöhter Bindungsaffinität und Ligandeneffizienz liefern. Reaktionen werden 
unter physiologischen Bedingungen selektiv durch natives STAT5, aber nicht durch 
andere Proteine ausgelöst. Die Bildung von Ligationsprodukten und die (Auto-)Inhibition 
der Reaktion werden gemessen und der Mechanismus wird erforscht. 
Durch STAT5 gebildeten Inhibitoren werden weiter in funktionellen 
biochemischen Assays validiert und es wird gezeigt, dass sie spezifisch die 
Phosphorylierung dieses Proteins in einem zellulären Modell der akuten myeloischen 
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Leukämie (AML), die DNA-Bindung von STAT5-Dimern, die Expression von 
Zielproteinen des Transkriptionsfaktors und die Proliferation von Krebszellen in Mäusen 
blockieren. Zusätzlich haben STAT5-Inhibitoren zusammen mit dem Tyrosinkinase-
Inhibitor PKC412 eine starke synergistische Wirkung auf Leukämiezellen. 
Wir haben die erste bisher bekannte Klasse von Inhibitoren identifiziert, die durch 
eine Protein-induzierte Mannich-Ligation gebildet wurden. Die durch STAT5 
entstandenen Inhibitoren zeigen günstige Wirkungen und ein vorteilhaftes 
Selektivitätsprofil gegenüber STAT5 und besitzen das Potential, Kandidaten für eine 
Kombinationstherapie mit Tyrosinkinase-Inhibitoren für vorklinische Versuche als 
gezielte STAT5-Therapien zu werden. 
Zu guter Letzt dienten diese kleinen STAT5 Inhibitor-Moleküle als geeignete 
Forschungswerkzeuge, um die Effekte der Ausschaltung von STAT5-Funktionen auf die 
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Scientists have been on a long mission to halt cancer progression and hunt down the 
most effective remedies to cure cancer. Despite many new anti-cancer agents have been 
designed to improve the current treatment regime, there is still a gap to be filled in targeted 
drug therapy. It is cleared that the future of cancer treatments is directing towards specific 
treatment which target different cancer pathways, rather than a universally applicable therapy 
across cancer.  
Traditional universal chemotherapeutic drugs are well described as jack of all trades 
but master of none due to their lack of specificity. Research findings have proven that cancer 
cells can outsmart universally applicable therapy such as tyrosine kinase inhibitor (TKI) by 
developing genetic alterations, resulting in DNA and protein mutations in tumor cells. This 




1.1 Overview of traditional chemotherapeutic approaches and their limitations 
Anticancer agents can be classified according to their biological target either from 
antimetabolites, DNA targeting agent or tumor targeted monoclonal antibodies (mAbs), just 
to name a few. Antimetabolites have similar structure to essential metabolites but are limited 
to participate in the biochemical process or reaction. They are designed to replace essential 
metabolites and their structures are generally based on pyrimidine or purine DNA bases or 
folic acid.
4
 This class of chemotherapeutic drugs inhibits and deplete the important building 
block required for DNA synthesis. One of the most commonly used antimetabolites in 
clinical practice is 5-fluorouracil (5-FU).
5
 It is designed through bioisosteric replacement by 
substituting one of the key hydrogen in uracil to fluorine. This bioisosteric replacement 
makes 5-FU a powerful cancer drug. It is administered as a prodrug which is then converted 
to active metabolite 5-fluorodeoxyuridine monophosphate and is proven to irreversibly 
inhibits the enzyme thymidylate synthase that play vital roles in the DNA synthesis (Figure 




 Over the years, there has been significant development of new antimetabolites which 
improve and expand this class of chemotherapeutic agents ranging from gemcitabine, 
capecitabine, permetrexed, fludarabine and to the most recent FDA approved pralatrexate.
7
 
Although antimetabolites are widely used as chemotherapeutic agents in the clinic to 
target cellular metabolism, their anti-cancer effects are exhibited mainly through cytotoxic 
effect. Patients that undergo antimetabolites-based chemotherapeutic regime suffer from 
severe side effects.
6
 Previous studies have proven that the treatment outcome of 






Figure 1.0: Antimetabolites interfere with normal synthesis of nucleic acid and prevent the 
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Another class of chemotherapeutic agents involves targeting DNA and their mode of 
action heavily depends on the exact interactions with DNA. This class of anti-cancer agents 
are classified into intercalators, minor groove binding agents, alkylating agents and 
antimitotic agents.
9
 Doxorubicin and daunomycin are two intercalators that are commonly 
used in treating cancer for many years. They are able to form stable, non-covalent complexes 
with DNA which inhibit the availability of DNA for replication and transcription around the 
point of intercalation. These agents heavily rely on the increased replication of rapidly 
dividing cells for their anti-cancer action and are generally non selective.
10
 This has resulted 
in adverse side effects and general cytotoxicity in patient but these drugs are still being used 






Figure 1.1: Crystal structure of the anti-cancer drug 4-morpholino-doxorubicin complexed 
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On the other hand, minor groove binding agents bind to the sugar phosphate backbone 
of the DNA double helix. It started to gain interest recently when trabectedin, a marine 
natural product, which binds to the minor groove of DNA backbones was approved in Europe 
for anti-cancer chemotherapy.
12
 Similarly, this class of drugs leads to severe toxicity due to 
low drug selectivity and specificity. Unlike other minor groove binding agents, trabectedin 
exhibits antitumor activity in multidrug resistant tumors and was found to selectively bind the 
AT-rich region of DNA.
13
 
The long term effects of universal chemotherapeutic drugs which lack target 
specificity allow cancer cell to manipulate their genomes and metabolism to halt further drug 
influx and increase efflux of accumulated drugs. This escape mechanism is also known as 
“the neostrategy of cancer cells and tissues”. Chemotherapy resistance occured due to several 
host or tumor related factors whereby genes that handle efflux pumps will be up regulated to 
reduce drug accumulation inside malignant cells. Surprisingly, drug-target interaction could 
also evolve somatically to promote drug resistancy.  For example, long term 
chemotherapeutic treatment with thymidylate synthetase inhibitor, 5-fluorouracil lead to over 
expression of thymidylate synthetase genes postulating mode of resistancy.    
Another limitation of universal chemotherapeutic drugs is the possibility of activation 
or amplification of alternative pathway. As signalling pathways are complex network, 
blocking one pathway in cell will turn on the associated alternative pathway to maintain 
tumor cell proliferation and survival. Cancer cell will activate alternative pathway to establish 
chemoresistance when upstream targets are blocked in the cell signaling pathway by 
conventional universal drugs. Current treatments still rely on universal chemotherapeutic 
drugs but unfortunately, local recurrence and metastasis occurs in approximately 40% of 
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1.2 Establishing fragment-based approaches  
Over the past decade, drug discovery experts and research scientists are making effort 
in finding alternative starting point for the discovery of high quality lead candidates that is 
less time consuming. A key approach that has garnered the most interest among researchers is 
the fragment-based drug discovery (FBDD) which potentially acts as an alternative starting 
point for lead discovery in drug development.  
Fragment based drug discovery undertakes a rather different route compared to the 
conventional approaches such as high throughput screening (HTS). In FBDD, a small 
collection of very small compounds that comprised of > 20 non-hydrogen atoms or “heavy 
atoms” was employed which furnish lower number but better streamlined possible fragments 




Small fragments are much more favorable because they form fewer interactions with a 
protein target thus are foreseen to bind easily to more sites on a wide range of targets, which 
in turn translates to a greater number of “hits”. On the other hand, larger molecules are less 
favorable as they pose greater molecular complexity and greater interactions with protein 
target as this limits the number of hits found.
17
 To put it into perspective- it is preferable to 
start with a small, weak affinity hit as it provides better structural insight for lead 
optimization in comparison to a larger, more potent compound.
18
 (Figure 1.2)  
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The fragment based approach was initially introduced on a theoretical basis before 
FBDD was put into practice physically. The idea was first tested using computational and 
structural biology method to study the binding of small molecules or fragments to the active 
site of protein. This theoretical findings was strengthen when studies have shown that 
intrinsic binding energy of each functional groups can be determined as “ goodness of fit” of 
a drug to its molecular target.
15,19
  
Fragment based method was first practically applied in the field of drug discovery in 
1996 by two Abbott scientists, Fesik and Halduk. Both of them used a nuclear magnetic 
resonance (NMR)-based method to detect and identify fragments that could possibly bind to 
the proximal subsites of the targeted protein.
20
 In the following years, researchers have 
jumped on the bandwagon of X-ray crystallographic screening for clinical compound 
discovery. Both methods have been tailored to be widely applicable in drug discovery field 
by numerous pharmaceutical companies. 
18
 
Upon primary fragments detection, they proceed with further optimization and 
fragment linking by attaching additional functional groups to achieve high affinity ligands. 
- 8 - 
 
Medicinal chemist applied three main methods for fragment elaboration, i.e. fragment 





Figure 1.3: Fragment elaboration methods commonly applied for fragment based drug design. 
Upon identification of suitable binding fragment in the binding pocket of a targeted protein, 
fragment can be modified to increase the receptor-ligand interactions. (a) fragment growing is 
a process of expanding the initial fragment to increase lead likability in order to enhance 
binding affinity of ligand .(b) fragment linking is useful  in order to link multiple fragments 
that portray affinity towards different sub regions in the protein binding pocket.  By 
introducing linkers to connect potential fragment hits increase the lead likability and novel 
class of compound can be discovered. c, fragment merging started off with a known lead that 
partially occupy the binding pocket. The initial lead is used as a probe to screen for suitable 
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fragments to fit the remaining space in the protein binding pocket. Linkers can then be used 




FBDD has been driven by several screening technologies but its application in more 
complex biological targets remains a challenge
22
 (Figure 1.4). One of the biggest issue that 
limit the development and full exploitation of fragment-based methods in drug discovery is 
the detection of protein-binding fragments which require further advancement in biophysical 
techniques. So often, protein binding fragments are present in high concentration due to their 
low affinity in nature which in turn saturates the detection signal. The detectability and 
identification of fragment hits heavily depends on the sensitivity and robustness of the 
biophysical techniques used. Therefore, several other approaches have been adapted from 
FBDD besides NMR and X-ray-crystallography.
20
 For instance, there are assays that apply 
high protein concentrations to overcome the bottle neck of ligand saturation such as 
fluorescence anisotropy or saturation transfer difference (STD) NMR.  
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Figure 1.4: A glimpse on the typical FBDD screening workflow. The workflow composes of 
important route in both primary and secondary screening in the drug discovery journey. The 
hierarchy is provide an overview but does not represent all drug discovery programs. 
Screening options at the primary and secondary screening stages were shown in bullet points. 
Fragments proceeded to secondary screening will eventually acquired structural information 
using NMR or X-ray crystallography to be progressed for hit generation. In secondary 
screening, fragment hits will be ranked using ITC technique (*).
23
 
Over the last decade, several approaches such as mass spectrometry (LC-MS)
24-27
, 
nuclear magnetic resonance (NMR)
28-30
, saturation transfer difference-NMR (STD-NMR), 
microscale thermophoresis (MST), X-ray crystallography
31-33
, isothermal titration 
calorimetry
34
, differential scanning fluorimetry (DSF)
35
 a.k.a thermal shift assay (TSA), 
fluorescence polarization (FP)
36,37
 and surface plasmon resonance (SPR)
38
 have been seen as 
core technologies in numerous pharmaceutical and biotechnology-based industries settings 
for the identification of low affinity fragment compounds.
39
 (Figure 1.5)  
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Figure 1.5: Biophysical techniques fitted to a range of fragment affinities.  Each technique 
was ranked based on how often they were applied in FBDD. NMR is mostly applicable in 
medium-throughput method, but can also be considered in low throughput based method 
depending on the protein availability. Another biochemical technique that has broad 
application in FBDD is highly dependent on probe affinity and most suitable to be used for 
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1.3 Protein Templated Fragment Ligation  
Protein Templated Fragment Ligation (PTFL) is defined as chemical reactions that 
involved two or more small molecules / fragments that employ the protein’s surface as 
catalyst to generate protein ligands with higher binding affinity. The chemical reactions in the 
definition include both reversible and irreversible ligation reactions. (Figure 1.6)  In 
reversible PTFL, chemically reactive small fragments adapt on the molecular level and 
optimize to form thermodynamically favoured ligand through recleavage of covalent 
chemical bonds. This adaptive and self-optimizing system is considered as an example of 
molecular learning.. It is often observed that reversible ligation reaction yield unstable 
products before isolation but could achieve better stability after isolation while products of 
irreversible ligation reaction are mostly stable. PTFL has been widely applied in FBDD by 
combining both chemical synthesis of protein ligands and protein activity modulation in one 
single step
24,40-42
 to achieve both time and cost efficiency.  
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Figure 1.6: Protein template fragment ligation methods for ligand discovery. Binding of 
small fragments to protein binding site reversibly escalate the formation of reversible or 
irreversible chemical bonding. On a side note, bound fragment can interact with the protein 
template itself by forming reversible/ irreversible chemical reaction. 
43
 
Fragment based ligation method has an added advantage in ligand detection due to 
their higher affinity of the fragments ligation product formed. In principle, starting fragments 
concentration is presence at a lower concentration to achieve partial inhibition which can then 
be saturated through the latter formation of stronger binding ligation product. This has 
overcome the shortcomings of concentration limits in other fragment assays as even low 
affinity fragments can be identified. Undoubtedly, challenges still remain due to several 
reasons. Fragment ligation method yields higher binding affinity ligation products than the 
starting fragments and their formation are auto inhibitory. Thus, the concentration of protein 
template added has become the limiting factor in ligation product formation. Eventually, the 




Another challenge that has been widely discussed arises from the reactivity of the 
starting fragments in the fragment ligation assays. In some occasion, the less reactive 
fragments acquired activation by electrophiles in fragment ligation assay. Unavoidably, 
fragments might react with protein nucleophiles as reaction partner which intentionally serve 
as a template for the assays. Consequently, control tests need to be carried out to distinguish 
the effect of one fragment from the effect of a fragment combination to avoid false positive 
results. In addition, it is also advisable to carry out independent secondary assays to eliminate 
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1.4 Detection of fragment binding and fragment ligation product  
 In recent years, medicinal chemist has been exploring the possibility of directly 
examined the bioactivity of fragment combination prior to product isolation and purification. 
So far, several bioassays have been developed to adapt bioactivity-guided fragment ligations 
that include both substrate competition and substrate enhancement assays. Substrate 
competition assay require the presence of a fluorogenic or chromogenic substrate such as 
FRET (Fluorescence Resonance Energy Transfer) substrate to be replaced by the fragment 
combination product. On the other hand, in substrate enhancement assay the substrate affinity 
is increased via reversible ligation leading to higher turnover rate of the substrate. Our group 
has reported the application of substrate competition assay in SARS coronavirus main 
protease for the discovery of potent non-peptidic inhibitors via dynamic ligation screening 
(DLS). (Figure 1.7) A fluorogenic tetrapeptidyl-7-amino-4-methyl courmarinyl 2-acetamide 
(AMCA) was used as a fluorogenic substrate to detect bioactive fragment combination. 
 
Figure 1.7: Schematic representation of dynamic ligation screening. Aldehyde and amine 
fragments react in an equilibrium reaction to form imine ligation product. The binding of 
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fragments into neighbouring pockets of the target protein (template) shifted the equilibrium 
towards imine ligation product formation, which known as template-assisted fragment 
ligation. Both fragments and fragment ligation product will then compete with the 
fluorescence substrate for protein binding for the enzyme. The formation of a fragment 
ligation product is detected by a significant reduction in substrate turnover, resulting in 
superadditive inhibition compared to the binding of single fragments alone.  
 Furthermore, fragment ligation product can also be detected via protein binding assay 
using fluorescence polarization. By attaching carboxy-fluorescein which serves as a 
fluorophore to the protein binding fragment, A distinctly determines the binding of secondary 
fragment B to be either additive or cooperative binding. The best cooperative binding of B 
elevates the binding affinity of A resulting in higher fluorescence polarization (FPAB < FPA). 
Both fragments A and B will then link covalently to generate potent inhibitor.  
 Another approach that was applied in ligand detection for protein template fragment 
ligation is through protein-saturation transfer difference NMR spectroscopy (
1
H-STD-NMR). 
This approach enables the detection of less stable ligation product in aqueous solution such as 
hemiacetals and hemithioacetals. 
1
H-STD-NMR works by exploiting the selective transfer of 
proton magnetization from protein to reversibly bound ligand and allow site-specific 
identification of protein binding fragments as well as the functional characterization of 
enzymatic sites.  
 Nonetheless, medicinal chemist has also adapted label free method to detect bioactive 
fragment ligation product in homogenous protein binding assays.  For instance, thermal shift 
assay were used to detect protein-ligand complexes. This method examined the protein 
defolding at increasing temperature by adding external fluorophores (dyes) such as Sypro 
Orange that shows increased fluorescence when they bound to the hydrophobic region of 
denatured, unfolded protein. Fragment binding increased protein stability through 
- 16 - 
 
enhancement of the protein’s melting temperature due to the free binding energy of ligand.  
However, the method provides initial clue on protein-ligand binding and detailed 
thermodynamic information is acquired by carrying out isothermal titration calorimetry. 
The discovery of various bioactivity based method compared to classical detection 
approach has accelerated the identification of bioactive fragment ligations products in 
protein-binding, enzymatic, and cellular assays.  
 
  
1.5 Drugs derived from Fragment-based methods (FBDD) 
In the past, fragment based drug discovery (FBDD) was often seen as an alternative 
approach to high throughput screening (HTS). However, in recent years both methods are 
complementing each other and adopting both strategies would bring distinct advantage. When 
FBBD and HTS are applied in parallel, FBDD facilitates the characterization of target 
druggability while HTS allows for the identification of structural moieties. As most 
pharmaceutical companies have adopted both methods in the discovery of potent inhibitors, 
their success stories of advancing weak fragment hits to potent lead candidates for a selection 
of proteins are shared in Table 1. 
44,45
 
Table 1: Successful examples of FBDD-derived drug.   






































1.6 Transcription factors 
Transcription factors are proteins that bind to the DNA-regulatory regions to initiate 
and modulate the rate of gene transcription.  Thus, the regulation of transcription factor 
availability and activity is the core parameters for gene expression. The availability of 
transcription factors is highly regulated by their level of production, degradation and 
subcellular localization.
46
 On the other hand, the activity of transcription factor is modulated 




The most common and rapid alterations in transcription factor activity involves 
protein phosphorylation and dephosphorylation, but it is proven that lysine acetylation also 
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posed tremendous impact on transcription factor activity. So often, acetylation of 
transcription factors modulates activity involving protein stabilization, cellular localization, 
and DNA-protein or protein- protein interaction. In addition, extracellular signaling 
molecules also play significant roles in triggering changes in gene expression that lead to 




1.7 Transcriptional control 
Transcriptional control was established in bacterial systems
49
 half a century ago. 
Subsequent studies from the pioneering work revealed that DNA-binding transcription factors 
in eukaryotic system recognize and occupy distinct DNA sequences at control elements
50
 
(CIS regulatory elements) and recruit transcription apparatus for gene expression.
51,52
 
Transcriptional activation of protein is described as a combinatorial interplay between site -
specific transcriptions factors and cofactors involved. (Figure 1.6) In addition, gene 
transcription is also core regulated by both tissue-specific gene expression and specific 
stimuli (both intra and extracellular).
46
 Gene regulation often occurs at the transcription level 
while deciding which genes will be transcribed to primary RNA transcript even though some 
cases of regulations after transcription do exist. Once the gene transcription has occurred, the 
following stages of gene expression such as RNA splicing will take place resulting in the 




1.8 Signal transducer and activator (STAT) family 
There are seven members in the STAT family including STAT1, STAT2, STAT3, 
STAT4, STAT5A, STAT5B and STAT6 (Figure 1.7).
53
 Of all the seven mammalian STAT 
proteins, STAT5a and STAT5b isoforms are particularly similar with approximately 91% 
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identical in amino acid albeit encoded by separate genes.
53-57
 The variability between 
STAT5a and STAT5b is primarily in the 12 C-terminal amino acids which contribute to 
subtle difference in molecular weight of 94 and 92kDa respectively. All STATs protein share 
conserved domains that play vital roles in phosphotyrosines binding, protein-protein 
interactions (PPI), DNA binding ability, and transactivation once bound to the promoter 
region of target genes.
58,59
 Interestingly, seven different STATs are known to share several 
conserved functional domains, but the transactivation domain at the C-terminus is the most 
diverse part.  
STAT1 and STAT2 are critical for interferon response and mice lacking STAT1 have 
impaired innate immunity with remarkably sensitivity to viral infections and other 
pathological agents. The role of STAT2 in interferon signaling was also confirmed through 
generation of knockout mice.
53,54
 Similar to STAT1 deficient mice, STAT2 null mice are 
prone to viral infections and less responsive to interferon signaling. In addition, double 
knockout of STAT1 and STAT2 has profound defects on interferon response consistent with 
the concept that STAT2 facilitates tyrosine phosphorylation of STAT1 in order to activate 
interferon α/β complex.60  
STAT4 is predominantly activated in response to IL-12 and play crucial role in IL-12 
signaling. In addition, STAT4 knockout mice reveal its deficiency causes defects in T helper 
cell differentiation along the Th1 pathway while STAT6 deficient mice are defective for IL-4 
induced T-cell proliferation and differentiation.
54,61
  
STAT3 is found to be constitutively active in several types of solid tumors, leukemia, 
and lymphoma. In myeloma and prostate malignant cells, IL-6 autocrine or paracrine loops 
was recognized as the main culprit for STAT3 over activation. Nevertheless, STAT3 was also 
reported to have multiple complex roles in hematopoiesis and immune tolerance. STAT3 
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knockdown mice have been shown to develop colitis and higher response towards T-cell, 




STAT5 is essential for competitive repopulation and proliferative responses towards 
cytokines in normal hematopoietic stem cells. Constitutive activation of STAT5 has also been 
closely associated with hematologic malignancies and cancer progression in chronic 
myelogenous leukemia (CML). Knocking down both STAT5a and STAT5b isoforms lead to 
infertility in female mice. In addition, STAT5 plays significant role in IL-2 signaling via 
gammaC and T cell proliferation for natural killer (NK) cells productions.
62,63
  
However, not all members in STAT proteins are involved in promoting cancer 
progression. In fact, activation of STAT1 has been associated with pro-apoptotic and anti-
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Figure 1.8: STAT protein domain structure. STAT protein domains comprise a short N-
terminal structure which involved in STAT dimerization and tetramerization. The adjacent 
coiled-coil domain interacts with other transcription factors while the DNA binding domain 
makes direct interactions with the promoter regions in gene transcription. Nevertheless, the 
DNA binding domain also defines the DNA-binding specificity and mediates distinct signals 
for specific interacting ligands. 
55
 
  On the other hand, the SH2 domain mediates binding to the phosphotyrosines on 
neighboring STAT molecules. The transactivation domain activates the expression of the 
target genes by interacting with DNA remodeling enzymes such as histone acetyltransferases. 
A carboxyterminal phosphoserines regulate the transcriptional process by enhancing the 
transcriptional activity in some STATs. STAT5a and STAT5b are closely related proteins but 




1.9 STAT5 protein structure and specificity  
Crystal structure of STAT5a (pdb: 1Y1U) was first revealed by Becker and colleagues 
in 2005. Like all members in STAT family, STAT5 has a modular structure of seven 
conserved protein domains comprised of a N-terminal domain, coiled-coil domain, DNA-
binding domain, Src-homology-2-domain (SH2), linker domain, phosphotyrosines tail 
segment and last but not least the transactivation domain. Structural and functional 
information of STATs is deduced mainly from crystallographic data as well as mutagenic and 
biochemical studies (Figure 1.9).
64
  
The structure of both STAT5 proteins is similar to the other members of the STAT 
family. The N-terminal domain stands as an independently folded structure and is required 
for protein interactions
65
, nuclear export and also mediates STAT5 tetramerization. 
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Apparently, N-terminal interactions between STAT5 dimers are found to facilitate STAT5 
tetramerization and thus promote cooperativity upon binding to tandem response element in 
STAT5 dependent gene regulation.
66-69
 
The SH2 domain, also known as phosphotyrosines binding domain is the most 
conserved domain that mediates specific interactions between STAT5 receptor, STAT5-JAK 
and STAT5-STAT5. The SH2 domain recruits STAT5 to the phosphorylated receptor for 
subsequent formation of transcriptionally active STAT dimers. Tyrosine residue (Y694 of 
STAT5A and Y699 of STAT5B) which located between SH2 and transactivation domains 
will undergo phosphorylation in order for STAT5 dimerization to occur. (Figure 1.8) 
Reciprocal interactions between the SH2 domains of one STAT5 monomer and the 





Figure 1.9: STAT5 dimers enter the nucleus and bind to a distinct DNA sequence (CIS 
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Drug selectivity between the two variants STAT5a and STAT5b has always gain 
interest and attention in the field of drug discovery as the selectivity problem is hard to tackle 
for the two STAT5 variants as compared with other members in STAT family. Interestingly, 
STAT5 isomers show non-redundant functions despite their high degree of sequence and 





Figure 1.10: STAT5 isomers functional domains and key tyrosine residue. The conserved 
tyrosine residue (Y694 of STAT5A and Y699 of STAT5B) is located between the SH2 and 
transactivation domains. Phosphorylation of the conserved residue in STAT5 is essential for 
STAT5 dimerization. NH2 indicates amino terminal, COOH, carboxyl terminal; CD, 
cooperative domain, DNA-BD, DNA-binding domain; TAD, transactivation domain.
64
   
The c-terminal transactivation domain is the most divergent domain between the 
members of the STAT family and is required for induction of gene expression by medicating 
interactions of STATs with other components of the transcription machinery. In addition, c-
terminally truncated STAT5 isoforms are dominant-negative transcriptional regulators and 
have been found in the bone marrow of AML patients. Previous research has demonstrated 
that genetically engineered c-terminal STAT3 mutants can cause neoplastic transformation 
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thus provide evidence that c-terminal transactivation domain of STAT protein play causative 





Figure 1.11: Crystal structure of STAT5a. (a) 3D conformational structure of STAT5a dimer 
color coded according to the domain shown in ribbon: the N-terminal (Nterm) four helix 
bundles (red), the β-barrel domain (yellow) and the SH2 domain (green). Secondary elements 
are attributed according to the program PyMOL. Cterm, c-terminal. (b) Overlapping of the 
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crystal structure STAT5a-SH2 domain with homology modeled of STAT5b-SH2 domain 
using Sybyl8.1 with RMSD= 0.598 show structural similarity of both STAT5 isomers.
64
 
1.10 Activation and function of STAT5 
1.10.1 The JAK-STAT signalling pathway  
Signal transducers and activators of transcription (STAT proteins) play essential roles 
in cellular functions and are critical for developments as they modulate gene expression in 
response to various growth factors, cytokines and interferons. STAT5 activation is largely 
carried out by tyrosine phosphatase. Signalling is initiated upon ligand binding at the 
cytokines and growth factor receptor, exuding a signal from the cell membrane to the 
nucleus.
54
 Throughout evolutions, the Janus kinase/ signal transducer and activator of 
transcription (JAK/STAT) signaling pathway is highly conserved and the activation of JAKs 
lead to activation and tyrosine phosphorylation of STATs. 
72
 
Sequentially, signaling molecules bind and activate JAK kinase and phophorylates 
key tyrosine residues on their receptors which allow the binding of STAT5 protein to the 
phosphotyrosines docking site via their SH2 domain. The STAT5 protein in turn are 
phosphorylated and dimerized before entering the nucleus to initiate gene transcription. The 
two variants of STAT5 isomers (STAT5A/B) are activated by more than 20 different 
cytokines, hormones and growth factors. Cytokines that often associated are interleukin (IL)-
2, 3, 4, 5,7,9,15,21, erythropoietin (EPO), thrombopoietin (TPO), prolactin (PRL), and 
granulocyte macrophage colony-stimulating factors (GM-CSF) and growth hormones 
(GH).
55,63
 The cellular model used in this work, murine pro-B cell line BaF3depends on 
interleukin-3 (IL-3) to activate STAT5 signalling for cell proliferation and survival. (Figure 
1.12) 
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Figure 1.12: Non-redundant JAK/STAT signaling. Schematic showing the preferential 
cytokine/growth factor usage of different JAKS for STAT5 phosphorylation based on gene-
targeting studies in mice.
73
 
A handful of small molecules inhibitors that aim to target JAK2 activity have been 
identified. Cardama and coworkers discovered a JAK1/2 inhibitor named ruxolitinib that 
proven to increase apoptosis in patient with JAK2-V617F mutation.
74
 Ruxolitinib shows 
promising results in preclinical evaluation and has progressed forward for clinical used.
75
 
Another JAK inhibitor, CYT387 (momelotinib) which is an ATP mimetic has also proven to 
inhibit JAK2 activity in BaF3/ JAK2-V615F cell lines with IC50 in submicromolar range 
(IC50=1.5 µM).
55,76
  In addition, TG101348
77
 was found to inhibit JAK2 in low nanomolar 
range (IC50=3 nM) with surprising high selectivity (334 fold) over JAK3. (Figure 1.13) 
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Figure 1.13: Chemical structures of JAK2 inhibitors that potently inhibit JAK2 and its 




1.10.2 The FLT3-STAT5 signalling pathway 
Constitutive activation of STAT5 in the signal transduction pathways resulting from 
mutations confer proliferative and survival advantage of leukemic cells. Mutations activates 
receptor tyrosine kinases and have been widely studied are FMS-like tyrosine kinase 3 (FLT-
3) followed by JAK2, RAS, C-KIT and SHP-2.
54,78
 Previous studies have proven that these 
mutations contribute to poor prognosis and high relapse rate in leukemia patients. 
Furthermore, statistics have shown that intensive chemotherapy can only achieved a cure rate 
of 30-40%.
79,80
 On the same page, acute myeloid leukemia (AML) patients carrying FLT3 
internal tandem duplication (FLT3-ITD) somatic mutation have experienced high relapse rate 
and lower survival rate. FLT3 –ITD mutation is a form of in-frame duplication that disrupt 
the negative regulatory function of juxtamembrane domain causing aberrant activation of 
tyrosine kinase activity and other closely related pathways such as the JAK2-STAT5, 
mitogen-activated protein kinase/ extracellular signal-regulated kinase (MAPK/ERK), 
PI3K/AKT/mTOR and RAS/Raf/MEK/ERK.. These have resulted in up regulation of their 
downstream effectors like Bcl-xl, c-Myc, pim-1, JAB and p21 that are essential for anti-
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apoptic and cell survival. Similar to other tyrosine kinase mutation, FLT3- ITDs 
constitutively activates FLT3, independence from its ligand and capable of stabilizing the 3D 
conformation of the activation loop for ATP binding.
79
 Gene translocation, FLT3-ITD leads 
to deregulation of signal transduction pathway causing excessive proliferation. (Figure 1.14) 
 
Figure 1.14: Overview of the difference observed between FLT3-ITD and FLT3-WT in 
AML patient. Wild type FLT3 is responsive towards modulators (FLT3 and IL27) whereas 




Up to date, there are more than 20 small molecule inhibitors against FLT3 reported 
but only few that have advanced through the clinical trial phases (Figure 1.15). Lestaurtinib, a 
first generation FLT3 inhibitor exhibits nanomolar inhibition towards both FLT3 and JAK2 
while also potently inhibit FLT3-ITD expressing AML samples.
81
 Another promising 
molecule worth mentioning is Sorafenib, a multiple kinase inhibitor exhibits 15 folds more 
potency in AML patient bearing FLT3-ITD mutation compared to wild type FLT3.
82
 Most of 
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the small molecules inhibitors were initially identified through high throughput screening of 
existing compound libraries. Disappointingly, not all hits fulfilled the pharmacokinetic and 
pharmacodynamic requirements and were halted in the early phase of clinical trials.  In 
general, most of the inhibitors suffer from short in vivo half life and mediocre target 
specificity in vivo. Therefore, researchers approach alternative ways by targeting the 
downstream target of FLT3, i.e STAT5 in order to provide one-two punch effect in 
combination therapy to fight leukemia.
83,84
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1.10.3 The BCR-ABL signal transduction pathway 
BCR-ABL is a unique fusion gene and is found in chronic myeloid leukemia (CML) 
patient. CML is a characterized by the Philadelphia (Ph) chromosome, which results from the 
reciprocal translocation of chromosome 9 and 22. This translocation leads to the fusion of 
ABL gene from chromosome 9 and the Breakpoint Cluster Region (BCR) gene from 
chromosome 22 thus generating the oncogenic BCR-ABL fusion gene. The expression of 
chimeric BCR-ABL oncoprotein constitutively activates kinase activity and enhances 
leukemic cell survival and proliferation.
87-89
 (Figure 1.16) 
 
Figure 1.16: Schematic illustration of Philadelphia (Ph) chromosome formation leading to 




Before gene translocation, ABL protein physiological shuttles between nucleus and 
cytoplasm. Intriguingly, it was found mainly in the cytoplasm after fused to BCR in order to 
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ease interaction with protein involved in oncogenic pathway. BCR-ABL crosstalk with 




Pharmaceutical company sees BCR-ABL as an attractive target for therapeutic 
invention. Novartis have carried out high throughput screening (HTS) and identified Gleevec 
(imatinib mesylate) as a potent kinase inhibitor.  Imatinib has successfully in treating patient 
inducing complete remission and being classified as gold standard for CML treatment. 
However, even with high success rate of curing CML, surprisingly there are subsets of CML 
cells that are non-sensitive and resistance towards imatinib which urge scientist to search for 
an alternative therapeutic target.
90
  A second generation derivative of imatinib, named 
nilotinib
91,92
 was designed and synthesized to tackle secondary resistance but was again faced 
with the same bottle neck issues. CML patients detected with BCR-ABL
T315I
 mutation hardly 
response to both imatinib and nilotinib.  A third generation tyrosine kinase inhibitor, 
Dasatinib
93
 was designed to target resistance in BCR-ABL
T315I
 but the dispersion of 
mutations across kinase domain limits the effectiveness of TKIs.
94
 (Figure 1.17) 
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Figure 1.17: Three different generations of small molecule inhibitors for Bcr-Abl protein and 
key interacting residues involves in binding. 
90,91,94
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Studies have also proven STAT5 inhibition decrease the survival and proliferation of 
CML cell bearing BCR-ABL mutations. This clearly indicates that STAT5 acts as an 
important downstream mediator of BCR-ABL in the oncogenic pathway. In addition, 
Hantschel et al. observed that STAT5 inhibition is much more efficient in treating CML cells 
with BCR-ABL than targeting other downstream target of BCR-ABL. On the same page, 





 generations tyrosine kinase inhibitors.
89,93,94
  
Undoubtedly, STAT5 is among the few genes that initiates and drives leukemia, 
therefore making it a potential therapeutic target in blood cancer.
57,87,95
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Figure 1.18: STAT5-the central hub in signalling node of aggressive leukemia. Canonical 
activation of STAT5 is initiated by cytokine binding to specific kinase receptor. Upon 
cytokines binding, receptors are activated through conformational changes followed by pY 
phosphorylation. Activated kinase receptor mediates phosphorylation of their downstream 
targets at the cytoplasmic end at specific sites. STAT5 bounds to the activated receptors 
JAK2 and FLT3-ITD as preformed parallel or anti-parallel dimers and is activated through 
SH2 domain phosphorylation. The activated STAT5 proteins form homo or hetero dimers via 
their SH2 domain and translocate to the nucleus to bind to the DNA and resulted in elevated 
target gene expression for leukemic cell survival and proliferation. On the contrary, BCR-
ABL is a constitutive active cytoplasmic tyrosine fusion kinase with a translocation between 





1.11 Negative regulation of STAT5 signalling 
STAT5 activity is tightly regulated to maintain appropriate signal intensity and 
duration in cell. In a healthy cell, STAT5 phosphorylation is regulated by constitutively 
expressed regulator such as phophateses and suppressors of cytokine signalling (SOCs) 
protein family.
97
 Furthermore, STAT5 signal will experience gradual decay via ubiquitin-
proteasome pathway and receptor down-regulation. 
98
 
There are three important negative regulators in JAK/STAT pathway and all of them 
come from different protein families. Src homology phosphatases SHP-1 and SHP-2 negative 
regulate STAT5 either by direct STAT5 dephosphorylation or acted on its upstream JAK 
receptor. The other common negative regulator composed of phosphotyrosines phosphatase 
IB (PTP1B) family. T cell protein tyrosine phosphatase (TC-PTP) regulates cellular STATs 
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activity through direct dephosphorylation of STATs or JAK kinase. The transmembrane 




Besides that, protein inhibitor of activated STAT3 (PIAS3) also plays vital role in 
repressing STAT5 activity.  PIAS is found to interacts with STAT5 and interfere with 
STAT5-DNA binding. Nonetheless, cytokine-induced SH2-domain-containing protein (CIS) 
and SOCS1, SOCS2 and SOCS3 are well discussed STAT5 regulator among the SOCS 
family. They are known to be downstream target of STAT5 and attenuate STAT5 signaling 
via negative feedback inhibition.  Studies also proven that they compete with STAT5 for 




1.12 Role of STAT5 in cancer and resistance in cancer  
Anti-leukemic treatment often encounters a huge bottle neck of chemoresistance that 
prone to develop over the course of chemotherapeutic treatments which provides a useful 




Overactivation of STAT5 are commonly linked to development of various type of 
hematologic malignancies as well as solid tumor cancers such as breast cancer, prostate 
cancer, head and neck cancer, hepatocellular carcinoma and  melanoma. Aberrant STAT5 
activation is often associated with constitutively active oncogenic tyrosine kinases and non-
receptor tyrosine kinases such as BCR-ABL
87
 (breakpoint cluster region protein and Abelson 





FLT3-ITD mutation is found in 30-50% AML patient, leading to persistent activation 
of STAT5 for cell survival and proliferation.  Overactivation of STAT5 is extremely crucial 
- 36 - 
 
for leukemic stem cell (LSC) self renewal, making AML patient prone to develop resistancy 
towards tyrosine kinase inhibitor. Surprisingly, the mechanism of STAT5 activation by 
mutant FLT3 are seen and labeled as non-canonical signaling which absence in normal cells. 
This criterion portrayed added advantage in the therapeutic index sparing normal 
hematopoietic cells and leukemic cells by using drug targeting STAT5.
79
 
 A driver mutation, STAT5N642H found in leukemia/ lymphoma patients has been 
extensively studied by Moriggl and colleagues. Previous studies have shown that 
STAT5N642H drives cancer progression by stabilizing activated STAT5-dimer and prolonged 
their activation state.
103
 (Figure 1.19) This STAT5b mutation is found in 2% of large 
lymphocytic leukemia (LGL) while no STAT5a mutation is detected. A few rare mutations in 
STAT5b were also reported namely E438K, G492C, P702A, I704L, and Q706L but their 
effect towards STAT5 are yet to be explored.
104
 Transgenic mice expressing human 
STAT5N642H show enhance STAT5 tyrosine phosphorylation even in the presence of low 
dose cytokines. This has further proven that STAT5N642H majorly contributes to the 
leukemicT-cell proliferation and survival in T-cell ALL (acute lymphoblastic leukemia) and 
T-cell lymphoma.
105,106
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Figure 1.19: STAT5N642H acts as a driver mutation enhance proliferation of T-cell leukemia 
and lymphoma via JAK-STAT signalling. 1-2, prolonged activation of STAT5N642H leads to 
sustain DNA binding which increased transcription of STAT5 target genes. 3, STAT5N642H 
amplified cytokine receptor signalling through up regulation of interleukin 2 receptor alpha 
(IL-2Rα). Vicious cycle (1-3) leads to cancer cell survival and progression. Development of 





1.13 Drugging the STAT5 pathway  
STAT5 protein, carrying major roles in driving leukemia has been validated as 
potential therapeutic target. In the past, chemotherapeutic treatment using multiple tyrosine 
kinase inhibitors has brought severe side effects in patients due to their off target cytotoxicity, 
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By taking a closer look in to transcription factor STAT5, this protein does not possess 
enzymatic activities thus making it a challenging target for the development of small 
molecules inhibitors that are specific and effective with high cell permeability. The most 
promising approach in targeting STAT5 protein is through functional inhibition of the 
protein-protein interaction (STAT5 dimerization) and Src homology 2 (SH2 domain).  
Phosphopeptide mimetics was initially shown to bind STAT5-SH2 domain, disrupting 
STAT5 dimerization but was failed to provide significant cellular activity.
62,71,108
  
The most discussed challenge in targeting STAT5 lay in finding the workable 
therapeutic window for leukemia cells while having minimal side effects in normal cells. 
STAT5 inhibition using tyrosine kinase inhibitor (TKI) often leads to long term off target 
toxicity and TKI resistance.  Even though TKIs obtained the most clinical success, many 
patients are dealing side effects from off-target binding due to the multi-targeted natured of 
TKIs as well as secondary resistance which often increase the chance of relapse. Targeting 
STAT5 using TKIs lead to targets amplification or mutation of target as an escape mode to 
prevent action of the inhibitor. In addition, drug-efflux proteins are up regulated to reduce the 
intra-cellular concentration of inhibitors or amplification of complementary pathway such as 
STAT3 to compensate the lost of functional STAT5 protein.  
Due to the critical role of STAT5 in mediating various mutated tyrosine kinase (TK) 
pathways, it is worth to discover selective and specific STAT5 inhibitors as an alternative to 
target cancer development. Hence, target inhibition of STAT5 pose great potential to 
eradicate cancer cells without causing resistance. Up to date, a handful of direct STAT5 
inhibitors have been developed, mostly only show activity in binding assays and cellular 
assays such as chromone based compounds, fosfosal, salicylic acid-based, an adenosine-5-
monophosphoate derivative, osmium complex and catechol bisphosphates derivatives.
58,109
 
Most of the STAT5 inhibitors were discovered through high throughput screening (HTS) of 
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chemical libraries and fragment based drug discovery. In addition, many of the reported 
STAT5 inhibitor still posed indirect effect on JAK/STAT or BCR-ABL signaling pathway 
due to unverified target specificity. Stafib-2, a biphosphate-containing small molecule was 
reported to inhibit STAT5 at nanomolar range and selective towards STAT5b over 
STAT5a.
71
 Another STAT5 specific inhibitor, AC-3-19, a salicylic-based STAT5 SH2 
domain inhibitor was also developed to selectively targeted STAT5.
56
 More recently, an 
improved salicylic-based STAT5 SH2 domain inhibitor, AC-4-130 was reported to bind 
STAT5b in 1D 
19
F NMR and also show potent inhibitory effect in cellular assay as well as in 
vivo animal studies, , but none of the inhibitors above were potent and selective enough to be 
translated into clinical use.
110
 
Undeniably, there is progress in development of STAT5 inhibitor but finding inhibitor 
that could target STAT5 specifically remains challenging. This is mainly due to the nature of 
transcription factor which exert most of their functions through protein-protein interactions 
and DNA-protein interactions. The key interacting pockets are often lack of well-defined 
hydrophobic pockets which typically serve as a starting point for the identification of small 
molecule inhibitors.
62,71
 Nonetheless, SH2 domain shows high degree of structural homology 
across STAT family making it harder to develop inhibitor that target STAT5 SH2 domain 
specifically.  
 
1.14 The application of FBDD and protein templated ligand formation of STAT5 
Transcription factors play vital role in regulating target gene transcription to achieve 
precise and balance regulation of cellular phenotype. STAT5 (STAT=signal transducers and 
activator of transcription factor) was chosen as target protein due to their critical role in 
mediating the effect of upstream kinases in signalling pathway, making them an attractive 
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protein for the development of targeted anti-cancer therapeutic agents. Aberrant activation of 
STAT5 is observed in various types of cancers but is majorly found to be activated in 
myeloid malignancies, lead to the development of leukaemia.
54,56
 As we gained better 
understanding of STAT5 signalling in cancer cells, direct inhibition of STAT5 might 
contribute to personalized medicine approach in the hope of lessening the side effect in 
treating cancer patients.   
At the present time, there is still room for further exploration in the chemical space by 
protein-templated reactions. Most of the PTFL reactions reported are mainly reversible, i.e., 
dynamic ligation reactions and only few are irreversible
111-114
, and therefore it is worthwhile 
to explore the possibility of using multicomponent reactions for protein dependent reaction. 
Given that the transcription factor STAT5 is a target for tumor therapy, protein-catalyzed 
reaction such as PTFL is a great attempt to explore site-specific identification of protein 
binding fragments since there is insufficient X-ray structural information on STAT5 protein-
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Aim of thesis  
Conventional chemotherapy are always seen as a universally applicable therapy that 
target bulk population of cells with high cytotoxic effect but still remains as the standard 
regime for treating myeloid leukemias. The major downside of this treatment approach is the 
lack of drug specificity and selectivity which in turns leads to large number of side effect. 
Such approach, hardly discriminate rapidly dividing non malignant and cancer cells.  
As targeting the upstream kinases in the signal transduction pathways has its own 
limitation, it is worth to explore the downstream target which has smaller niche and involved 
lesser crosstalk in multiple transductions pathway, It is foreseeable that by designing 
targeting therapeutics for downstream target has more limited nonspecific mechanism.  Over 
activation of STAT5 due to deregulated signalling pathways often leads to oncogenic 
transformation proofing that transcriptional factor activity have powerful consequences. 
Therefore, it is worthwhile to take a closer look into finding inhibitors that could target 
transcription factor and to halt the over expression of oncoproteins.  
The goal of this thesis was to develop a novel experimental strategy that based upon 
protein-templated fragment assembly reaction for the discovery of highly potent STAT5 
inhibitors. In this strategy, a protein-binding phosphate mimetic, which was identified earlier 
by the AG Rademann from screening of a fragment library was used as a starting point. Aim 
of the research was to investigate, if and how this initial fragment could be extended to more 
potent inhibitors of the STAT5-SH2 domain by using a protein-templated three-component 
Mannich ligation.  
In our studies, we attempt to take a rather different approach where STAT5 protein is 
recruited to catalyze multicomponent reactions of a phosphate mimetic, formaldehyde and 
1H-tetrazole to furnish potent protein ligands that equipped with high selectivity and 
specificity as well as ligand efficiency. As proof of concept, several methods for monitoring 
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of the protein-templated reaction ought to be developed. The formed ligation product from 
protein-catalyzed reaction will be investigated using binding assays such as fluorescence 
polarization assay and also thermal shift assay as well as high-performance liquid 
chromatography-mass spectrometry (HPLC-MS) analysis. 
We will also take a closer look on the feasibility of the reaction by testing the protein 
templated Mannich ligation under physiological conditions and also in a range of pH. In 
addition, the templated reaction and the formed inhibitors will then be tested with STAT5 
closely related proteins such as STAT1 and STAT3 to determine the drug specificity and 
selectivity as STAT family shares high structural homology of SH2 domain. Nevertheless, 
the formed inhibitors will be examined against phosphatases like SHP2 and PTPIB to prevent 
non selective binding and inhibition.  
In order to study the binding of potent inhibitors formed via templated reaction, 
molecular modeling and docking will be carried out. Nevertheless, binding analysis software, 
BINANA will be use to provide insight on the binding mechanism of the formed inhibitors 
with STAT5 while also identified the key binding residues in protein binding pocket.  
To assess the possible implications on formed inhibitors in targeting STAT5 in 
leukemic cells, in vivo and in vitro studies were carried out. The formed inhibitors are 
carefully investigated in both leukemia and other cancer cell lines for cell cytotoxicity studies. 
The activity of the formed inhibitor in blocking cell proliferation and survival were 
determined in a xenograft mouse model. Biochemical studies will be carried out to verify the 
ability of formed inhibitors in blocking phosphorylation of STAT5, disrupting DNA-binding 
and halt gene transcription that drives cancer cell proliferation and survival. We were also 
keen to examine the synergistic effect of our STAT5 inhibitor with a staurosporine-derived 
- 44 - 
 
FLT3-inhibitor PKC412 which inhibits the upstream tyrosine kinase receptor to gain insight 
on new therapeutic approaches in tackling leukemia and potentially other cancers.  
Together this study will explore the formation and identification of a specific protein-
binding ligand via protein templated reaction. Furthermore, it also contributes to a better 
understanding on how the ligand bound and inhibits the target proteins, STAT5. Ultimately, it 
should broaden the application of protein templated reactions and also provide molecular 
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3.1 Discovery and validation of a phosphate-mimetic fragment targeting STAT5 via 
HTS 
A robust, high throughput assay fluorescence polarization (FP) assay is employed for 
an accurate assessment of STAT5 inhibitor. Berg et al. applied the same biochemical 
technique to identify specific STAT5b inhibitors whereas Gunning et al. set up a 
complementary high throughput FP assay for STAT5a. To date, only one crystal structure of 
STAT5a isoform is available on the protein data bank (PDB: 1Y1U) and no resolved crystal 
structure of STATb. The lack of structural data impedes the use of structure based drug 
design (SBDD) to identify selective STAT5b inhibitors. 
56,58,62,71,115
 
In addition, target validation against STAT5b-SH2 domain is extremely crucial since 
selective STAT5b-SH2 domain inhibitors can block aberrant dimerization and transcriptional 
activity without interfering with other essential cellular functions mediated by other structural 
domain of STAT5. For instance, the C-terminal domain in STAT5 acts as a physiological 
substrate for insulin receptor. This highlights the need for setting up FP assay targeting 
STAT5b-SH2 domain in order to develop STAT5 inhibitors that could potentially STAT5b 




3.1.1 High Throughput STAT5b Fluorescence Polarization assay 
High-throughput screening (HTS) assays enable the testing of huge numbers of 
chemical substances for activity in diverse areas of biology. The biological responses 
measured in HTS assays span isolated biochemical systems containing purified receptors or 
enzymes to signal transduction pathways and complex networks functioning in cellular 
environments. Biochemical based high-throughput screening is widely used to discover small 
molecule drugs that modulate protein-protein or protein-peptide interactions.
70
 Here, we 
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utilized fluorescence polarization (FP) assay for high throughput screening of large small-
molecules libraries for modulators of the activity of the SH2 domain of STAT5b (Figure 
3.1).
116
 Strong affinity binding of STAT5b to either its upstream receptor or reciprocally to 
itself requires the key pY-SH2 domain interactions. A high affinity phosphotyrosine 
octapeptide, 5-CF-GpYLSLPPW 1 derived from Granulocyte-Macrophage Colony-
Stimulating Factor (GM-CSF) receptor has been developed as a fluorescent probe for the 





Figure 3.1: High throughput screening using fluorescence polarization assay is a robust way 
to screen for inhibitors. A schematic view of the different stages which came upon a drug 
discovery process based on traditional HTS. 
 
A collection of 17,000 fragments and fragment combinations composed in accordance 
with the substructure composition of the World Drug Index (WDI) was screened for inhibitor 
of the phosphopeptide-STAT5b interaction. Primary amine fragments were tested in the FP 
assay in the presence of electrophilic phosphotyrosine mimetic 2 as described earlier for 
protein tyrosine phosphatases (PTP) in order to distinguish secondary site binders that 
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enhance the inhibition of 2 from inhibitors that are not affected by 2 (Figure 3.2, unpublished 
work by Dr. Samuel Beligny).  
 
 
 Figure 3.2: Fragment ligation assay for detecting nucleophilic fragments, which can either 
enhance the binding of 4-formyl-phenyl phosphate 2, or replace 2 competitively. 
(Unpublished work by Dr. Samuel Beligny) 
 
 The assay was adapted to the 384-well microtiter plate format with high statistical 
reliability (Z´= 0.75) which is appropriate for high throughput screening. Potential hits can be 
recognized by a decrease in the fluorescence polarization through displacement of fluorescent 
probe 1, which initially bounded to the STAT5 protein In addition, the non-labeled 
phosphotyrosine peptide AcpYLSLPPW was included as a positive control. 
Binding of fragments to the recombinantly expressed STAT5b-SH2 domain fused to 
maltose binding protein (MBP) as affinity tag was recorded by measuring fluorescence 
polarization (FP) of the carboxyfluoresceine-labeled phosphotyrosine octapeptide 1 (Figure 
3.3).  
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Figure 3.3: (a) Schematic illustration of the fluorescence polarization (FP) binding assay. 
Binding curves of carboxyfluorescein phosphopeptides 5-CF-GpYLSLPPW (1) for STAT5b 
(b) and 5-CF-GpYLPQTV for STAT3 (c) The dissociation constants (KD) of the peptides 
were determined to be 55 ±6 nM for STAT5b and 94 ±2.8 nM for STAT3.  
 
The library was then subjected to a high-throughput MBP-STAT5b fluorescence 
polarization (FP) assay to determine their binding affinity towards STAT5b-SH2 domain. 
The competitive displacement assay examines the small molecule displacement of a high 
affinity STAT5b-SH2 domain fluorescence phosphopeptide 1, resulting in reduced 
polarization of the fluorescence emission due to rotational movement of the free, and 
unbound fluorescence phosphopeptide 1.  
Among the primary amine fragments tested, one fragment, 4-amino-furazan-3-
carboxylic acid 3 (M = 129 g/mol) displayed a KD value of 420 µM, corresponding to the 
ligand efficiency of 2.1 kJ/mol per non-hydrogen atom, higher than that of the nanomolar 
phosphopeptide 1, the phosphotyrosine mimetic 2, and the best reported STAT5 inhibitors 
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(Figure 3.4). Ligands with such high ligand efficiency are rather found for enzymatic binding 




Figure 3.4: High throughput fluorescence polarization assay against a collection of 17,000 
fragments in the ChemBioNet using fluorescence probe, 1 in the presence of 
phosphotyrosines mimetic, 2 give rises to one potent fragment, 4-amino-furazan-3-carboxylic 
acid 3 displayed a KD value of 420 µM with high ligand efficiency (2.1 kJ/mol per non-
hydrogen atom).  
 
 
3.1.2  Thermal Shift Assay 
3.1.2.1 Determination of melting temperature, Tm of MBP-STAT5b protein 
The fluorescence-based thermal shift assay is a general method for identification of 
inhibitors of target proteins from compound libraries.
70,118
 Using an environmentally 
sensitive fluorescent dye to monitor protein thermal unfolding, the ligand-binding affinity can 
be accessed from the shift of the unfolding temperature (ΔTm) obtained in the presence of 
ligands relative to that obtained in the absence of ligands. The thermal unfolding of MBP-
STAT5 protein monitored by LightCycler is shown in Figure 3.5. The fluorescence intensity 
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increases on protein unfolding because the fluorescent dye Sypro orange has a higher 
quantum yield in a lower dielectric medium and protein unfolding exposes the hydrophobic 
region corresponding to a lower dielectric environment. However, after reaching the plateau, 




Figure 3.5: MBP-STAT5 protein melting temperature measured in Thermal Shift Assay 
(TSA). 
 
3.1.2.2 Fragment 3 thermally stabilizes MBP-STAT5 
A ligand bound to the active site of a protein, has the propensity to increase its 
thermal stability (Tm) through newly formed protein-ligand interactions. The difference in 
melting temperature (ΔTm) of the protein and of the ligand-protein complex has been shown 
previously to correlate to ligand's concentration and binding affinity. In this manner, a 
melting curve is generated, the Tm determined, and changes in Tm (ΔTm) induced by 
prospective binding ligands can be calculated. The midpoint temperature changes 
(ΔTm=Tm−T0) in the presence of fragments 3, 25 and 26 at 0.156mM -2mM are shown in 
Figure 3.6.  
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Binding of 3 to STAT5b-SH2 was confirmed using the thermofluor assay, a thermal 
shift assay (TSA), as an independent biophysical assay. Binding of fragment 3 augmented the 




Figure 3.6: Melting temperature of MBP-STAT5b in the presence of fragments 3, 25 and 26. 
(a) Fragment 3 induced a significant shift in the melting temperature (ΔTm=3 ºC) of MBP-
STAT5b protein at 1mM. (b-c) Fragments 25 and 26, respectively, show no or minute Tm 
shift (1 ºC) in the thermal denaturation curves of MBP-STAT5b. The fluorescence changes 
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shown in the plot with increasing temperature were fitted to the Boltzmann equation by non-
linear regression to obtain the melting temperature, Tm. 
Potential binding modes of the phosphotyrosine 2 and the fragment hit 3 were 
scrutinized using a homology model of STAT5b derived from the crystal structure of 
STAT5a (pdb: 1Y1U) due to the absence of STAT5b crystal structure for molecular 
docking.
64
 Sequence alignment of mouse STAT5a to human STAT5b were adopted from Lin 
et al. as shown in Figure 3.7 using Sybyl8.1. As illustrated in figure 3.7, the residues 
spanning the SH2 domain of both STAT5a and STAT5b are highly conserved with exception 










The phosphotyrosine binding site in the STAT5-SH2 domain is shallow compared to 
the deeper binding pockets of PTP coordinating phenyl phosphate 2 by only two amino acid 
residues, Arg618 and Ser622.
120,121
 As a result, the benzene ring of 2 is not buried in a cavity 
like in the case of PTPs but rather exposed to the solvent at the protein surface. Binding of 
fragment 3 is mediated by the Coulomb interaction between the carboxylate anion and the 
cation of protonated Arg618 and H-bonds involving Arg618, Ser622, and Asn642 (Figure 
3.8). 




Figure 3.8: Discovery of phosphate-mimetic fragment 3. (a) Fluorescently labeled 
phosphotyrosine peptide 1 was used in an FP assay for the screening of a fragment library 
furnishing 4-amino-furazan-3-carboxylic acid 3 as a phosphate-mimetic. Phosphotyrosine-
mimetic fragment 4-formyl-phenyl phosphate 2 was employed to investigate fragment hits 
for second site binding. (b-c) Molecular docking results of fragments 2 and 3 into homology 
model of human STAT5b-SH2 domain, generated from the published structure of STAT5a 
(PDB accession codes, 1Y1U). Hydrogen bonds with key residues in the hydrophilic binding 




3.2 Hit-to-lead optimization of selective STAT5 inhibitors 
Fragment 3 was identified as an attractive starting point to initiate chemistry. 
Although fragment 3 has moderate activity in the fluorescence polarization and thermal shift 
assay
 
with Ki= 420 µM, it contains exceptionally high ligand efficiency and a novel core 
from which further modifications can be generated. In general, the smaller the fragment hits 
the lesser the observational activity of the inhibitors. Notably, in silico molecular docking of 
fragment 3 illustrated its binding in the STAT5b-SH2 domain forming two essential 
hydrogen bonds with Arg 618 and Ser 622. Surprisingly, fragment 3 also form and additional 
H-bond with Asn642 which allow it to bind stronger to the STAT5b-SH2 domain. 
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Derivatives of fragment 3 were synthesized and tested in order to investigate structure-




3.2.1 Fragment expansion through protein-induced Mannich ligations.  
First, the novel phosphate mimetic 3 was expanded by amidation (Figure 3.9a), a 
reaction recently introduced to protein-templated fragment ligations.
 
The N-acetyl derivative 
4 and all other tested amides including 5, however, were inactive in the FP assay (Figure 
3.10). In order to reduce the steric demand from a carbonyl to the more flexible methylene 
linkage, the Mannich ligation was investigated as fragment expansion method (Figure 3.9b). 
Fragment 3 was found to react readily with formaldehyde (FA) and various N-heterocycles in 
aqueous buffer at pH 5.0 at room temperature yielding Mannich ligation products while no 
reaction was observed without protein at pH 7.4.  
 
. 
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Figure 3.9: Expansion of fragment 3 through protein-induced reactions. (a) Amidation of 3 yielded compounds 4 and 5 which were inactive in the FP assay. (b) 
Mannich ligation was investigated as an alternative fragment expansion method to obtain the active compounds 6-19 containing a linker with reduced steric 
hindrance and better structural flexibility. 
 
 




Figure 3.10: Fluorescence polarization curve for the binding of compound 4 (a) and 5 (b) to 
recombinant STAT5-SH2 domain shows no improvement in binding upon structure 
expansion by amidation  
 
3.2.1.1 Mechanistic analysis of the protein-induced reactions 
In order to implement protein-dependent Mannich ligations, the compatibility of the 
reaction with the protein MBP-STAT5b-SH2 and with the FP assay was investigated. 3-(N-
Morpholino)-propane sulfonic acid (MOPS, 50 mM, pH 7.4) was used as a buffer containing 
no primary and secondary amines that could interfere with the reaction. FP of MBP-STAT5b-
SH2 (125 nM) with peptide 1 (10 nM) was recorded in the presence of increasing 
concentrations of FA at pH 7.4. No change of FP was observed at concentrations up to 250 
µM FA, while at higher concentrations FP values increased considerably (Figure 3.11a). 
Likewise, up to 250 µM no effect of FA on the melting point of STAT5b-SH2 was recorded 
in the TSA, although higher FA concentrations reduced the intensity of the fluorescence 
signal suggesting interference of FA with the fluorescent dye (Figure 3.11c).  




Figure 3.11: Assembly of STAT5 inhibitor 10 through protein-induced Mannich ligations. (a) 
FA was tolerated at up to 250 µM in the FP assay of MBP-STAT5b-SH2. (b) FA did not 
affect the STAT5b protein stability in the TSA at ≤ 250 µM. (c) Protein-induced formation of 
10 in the FP assay with increasing FA concentrations. (d) Protein-induced formation of 10 
from fragments 3 and 1H-tetrazole 25 with increasing FA concentrations in the TSA (ΔTm = 
7º C). 
 
For in-situ Mannich ligation assays, fragment 3 was incubated with one hetaryl 
nucleophile and FA (all 250 µM) per microtiter-plate-well in water resulting in pH 5.0. After 
12 h incubation at room temperature, protein MBP-STAT5b (125 nM in 50 mM MOPS 
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buffer pH 7.4) with the peptide probe 1 were added and further incubated for 15 min before 
FP was recorded. Several of the added heterocycles led to substantially decreased FP values – 
suggesting the formation of a Mannich ligation product as inhibitor of STAT5b with 
increased affinity. Active Mannich ligation products were re-synthesized, purified, and tested 
in the FP assay (Appendix Table 2-3). 
 Remarkably, the addition of five-membered N-heterocycles (“azoles”) to the 
formimine of fragment 3 led to strongly enhanced inhibition of STAT5b. The 1, 2, 3-triazol-
1-yl product 6 as well as the benzo-1, 2, 3-triazol-1-yl (7) increased the affinity by a factor 
of >2, pyrazol-1-yl 8 >3-fold, 1, 2, 4-triazol-1-yl 9 > 9-fold and tetrazol-1-yl 10 300-fold 
resulting in a KI of 1.4 µM (Figure 3.12). The reaction with 5-substituted tetrazoles yielded 
strongly active inhibitors 11-17, some even with sub-micromolar affinities, including 4-(5-
phenyl-tetrazol-1-yl-methylamino)-furazane-3-carboxylate 11 (1.4 µM), 5-(3-
trifluoromethyl-phenyl)- 12 (0.9 µM), 5-(3-fluorophenyl) 13 (0.6 µM), 5-benzyl 16 (2.9 µM), 
and 5-biphenyl 17 (0.8 µM). Esters of the furazane carboxylic acid (18, 19) were prepared as 
prodrug derivatives. 4-(Tetrazolyl-1-methyl-amino)-furazan-3-carboxylic acid 10 is the 
STAT5 inhibitor with the highest ligand efficiency of 2.23 kJmol
-1
 per non-hydrogen atom.  
All starting azoles like tetrazole 25 were completely inactive at concentrations of 5 
mM, thus the inhibitors constitute examples of super-additive fragment combinations. As a 
consequence, the observed protein-dependent ligation reaction did not proceed as a protein-
templated reaction that requires the binding of both reacting fragments to the protein. 




Figure 3.12: Compound 10 has the highest ligand efficiency (LE) of all inhibitors. (a) Ki 
values and ligand efficiencies of compounds 6-10. (b) Fluorescence polarization curve for the 
binding of compound 6, 8, 9, and 10 to recombinant STAT5-SH2 domain. 
 
3.3 Quantitative analysis of the protein induced Mannich reaction  
Protein-dependent reactions of fragment 3 with FA and 1H-tetrazole 25 were 
investigated by using the binding assays (FP, TSA), and HPLC-MS analysis. Incubation of 
fragments 3 and 25 (250 µM each) with MBP-STAT5b-SH2 (250 nM) with increasing 
concentrations of FA at pH 7.4 led to decreased FP values, suggesting the formation of an 
inhibitor (Figure 3.11b). The protein-dependent formation of a STAT5 inhibitor was 
confirmed in the TSA: Incubation of fragments 3 and 25 with increasing concentrations of 
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Figure 3.13: Protein-induced ligand formation through Mannich ligations. (a) Schematic 
illustration of protein-induced formation of ligand. (b) Formation of 10 detected in the 
HPLC-QTOF-MS (average of three independent experiments). 1: No formation of 10 from 
FA, fragments 3 and 25 (all 250 µM) at pH 7.4 in MOPS buffer without protein. 2: Protein-
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induced formation of compound 10 with protein MBP-STAT5b-SH2 (250 nM) at pH 7.4. 3-6: 
Inhibition of protein-induced formation of 10 by peptide 1 (3, 4) or inhibitor 16 (5, 6). 7, 8: 
No formation of compound 10 in the presence of Maltose Binding Protein (1 µM) or GST-
STAT3 (250 nM). 9-11: Compound 10 was not formed in the presence of phosphatases, SHP-
2 (250 nM) and PTP1B (250 nM) nor in the presence of mutant STAT5b-N642A at pH7.4 in 
MOPS buffer. 12: Formation of compound 10 at pH 5.0 without protein. (c) Formation of 
compound 16 detected in the HPLC-QTOF-MS. Lane 1: Negative control: formation of 16 
from FA, fragments 3 and 26 at pH 7.4 in MOPS buffer without MBP-STAT5b-SH2. 2: 
Protein-induced formation of compound 16 at pH 7.4. Lanes 3-6: Protein-induced formation 
of compound 16 blocked by peptide 1 (3, 4) or inhibitor 10 (5,6). 7: Formation of compound 
16 in the presence of Maltose Binding Protein. 8: Formation of compound 16 at pH 5.0 
without protein. 
   
High resolution HPLC-QTOF-MS analysis was employed to quantify Mannich 
ligation product 10 formed with or without protein present (Figure 3.13). At pH 7.4 
absolutely no inhibitor was formed from 3, 25, and FA, if MBP-STAT5-SH2 protein was not 
present (trace 1). With 250 nM MBP-STAT5-SH2 in the buffer at pH 7.4, 432 nM of 10 were 
formed over 24 h (average of three independent experiments). The protein-dependent reaction 
was saturated after 24 h, no significant changes in product concentration were observed 
between 24 and 48 h reaction time suggesting product inhibition of the ligation reaction. 
Addition of phosphopeptide 1 or inhibitor 16 to the protein-induced reaction suppressed the 
formation of 10 completely or partly in a concentration-dependent manner (traces 3-6). If 
instead of the MBP-STAT5-SH2 protein only the protein tag MBP (1 µM) or the catalytic 
domains of tyrosine phosphatases SHP2 or PTP1B (250 nM) were added, no product was 
formed at all (traces 7, 9, 10). In contrast, incubation of reagents 3, 25, and FA at pH 5.0 led 
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with or without protein to the formation of 7 µM of inhibitor 10 in a protein-independent 
background reaction (trace 12). Similar data were obtained for the protein-dependent reaction 
of fragments 3, FA, and benzyl-tetrazole 26 although traces of a background reaction were 
observed in this case (Figure 3.13c). In contrast, no protein-dependent reaction was observed 
when replacing the 1H-tetrazoles by 1, 2, 4-triazole (Figure 3.14c), most likely due to its 
lower acidity compared to 1H-tetrazoles (Figure 3.15). 
 
 
Figure 3.14: (a) Schematic illustration of competitive protein-induced ligand formation. (b) 
Compound 10 formed predominantly over 9 when fragment mixtures (3, 25, and 1, 2, 4-
triazole) were incubated with FA in the presence of MBP-STAT5b-SH2. (c) Formation of 
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compound 9 and 10 were detected in the HPLC-QTOF-MS. Lane 1: negative control, no 
formation of 9 or 10 from FA, fragments 3, 25 and 1, 2, 4-triazole at pH 7.4 in MOPS buffer 
without MBP-STAT5b-SH2. 2: Formation of compound 10 with protein at pH 7.4. 3: No 
formation of compound 9 was detected with protein at pH 7.4. 4: Formation of compound 9 




Figure 3.15: pKa value of pentazoles (pyrrole, diazoles, triazoles and tetrazoles) 
 
3.4 Identification of Asn642 as key binding residue for STAT5 –inhibitor 
interactions 
Protein-ligand docking plays an integral part in drug discovery spanning from the 
initial target identification and validation through lead discovery and optimization. It is 
beneficial to employed protein-ligand docking to accurately predict ligand conformation 
bound to a target molecules active site and speed up the crucial hit-to-lead optimization 
process. Nevertheless, computational tools such as molecular docking allows chemist to 
explore a wider chemical space while reducing the number of compounds being synthesized 
and tested in vitro which are more cost effective and less time consuming.
58,62,71
 
Autodock version 4.2 docking software has been employed to evaluate the ligand 
binding within the STAT5-SH2 domain. Autodock combines a grid-based method for binding 
energy evaluation and pre-calculate ligand-protein interaction energy in order for subsequent 
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Using AutoDock4.2, we performed global searches of the conformational space along 
with careful local searches to derive the best conformational fit within the STAT5b-SH2 
domain. Docking simulations were carried out with a rigid protein structure, allowing for 
ligand flexibility using a Lamarckian Genetic Algorithm (LGA) with the global and adaptive 
local search parameters through 100 trials of the “long” GA runs. Upon run completion, 
confirmation were specifically populated with the most favorable free energy of binding (ΔG) 
and is ready to chosen for further analysis. In short, the free energy is an important indication 
to distinguish the protein-ligand binding affinity as it is defined as the summation of all the 
terms of dispersion/ repulsion, hydrogen bonding, electrostatics, desolvation and torsional 
energy.  
Molecular docking suggested that the large increase in binding affinity of compound 
10 was contributed by expansion of the binding interaction into the adjacent amphiphilic 
pocket containing residues Trp641, Leu643 and Met639 via hydrophobic contacts. The H-
bond, between the 4-amino group of 10 and the carbonyl of Asn642 was retained and 
possibly enforced by the higher polarity of the NH-bond
56,58,71,110
 in 10 (Figure 3.16). An 
additional H-bond was proposed by BINding ANALyzer (BINANA)
124
 between the tetrazole 
ring and the amide-NH2 of Asn642 and strengthened the binding of compound 10 in the 
binding pocket. Similarly, compound 16 which has shows stronger inhibitory effect in cells 
binds to STAT5 by forming H-bond with key residues Asn642, Ser622 and Arg618 and 
hydrophobic interactions with residues Trp631 and Trp641.Other tetrazoles derivates 
(compound 11-14) were docked and bound to STAT5-SH2 domain by forming essential 
hydrogen bonds with Asn642, Ser622 and Arg618 (Figure 3.17). 
 




Figure 3.16: 3D-binding model of compound 10 and 16 bound to STAT5b. Hydrogen bonds 
are illustrated as red dashed lines and key interacting residues in yellow stick. Figures were 
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Figure 3.17: Molecular docking results of compound into STAT5a-SH2 domain (pdb: 
1YIU). Stereoview of compounds 11(a), 12(b), 13(C) and 14 (D) coordination in the binding 
pocket showing hydrogen bond forming residues. Protein is represented as cyan surface. All 
compounds were bound to STAT5a-SH2 domain by forming hydrogen bonds with side 
chains of Asn642, Arg618 and Ser622. Protein was displayed as grey surface with key 
interacting residues and ligands shown as sticks. Hydrogen bonds were shown as red, dashed 
lines. Color-coded by element: N in blue, O in red and carbon in white. Pictures were 





Scheme 3.1: Mechanism of the protein-induced formation of 10 from 3 with FA and 25 
(R=H). (i) Binding of 3 via Arg618, Ser622, and Asn642, activation of FA with Asn642. (ii) 
Activation of the forminium cation of 3, coordination of the incoming tetrazolium anion of 25 
by Asn642 leads to formation of Mannich ligation product 10 (iii) 
 
The proposed binding mechanism and binding mode of fragment 3 to STAT5b-SH2 
domain was based on molecular docking in STAT5b homology model. This proposed 
binding mode highlights the importance of residue Asn642 in protein-ligand binding. In order 
to challenge the postulated importance of Asn642 for the reactivity of fragment 3 with 
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STAT5b-SH2, the fragment ligation of 3, FA, and 1H-tetrazole at pH 7.4 was investigated 
with GST-STAT3, a protein without Asn in the otherwise similar phosphotyrosine 
recognition site (Figure 3.13, trace 8). With STAT3 instead of STAT5b absolutely no 
fragment ligation product was formed. In addition, the mutant MBP-STAT5b-SH2 N642A 
was generated by site-directed mutagenesis to address its significant contribution in binding 
to STAT5b-SH2 domain. To our surprise, the mutant protein displayed a strongly binding 
affinity to peptide 1 with ca. 5 µM (instead of 55 nM for the wildtype) and bound inhibitor 10 
with 31 µM (instead of 1.5 µM for the wildtype). The affinity of MBP-STAT5b-SH2 N642A 
for 10 was significantly lower (20 fold) compared to the wild type STAT5b (Figure 3.19). 
Accordingly, the conditions of the fragment ligation reaction yielded no product with 
the mutant protein as well (Figure 3.13). Plausibly, the side chain carbonyl group of Asn642 
binds to the amino group of compound 3 via accepting an H-bond (Scheme 3.1). As a result, 
the amide-NH2 of Asn642 is free to coordinate and activate the incoming FA as an H-bond 
donor, leading to the formation of the formiminium derivative of 3, which is again stabilized 
by its H-bond to the Asn-carbonyl. Next, the amide-NH2 could coordinate the incoming 1H-
tetrazolium ion which reacts to the observed ligation product 10. These data illustrate key 
residues Asn642 as the determining factor for selectivity for protein-ligand binding. 
116
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Figure 3.18: Site-directed mutagenesis N642A was performed on the STAT5b sequence. (a) 
Sanger sequencing data confirmed that the AAT codon (Asn) is replaced to GCT (Ala) at the 
amino acid site 642.  Molecular illustration of key binding residues, Asn642 substituted with 
alanine and affected the ligand binding for compound 3 (b) and 10 (c) by losing essential H-
bonds. STAT5 protein was shown as cyan ribbon; key interacting residues were depicted as 
yellow stick; Residue subjected to alanine mutation was shown as purple sticks; hydrogen 
bonds with key residues in the hydrophilic binding pocket of the STAT5-SH2 domain were 
illustrated as red dashed lines.






Figure 3.19: Compound 10 shows 30-fold reduction in affinity towards STAT5b protein 
when key binding residue Asn642 is mutated to Ala642. (a) Binding curve of phosphopeptide 
1 to STAT5b-N642A. (b) Fluorescence polarization curve for the binding of compound 10 to 
recombinant STAT5b-N642A domai
- 71 - 
 
Summary Protein induced Mannich ligation in STAT5 and ligand detection methods. 
 
Figure 3.20: (i) Template-assisted formation of highly selective STAT5 inhibitor via 
Mannich reaction. Ligated product can be detected via (ii) LC-Qtof-MS, (iii) Fluorescence 
polarization and (iv) Thermal Shift Assay.  
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3.5 Specificity of STAT5 inhibitors with isolated proteins and in cell lysates 
Selectivity and specificity of compound 10 for STAT5b protein was tested against 
STAT3 and SHP2 protein. To comprehensively determine the potential off-target effects, 
compound 10 was tested with closely related STAT3 and the catalytic domain of protein 
tyrosine phosphatase SHP2 (PTPN10) and at concentrations up to 1 mM no binding or 
inhibition was observed (Figure 3.21). Encouragingly, 10 portrayed negligible effects against 
the closely related proteins and suggested that inhibition of pSTAT5 is solely due to 
interaction with STAT5b-SH2 domain and not via non specific interactions with other 
cellular proteins.  
 
 
Figure 3.21: STAT5 inhibitors 10 and 16 were inactive towards SHP2. Enzyme kinetic 
assays of compound 10 (a) and 16 (b) with SHP2 protein. Both compounds show no 
significant inhibitory effects on the enzymatic activities of SHP2 protein. Dose-response 
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fluorescence polarization curve illustrates no binding of compound 10 (c) and 16 (d) to 
recombinant STAT3 protein. 
 
In order to examine the potential effect of compounds on STAT5b activity, a STAT5-
DNA binding assays was performed. Firstly, phosphorylated STAT-dimers were extracted 
from nuclei of BaF3/FLT3-ITD cells and were pre-treated by incubating with a serial 
concentration (10-1000 µM) of compounds 3, 10 and 16 respectively. Then, a double-
stranded oligonucleotide containing STAT5b consensus site was added into each mixtures 
before the binding of STAT1, 3, 5a, and 5b to DNA was detected using an ELISA specific for 
the respective protein-DNA-complexes.
58,125,126
 Intriguingly, 10 inhibited STAT5b-DNA 
binding by more than 50% at 30 µM.  We also tested the effect of 10 on STAT5a DNA 
binding activity and found out that the inhibitory effect is 20% lesser under comparable 
conditions. Compounds 3, 10, and 16 inhibited formation of the DNA-complex of STAT5a 
and STAT5b (Figure 3.22a), but not of STAT1 and STAT3 (Figure 3.22c). This result also 
suggests that 10 selectively block the interaction of STAT5b and DNA over other STATs in 
the family. 
Furthermore, we also carried out EMSA analysis to further validate the inhibitory of 
compound 10 in the formation of STAT5: DNA complex.  In EMSA analysis, STAT5: DNA 
complexes have a higher molecular weight therefore migrate slower than protein-free DNA. 
The STAT5: DNA complexes were then identified using STAT5 specific antibody. 
Importantly, nuclear extract of BaF3:FLT3/ITD was used for evaluation since they produced 
larger quantity of the STAT5 dimer/tetramer complex and ease the detection by providing 
more pronounced effects. Compound 10 was then added into the STAT5-DNA complex 
mixture before running on gel electrophoresis. Likewise, inhibition of the STAT5: DNA 
complex by compound 10 was detected in the Electro Mobility Shift Assay (EMSA) (Figure 
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3.22b).The gel electrophoresis show a clear reduction of STAT5-DNA complex when treated 





Figure 3.22: STAT5 inhibitor 10 blocks STAT5 dimerization in BaF3/FLT3-ITD nuclear 
lysates. (a) 10 and 16 inhibit formation of trimeric (STAT5b)2-DNA complexes in an ELISA. 
(b) (i) 10 inhibits binding of STAT5 dimers, isolated from nuclear extracts of BaF3/FLT3-
ITD cells, to its target DNA in the ElectroMobility Shift Assay (EMSA) and (ii) shows 
selectivity for disrupting STAT5a,b-DNA complexes in the TransAM
®
 STAT family ELISA. 
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 Figure 3.23: Compound 10 (a) and 16 (b) stabilized STAT5 protein shifting the melting 
temperature (ΔTm) of MBP-STAT5b-SH2 protein by 9 ºC in the thermal shift assay (TSA) 
but did not bind to maltose binding protein (MBP)(c-d). 
 
Compound 10 and 16 bound to isolated MBP-STAT5b-SH2 shifting the melting temperature 
(Tm) by 9 ºC (Figure 3.23). The specificity of compound 10 was further investigated in 
complex cell lysates using cellular thermal shift assays (CETSA).
127
 We first performed 
cellular thermal shift assay to investigate STAT5a and STAT5b melting temperature in cell 
lysates in order to investigate inhibitor engagement of STAT5 (Figure 3.25). BaF3/FLT3-ITD 
cell lysates were incubated with 10 and exposed to a temperature gradient from 43-73°C. 




Figure 3.24: Compound 10 (a) and 16 (b) did not induce thermal stability even at high 
concentration in STAT3 protein indicating binding specificity of both compounds towards 
STAT5 protein. 
 
Supernatants were analyzed by gel electrophoresis and immunoblotting was performed with 
STAT5a/b antibodies. Inhibitor 10 shifted the melting temperatures of STAT5a/b by 5 and 8 
°C, respectively, indicating the thermal stabilization of STAT5 proteins through ligand 
binding in cell lysates (Figure 3.26).




Figure 3.25: (a-b) CETSA-melting curve of STAT5a and b. Representative Western-blot 
signals corresponding to STAT5a and b show a decrease in intensity at elevated temperatures 
Band intensities obtained from Western blot-analysis were related to the highest Western blot 
signal which has been set to 100%. Relative band intensities were plotted against incubation 
temperatures and fitted to Boltzmann sigmoidal curve. 




Figure 3.26: Compound 10 binds to STAT5a (a) and STAT5b (b) in complex cellular lysates 
as demonstrated by cellular TSA (CETSA) resulting in shifted melting curves at 50 µM 
compared to vehicle (DMSO). Relative STAT5a and STAT5b band intensities were plotted 
against corresponding incubation temperatures and fitted to Boltzmann sigmoidal curve. 
- 79 - 
 
3.5.1 Determination of STAT5 inhibitors target specificity using peptide 27 in 
neutravidin  pulldown. 
The most commonly used method to identify interaction partners of a specific peptide 
sequence is to employ the peptide as a bait to be used in affinity pull-down experiment and 
potential binding partners could be directly detected. Furthermore, pull-down assay can also 
help to confirm the existence of protein-protein interaction which has been determined via 
other research techniques such as co-immunoprecipitation (co-IP). Here, we designed and 
applied a dual label peptide, 27 to distinguish and verify postulated protein-protein 
interactions by competitive displacement of bindings. Peptide 27 is designed with two 
different tags i.e. biotin and carboxyfluorescein tag at each terminal. Biotin tag is chosen for 
affinity purification purposes due to its high binding affinity and its small size whereas 
carboxyfluorescein tag help to monitor bait protein binding, purification and localization.
128
 
Peptide 27 binds STAT5 at submicromolar concentration and could be used as bait to fish out 
potential STAT5 interaction partners or/ and determine the selectivity of STAT5 inhibitors 
using competitive displacement assay.  
As shown in Figure 3.28, peptide 27 was added to bovine serum albumin (BSA) as 
control experiment to evaluate non-specific bindings. Predictably, peptide 27 does not bind 
and cross linked with BSA and therefore show non product in neutravidin pull down as 
anticipated. In addition, a serial concentration of peptide 27 was added to 25 µM of 
recombininat MBP-STAT5b to determine protein-peptide saturation point. Peptide 27 was 
shown to bind and photo-crosslinked STAT5 in a concentration dependent manner and 
reached a saturation point at 25µM (Figure 3.29).  
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Figure 3.27: Peptide 27 does not interact and photocrosslinked with bovine serum albumin 
(BSA) and neutravidin pull down only allows purification of Biotinylated Bovine Serum 
Albumin (BSA) which acts as a positivie control. 
 
 
Figure 3.28: A serial concentration of peptide 27 (0-100 µM) were incubated and 
photocrosslinked with MBP-STAT5 (25 µM) before subjected to neutravidin beads pull 
down.  
Binding of biotinylated MBP-STAT5 to Neutravidin beads increased proportionally with the 
amount of peptide 27 added as indicated in the elution fraction on western blotting. 
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3.5.2  Competitive displacement of peptide 27 using STAT5 inhibitors 
We further employed peptide 27 to verify the target selectivity and specificity of 
STAT5 inhibitor, 10.  As a control experiment, we used a non fluorescent phosphotyrosine 
peptide, 5-Ac-GpYLSLPPW-NH2 to displace peptide 27 in STAT5 binding. We observed 
reduction in the photocrosslinking efficiency of peptide 27 affecting the final readout in both 
fluorescence intensity and band intensity in streptavidin blot (Figure 3.29b-c). Then, we 
substituted the Ac-peptide with the STAT5 inhibitor, 10 and observed reduction in both 
fluorescence intensity and pull down yield in a concentration dependent manner. This 
strongly indicates that small molecule 10 binds competitively to STAT5-SH2 domain by 
displacing high affinity peptide 27, proving its high selectivity towards STAT5. 
On the same page, peptide 1
117
 which possess strong affinity (Kd= 55 nM) towards 
STAT5 was also shown to interfere with the photocrosslinking event and biotinylation by 
competitively displace peptide 27 (Figure 3.30).  As shown in Figure 3.30b, 
photocrosslinking event of peptide1 is concentration dependent and is affected when high 
affinity peptide 1 was added. Both peptide 1 and 27 compete for the same binding site, 
STAT5-SH2 domain indicating the high selectivity of both peptide towards STAT5. 
Therefore, dual labeled peptide 27 can be used as a bait to fish out specific STAT5 
interaction partners for cellular signaling studies.  
We then tested out the same experiment in a much complex environment using 
BaF3:FLT3/ITD cell lysates. Peptide 27 (100 µM) was added into the cell lysates and 
incubated for an hour before photocrosslinking for 15 minutes. The mixture was then 
subjected to neutravidin pulldown to fish out potential interaction partners. To our surprise, 
peptide 27 acts as bait and interacts with a range of proteins in the complex cell lysates 
enhancing the neutravidin pulldown yield and noticeable bandshift. It is worth looking into 
and identifies potential interaction partners using LC-MS/MS (Figure 3.31). Quantitative, 
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high resolution MS results facilitates the identification of specific peptide-protein interactions 
from crude cell extracts in a single-step affinity purification using neutravidin beads at near 
physiological conditions. This one step purification method is superior but required stringent 
washing conditions follow by SDS PAGE, in order to distinguish high abundant and high 
affinity binders, avoiding unwanted bias. The specific interaction partners are then quantified 
by a SILAC ratio of 1:1, to distinguish them as real binders of peptide 27. In addition, using 
quantitative MS has two major advantages the determination of binding partners of peptide 
27. Firstly, unwanted bias can be easily avoided by normalizing the total amount of 
background binders in bait pull-down and control. Secondly, it is much easier to distinguish 
specific interaction candidates even in the presence of highly abundant background binders. 
Therefore, a near physiological buffer can be used during peptide incubation and washing 
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Figure 3.29: (a) Schematic illustration of the dual-labeled STAT5-binding peptide, 5-CF -
K(biotin)GpcFLSLPPW-NH2 27 (CF= carboxyfluorescein, pcF=phosphonocarboxy-
phenylalanine) photo-crosslink STAT5b upon UV irradiation. (b) Photo-crosslinking of 
peptide 27 to STAT5 protein was displaced by the non-fluorescent; phosphotyrosines 
containing control peptide, 5-Ac-GpYLSLPPW-NH2 affecting fluorescence intensity and 
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biotinylation in a concentration dependent manner. (c-d) Relative STAT5 biotinylation and 
fluorescence intensity level were plotted using GraphPad Prism 5
129
 after quantification using  
Image J
130
 software to reflect the efficiency of photo-crosslinking of peptide 27. Experiments 
were repeated twice; errors bars represent SD. (e) Compound 10 was able to interfere the 




Figure 3.30: (a) Schematic illustration of competitive displacement of the dual-labeled 
STAT5-binding peptide, 5-CF-K(biotin)GpcFLSLPPW-NH2 27 (CF= carboxyfluorescein, 
pcF=phosphonocarboxy-phenylalanine) by high affinity peptide probe 1 in MBP-STAT5b-
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SH2 photo-crosslinking upon UV irradiation. (b) Photo-crosslinking of peptide 27 to MBP-
STAT5b-SH2 in a concentration dependent manner. (c) Photo-crosslinking of peptide 27 to 





Figure 3.31: Photocrosslinking of peptide 27 to MBP-STAT5-SH2 protein followed by 
neutravidin beads pulldown. Peptide 27 bounds and photocrosslinks recombinant MBP-
STAT5 protein and shows successfully pulldown of other STAT5 interaction partner in 
complex BaF3/FLT3-ITD cell lysates. It is worth to study STAT5 interaction partner using 
LC-MS/MS by excising eluent gel bands on the coomasie blue staining. 
 
3.5.3 SILAC-based peptide protein interactions identify candidate bindings to  
peptide 27. 
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 Stable Isotope Labelling of Amino acids in cell culture (SILAC) is carried out by 







Therefore, these two cell populations are metabolically encoded with either heavy or light 
amino acids. Background protein presents in similar amount in control and bait eluate, and 
the SILAC peptide pairs (heavy and light) will have 1:1 intensity ratio.
132
 On the other hand, 
specific interaction partners to peptide 27 is easily distingush as they will possess heavy/light 
ratio(vice versa) significantly differ from 1:1. This significant difference is beneficial to 
detect interactions of protein to peptides.  
 To identify the possible interaction partner from our previous finding in 
BaF3:FLT3/ITD cell lysates, we carried out SILAC quantiitative proteomics method using 
peptide 27 as bait protein for photocrosslinking. After culturing both heavy and light 
BaF3:FLT3:IT D cells lines, we harvested 1 mg/mL of the cell lysates and allowed it to bind 
peptide 27 with or without the presence of peptide 1 before photocrosslinking. In order to 
avoid unwanted bias, cross over pulldown  experiment was included whereby the peptide 1 
incubated with light extract (competitive) which should give inverted ratio for specific 
binders (Figure 3.32). The eluates were then run on SDS PAGE before LC-MS/MS detection. 
For better retrieval of high confidence interaction partners by quantitative filtering, a cut of 
value of  P<0.0001 was implemented in the forward and reverse screen. The log SILAC ratio 
of proteins identified with at least two unique peptides in each mass spectrometry run is 
plotted as the forward pull-down (x axis) against the reverse labeling pull-down (y axis). 
Specific interaction partners show inverse ratios between forward and reverse experiments 
and is grouped into the upper left quadrant.
128
 
 Our method allows us to pull down approximately 400 proteins from complex cell 
lysates  and successfully shown that STAT5s is one of the significant binders to peptide 27 in 
BaF3:FLT3/ITD cells. As expected, we also detected enrichment of other members in STAT 
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family such as STAT1 and STAT3 due to high structural homology. In addition, scatter 2D 
plot of peptide 27 pull-down also indicates that STAT5a is plotted in the upper left quandrant 
(Figure 3.33).. Among 400 identified proteins before filtering, the known interaction partner 
for the STAT5A has the higher SILAC ratio in the forward but small in the cross-over 
experiment (Figure 3.33c). 
 As shown in Figure 3.34, the presence of compound 10 (50 µM) is able to 
competitively disrupt the binding and photocrosslikning event of peptide 27 in complex 
BaF3:FLT3/ITD cell lysates.  Higher amount of STAT5 were detected in the eluent when 
only peptide 27 is added and photocrosslinking event was taken place. Skipping the 
photocrossliking event, lesser amount of STAT5 protein is detected in the eluent. 
Comparably, the amount of STAT5 presence in the eluent reduced drastically with the 
presence of compound 10 thus indicating competitive displacement event. The quantitatitve 
LC-MS/MS data was tabulated and plotted as bar graph to illustrate STAT5 yield in the 
eluent with or without the presence of 10. Here, we have successfully validate that 10 is able 
to interfere the photocrossliking event of peptide 27 indicating specific interaction of 10 and 
STAT5 (Figure 3.34). 
 




Figure 3.32: Schematic representation of SILAC labeling and proteome analysis. Cells are 
split and cultured in heavy or light medium containing different amino acid isotopes. Dual 
labelled peptide, 27 were incubated and photocrosslinked with/without the presence of 
fluorescence peptide ,1.The cells are collected and their proteins are purified for further mass 
spectrometric analysis. The protein levels in the two samples are compared by quantifying the 
heavy and light peptides, because isotopic labeling will affect their migration times. 
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Figure 3.33: (a) Identify specific interacting partners of peptide 27 in BaF3/FLT3:ITD cells. 
BaF3/ FLT3:ITD cells were maintained in “heavy” medium, while control cell were grown in 
“light” medium. Whole cell lysates extracted from each cell pool were incubated with peptide 
27 in the presence or absence of peptide 1 for 1 hr before subjected to photocrosslinking at 
365 nM for 15 min in cold room (4ºC). Lysates were then pool and mixed 1:1 based on the 
total protein mass and pull-downed using neutravidin beads. Immunoprecipitated protein 
were then separated by SDS-PAGE separation, in gel trypsin digestion, and LC-MS/MS 
analysis. (b) Identification of  photocrosslinked protein by neutravidin beads in pre or mixed 
cell lysates (1:1) by immunoblotting. (c) Scatter 2D plot of for peptide 27 pull-down results. 
The log SILAC ratio of proteins identified with at least two unique peptides in each mass 
spectrometry run is plotted as the forward pull-down (x axis) against the reverse labeling 
pull-down (y axis). Specific interaction partners show inverse ratios between forward and 
reverse experiments, grouping them into the upper left quadrant. Among 400 identified 
proteins before filtering, the known interaction partner for the STAT5A is represented by a 
red bullet, having the higher SILAC ratio in the forward but small in the cross-over 
experiment. 
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Figure 3.34: Compound 10 affect the photo-crosslinking event of peptide 27 by competitive 
displacement in BaF3/FLT3-ITD cell lysates. (a-b) Coomasie blue staining and western 
blotting studies of neutravidin beads pull down eluent upon competitive displacement of 
peptide 27. I LC-MS/MS analysis of neutravidin pull down eluent in the presence of peptide 
27. (i) Higher amount of STAT5 were found in the eluent when peptide 27 were incubated 
and photo-crosslinked with BaF3/FLT3-ITD cell lysates. (ii) Lesser amount of STAT5 were 
eluted when BaF3/FLT3-ITD cell lysates in the presence of compound 10 which interfere the 
binding of peptide 27 by competitive displacement. Compound 10 was able to interfere the 
photo-crosslinking event of peptide 27 indicating specific interaction of 10 with STAT5. 
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Figure 3.35: Binding of 10 to STAT5 in BaF3/FLT3-ITD cell lysate was determined by 
photocrosslinking. (i) The dual-labeled (carboxyfluorescein and biotin) peptide probe 27 
binds to STAT5 with submicromolar affinity and photocrosslinked (ii) with target proteins by 
activating the 4-phosphoncarbonyl residue that acts as a photoactive phosphotyrosine 
mimetic. (iii) Crosslinked proteins can be isolated by biotin pull-down using Neutravidine 
beads. (iv) Displacement of 27 (100 µM) by compound 10 (50 µM) in BaF3/FLT3-ITD cell 
lysates (1mg/mL) resulted in significantly reduced photo-crosslinking of 27 and STAT5 as 
demonstrated in the Western blotting using STAT5 antibodies (right lane), whereas other 
biotinylated proteins were not reduced (middle lane). 
 
The specific interaction of inhibitor 10 with STAT5 was further challenged by 
interfering with the photo-crosslinking of STAT5b-SH2 and the dual-labeled STAT5-binding 
peptide 5-CF-K(biotin)GpcFLSLPPW-NH2 27 (CF= carboxyfluorescein, pcF= phosphono-
carboxy-phenylalanine). Peptide 27 was demonstrated to photo-crosslink STAT5b after being 
exposed to UV irradiation at 365 nm and 10 suppressed the photo-crosslinking in a 
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concentration-dependent manner (Figure 3.29). When peptide 27 was incubated with 
BaF3/FLT3-ITD cell lysate, irradiated for 15 min at 4 ºC and subjected to pulldown using 
avidin beads, compound 10 repressed STAT5-crosslinking by displacing peptide 27 
competitively in the complex lysate (Figure 3.35). 
 
3.6 Functional evaluation of STAT5 inhibitors in living cells and animals.  
The biological activity of inhibitors was studied in a cellular disease model using the 
murine pro-B-cell line BaF3 stably transfected with the internal tandem duplication (ITD) 
mutation of the human FLT3 receptor (FLT3-ITD).
133
 In these cells STAT5 is constitutively 
phosphorylated without cytokine activation. As the FLT3-ITD mutation is found in 35 % of 
AML patients it can be considered as a relevant model for this disease. 
134
 
At first, STAT5 phosphorylation at tyrosine residues (Tyr694/Tyr699) was 
investigated. 5-Aryl-substituted derivatives like 11-13 could not be tested in cells as they 
precipitated in buffer. Next, compound 10, 16 and 18 was assessed for whole cell potency 
against BaF3/FLT3-ITD (mouse FLT3-ITD) cell lines, MV-4;11 (human FLT3-ITD), K562 
(human Bcr-Abl) and respectively. Cell viability was assessed following treatment at various 
concentrations of inhibitor using Alamar-Blue cell viability assay (48 h). As compared to 10, 
IC50 values for 16 were 2−3-fold higher in potency, with activities ranging from 20-30 μM. 
Encouragingly, 16 displayed the potent activity in STAT5 driven cell lines. We next 
evaluated 16-mediated inhibition of STAT5 phosphorylation levels. BaF3/FLT3-ITD cells 
were treated with serial concentration of 16 (ranging from 25-200 μM) for 6 h, the cells were 
harvested, and the levels of phosphorylated STAT5 (Y694) were determined via 
immunoblotting (Figure 3.36a). The strongest inhibition was observed for 16 with >50% 
reduction of STAT5 phosphorylation at 25 µM (Figure 3.36b) with no change in the total 
STAT5 concentration. These findings indicate that the 16 exerts selective and potent 
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inhibitory effect towards dimerization of STAT5 but do not affect the total content expression 
of STAT5 protein which is extremely crucial to avoid off-target effect.  
 
 
Figure 3.36: STAT5 phosphorylation was reduced upon compound 16 treatment. (a) 16 
blocks tyrosine phosphorylation of STAT5 in a dose dependent manner as shown by Western 
blot analysis in BaF3/FLT3-ITD cells after 6 h treatment. (b) Relative STAT5 
phosphorylation levels were plotted as after quantification using Image J
130
 software. 
Experiments were repeated twice; errors bars represent SD. Immunoblotting for beta-actin 
was used as a control for uniform protein loading. 
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Figure 3.37: Methyl ester (compound 18) acts as a prodrug and potentially cleaved by 
cellular esterase to liberate the active compound (compound 10). (a-b) Compound 18 is 2x 
more potent than compound 10 in inhibiting the proliferation of BaF3/FLT3-ITD cell after 48 
h as determined by the Alamar Blue assay. (c-d) Compound 18 decreases tyrosine 
phosphorylation of STAT5 in a dose dependent manner leading to inhibition of cell 
proliferation in BaF3/FLT3-ITD cells; on the other hand, the phosphorylation of STAT5 was 
mildly inhibited by 10 only with at concentration >100 µM. (e) Compound 18 reduced 
STAT5 phosphorylation steadily in a time course experiment served as a potential STAT5 
prodrug  inhibitor
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In contrast, the phosphorylation of STAT5 was inhibited by 10 only with an IC50 
value of >100 µM (Figure 3.37c). We suspected that the low cellular activity of 10 was 
hampered by low cellular uptake due to its high polarity. This suspicion was substantiated by 
the higher activity of ester derivative 18, which might act as prodrug being activated by 
intracellular esterases.
56,71,135
 A time course experiment indeed showed that compound 18 
reduced STAT5 phosphorylation steadily over 10 h (Figure 3.37e). Both compounds 16 and 
18 had no effect on the overall expression of endogenous STAT5 and STAT3 (Figure 3.37c-d 
and 3.38a-b). To further determine the selectivity of 16 for STAT5, we tested for off-target 
kinase activity, a possible alternative target for an effector of STAT5 phosphorylation. 16 and 
18 showed negligible effects against FLT3 kinase, an upstream STAT5 activating kinase as 
well as homologous STAT3. These data suggest that inhibition of pSTAT5 is due to 
interaction with STAT5′s SH2 domain and not through inhibition of upstream kinases (Figure 
3.38). These in vitro functional assays also proven the selectivity and specificity of 
compound 16 in binding to STAT5b which requires three dimensional conformation that can 
interact effectively with STAT5b-SH2 domain. 
 
 
Figure 3.38: Compound 16 (a) and 18 (b) specifically inhibit phosphorylation of STAT5 but 
exhibit no affect on phosphorylation and endogenous expression of STAT3.  
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To further investigate selectivity of compound 16 and 18, MDA-MB-231 breast 
cancer cells which harbor high pSTAT3 and negligible pSTAT5 activity, were assessed for 
differential pSTAT inhibition by 50 μM (Figure 3.39). Encouragingly, pSTAT3 was not 
inhibited at doses corresponding to pSTAT5 inhibition within the leukemic cell line and total 
STAT3 were also not affected. It was shown that both compounds exhibit negligible 
cytotoxicity in MDA-MB-231 than in the high pSTAT5 leukemic cell line.
58
 This suggest 
that compound 16 target STAT5 selectivity without interfering with other crucial proteins in 




Figure 3.39: Compounds 16 and 18 show no effect on pSTAT3 in MDA-MB-231 cells, 
which rely heavily on pSTAT3 but not pSTAT5 activity for cell proliferation. 
Encouraged by the ability of 16 to significantly block STAT5 DNA-binding, we next 
investigated whether 16 could antagonize STAT5-driven transcriptional activity in living 
cells. BaF3/FLT3-ITD cells transfected with a dual firefly/Renilla luciferase system were 
treated with 16 for 6 h and the activity of the STAT5-transcribed luciferase reporter gene was 
found to reduce significantly in a dose-dependent manner (Figure 3.40b). The results revealed 
that 16 attenuated STAT5b-directed transcription in a dose-dependent fashion, with an 
IC50 value of ca. 50 μM. By attenuating STAT5 dimerization, 16 blocked the ability of 
pSTAT to activate the luciferase reporter construct
136,137
, thus effectively blocks subsequent 
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events associated with STAT5 activity including nuclear translocation and transcriptional 
activity. These results also indicate that 16 could inhibit STAT5b-directed transcription in 
living cells, and is consistent with its effects on the STAT5-DNA interaction as described 
above. 
. Inhibition of the endogenous transcription of STAT5 target genes by 16 and 18 was 
studied, too. BaF3/FLT3-ITD cells were treated with inhibitors for 6 h, mRNA was harvested 
and analyzed by quantitative RT-PCR. Transcription and protein expression of three target 
genes of STAT5, Pim1 kinase, Bcl-xl, and Cis, which play essential roles in cell cycle 
progression and survival, was found to be strongly reduced (Figure 3.40c).The effect of 
STAT5 inhibitors 10, 16, and 18 on the proliferation of cancer cells carrying the common 
FLT3-ITD mutation after 48 h was quantified by the Alamar Blue assay (Figure 3.36c, Figure 
3.27a-b). All three compounds showed a clear dose-dependent inhibition of cell proliferation.  
For comparison, the compounds were tested with four non-STAT5-dependent cell 
lines (HT-29, COS-7, HeLa and MDA-MB-231) and the cytotoxicity was negligible at up to 
500 µM (Figure 3.41). This experiment ensures minimal off-target effect and determines the 
therapeutic window of 16. Most encouragingly, the compounds also showed no effects on 
STAT3 phosphorylation and on endogenous STAT3 expression (Figure 3.39).
58
  
The percentage of necrotic vs. apoptotic cells death after treatment with 16 was 
studied by flow cytometry staining with a fluorescent annexin-V conjugate and with 
propidium iodide (PI), likewise reduced STAT5 phosphorylation was studied using a 
fluorophor-conjugated anti-pSTAT5 antibody (PE-Cy7 Mouse anti-STAT5, pY694, Figure 
3.40a). 
Downstream of STAT5 namely Pim1 kinase, Bcl-xl, and Cyclin D1 were further 
assessed for modulation of the STAT5 transcriptional targets at protein level upon treatment 
with 16 using immunoblotting (Figure3.42). We reasoned that 16 and 18 should decrease 
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gene expression and induce apoptosis by 24 h. BaF3/ FLT3-ITD were dosed with 16 and 18 
at the same serial concentrations (12.5-200) μM respectively for selective STAT5 inhibition. 
At 6 h, we observed dose-dependent decreases in the protein expression of downstream 
targets which correlates with the gene expression pattern evaluated in the RT-PCR 




Figure 3.40: Activity and functional effects of STAT5 inhibitor 16 in STAT5-dependent 
cells. (a) (i) BaF3/FLT3-ITD cells were treated with compound 16 after which annexin 
V/propidium iodide staining and flow cytometry were performed; (ii) Intracellular levels of 
phosphorylated STAT5 were evaluated by flow cytometry after 6 h exposure of cells to 
compound 16 for 50 µM. (b) Compound 16 inhibits transcriptional activity of STAT5 in 
BaF3/FLT3-ITD cells as measured by normalized Fluc/Rluc ratio in dual luciferase reporter 
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assay. (c) Expression of downstream targets of STAT5 Pim 1, BcL-xL and Cis was reduced 




Figure 3.41: (a-d) Compounds 16 and 18 show no cytotoxicity in STAT5-independent cancer 
cell lines MDA-MB-231 (human breast cancer), monkey fibroblasts (COS-7), HT29 (human 
colon adenocarcinoma) and HeLa (human cervix carcinoma). 
 
 




Figure 3.42: Cellular treatment with 16 (a) and 18 (b) impair the expression of its 
downstream target genes. 
 
Target specificity of compound 16 to STAT5 in living cells was evaluated using 
isothermal dose-response fingerprints (ITDRF), a variation of CETSA
127,138,139
 experiments. 
BaF3/FLT3-ITD cells were treated with 16 at concentrations between 0 to 100 µM for 6 h. 
All samples were heated for 3 min to 60 ºC, the denaturation temperature based on the Tm 
curves in the CETSA experiment (Figure 3.25), lyzed and immunoblotted with STAT5a/b 
antibodies. The amount of STAT5 protein found in the blot was plotted against logarithmic 
concentration of the inhibitor, indicating the in-cell occupancy (OC50) of STAT5a/b of 63 and 
28 µM, respectively, correlating well with the inhibition of target phosphorylation and cell 








Figure 3.43: (a-b) In cell occupancy of STAT5a and STAT5b by compound 16 in 
BaF3/FLT3-ITD, determined using ITDRF. ITDRF of compound 16 on STAT5a and 
STAT5b denaturization at 60 ºC for 3 min based on raw data from Western blotting 
chemiluminescence readings. CETSA, cellular thermal shift assay; ITDRF, isothermal dose-
response fingerprint; OC50, the concentration at which 50% of the STAT5 in the cell was 
occupied by inhibitor. 
 
We further evaluated 16 in K562 cell to determine STAT5 phosphoreduction and the 
therapeutic window. The pSTAT5 expression was examined using flow cytometry after 
staining cells with a fluorophore-conjugated anti-pSTAT antibody (Phosflow™ PE-Cy™7 
mouse anti-Stat5 (pY694) upon treatment with 16; whereas cell cycle effect was determined 
using propidium iodide (PI) and annexin V staining. As shown in Figure 3.44a, K562 cells 
treated with compound 16 show an increase in both necrotic and apoptotic cells compared to 
the untreated control group. Most encouragingly, there existed promising inhibition potency 
in cell viability and pSTAT5 inhibition at 50 µM Intracellular levels of phosphorylated 
STAT5 (pSTAT5) were evaluated by flow cytometry after 6 h exposure of cells to compound 
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16 at a serial concentration 16 (Figure 3.44). At the same concentration, 16 is able to induce 
almost 50% apoptotic rate in K562 cell population. Phospho-flow
140
 evaluates the 
intracellular levels of phosphorylated STAT5 (pSTAT5) after 6 h exposure of cells to 
compound 16 at a serial concentration. The median fluorescence value of K562 stained with 
anti-pSTAT5 after 6 h exposure to compound 16 at 100 µM has successfully reduced 80% of 
pSTAT5 activity thus revealed inhibitory activities on pSTAT5 in both CML and AML cell 
lines. 
To obtain insight into the consequences of STAT5 inhibition in MV-411 cells 
(human FLT-ITD
+
 AML). We then treated MV-411 cells with compound 16 after which 
annexin V/propidium iodide staining and flow cytometry were performed. Undoubtedly, 
compound 16 inhibits the proliferation of K562 cells after 48 h as shown in the Alamar Blue 
assay.
58
   Nevertheless, compound 16 blocks tyrosine phosphorylation of STAT5 in a dose 
dependent manner as shown by Western blot analysis (Figure 3.45c) in MV-411 cells after 6 
h treatment. Interestingly, 16, led to a significant increase in apoptosis in a dose-dependent 
manner in similar pattern as other STAT5 driven cell lines (Figure 3.45).  Compound 16 
portrays high potential in targeting STAT5 protein selectively in leukemic cell lines. 
In summary, we have identified the first binding inhibitor of STAT5 protein via 
protein induced Mannich ligation. Moreover, lead compound 16 has been shown to potently 
and selectively disrupt STAT5-phosphopeptide interactions as compared to STAT3. With no 
off-target kinase activity, 16 was shown to suppress pSTAT5 thereafter reduce leukemic cell 
viability.  
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Figure 3.44: Inhibitory effects of STAT5 inhibitor 16 in K562 cells, human derived chronic 
myeloid leukemia (CML) cell lines. (a) K562 cells were treated with compound 16 after 
which annexin V/propidium iodide staining and flow cytometry were performed. (b) 
Compound 16 inhibits the proliferation of K562 cells after 48 h as determined by the Alamar 
Blue assay. (c) Intracellular levels of phosphorylated STAT5 (pSTAT5) were evaluated by 
flow cytometry after 6 h exposure of cells to compound 16 at a serial concentration. (d) 
Compound 16 blocks tyrosine phosphorylation of STAT5 in a dose dependent manner as 
shown by Western blot analysis in K562 cells after 6 h treatment. Experiments were repeated 
twice and immunoblotting for beta-actin was used as a control for uniform protein loading. 




Figure 3.45: Inhibitory effects of STAT5 inhibitor 16 in MV-411 cells. (a) MV-411 cells 
were treated with compound 16 after which annexin V/propidium iodide staining and flow 
cytometry were performed. (b) Compound 16 inhibits the proliferation of K562 cells after 48 
h as determined by the Alamar Blue assay. (c) Compound 16 blocks tyrosine phosphorylation 
of STAT5 in a dose dependent manner as shown by Western blot analysis in MV-411 cells 
after 6 h treatment. Experiments were repeated twice and immunoblotting for beta-actin was 
used as a control for uniform protein loading. 
 




Figure 3.46: Stat5a/b knockdown in K562 cells indicate that cellular effect are primarily due 
to loss of Stat5a/b activity and not to off-target effects of compound 16. (a) K562 cells were 
transfected with control siRNA (control siRNA-A, sc-37007, Santa Cruz, CA) or siRNA 
directed against STAT5 (sc-29495, Santa Cruz Biotechnology, Santa Cruz, CA) as indicated. 
Protein knockdown was confirmed by western blotting using antibodies against STAT5. β-
Actin served as loading control. (b) Western blot analyses of STAT5 protein in K562 cells 
treated with compound 16 and/or STAT5 siRNA. (c) The effect of compound 16 on K562 
cell viability was tested after genetic knockdown of STAT5. Cells were first transfected with 
STAT5 siRNA or control siRNA and incubated for 24 h before treated with compound 16 (50 
µM) or DMSO for 48 h. Viable cells was distinguished using an ATP-dependent 
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3.7 STAT5 knockdown elucidates target specificity of compound 16. 
Previous study has shown that overexpression of constitutively active STAT5 can 
rescue leukemic cells from cell death induced by a specific STAT5 inhibitor. We have 
instead used the genetic knockdown with siRNA to deplete endogenously expressed STAT5 
and to verify thereby the selectivity of our inhibitors toward STAT5.To test out the 
hypothesis whether the reduction in K562 cell viability was mainly due to STAT5 inhibition 
by 16, we assessed the effect of STAT5 knockdown on K562 cell viability. Indeed, genetic 
knockdown of STAT5 by STAT5-siRNA in the STAT5-driven leukemic cell line K562 
depleted STAT5 expression in comparison to control siRNA, which had no effect (Figure 
3.46a). As expected, compound 16 did not affect STAT5 expression, neither in the case of 
STAT5-siRNA nor in that of control siRNA treatment (Figure 3.46b-c). Cell viability was 
reduced by >50% when K562 cells were treated with inhibitor 16 and control siRNA, while 
there was no effect on viability with only control siRNA (Figure 3.46a). On the contrary, 
STAT5-siRNA reduced viability by ca. 80% without any additional effect of compound 16. 
These results strongly suggest that the effect of compound 16 on cell viability is exerted by 




3.8 Drug combination studies using Chou-Talalay method.  
 Drug combination studies are widely applied in cancer and auto-immunodeficiency 
diseases (AIDS). The main objectives of drug combination are to achieve synergistic 
therapeutic effect in order to reduce dose and toxicity and also delay the development of drug 
resistance. 
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Synergism created between different therapeutic drugs minimizes toxicity as well as side 
effect as lower drug concentration could be administered to achieve similar therapeutic effect.   
The Chou-Talalay method for drug combination is based on the median-effect 
equation and also encompasses general equation including the Michaelis- Menten, Hill, 
Henderson-Hasselbalch, and Scatchard equations which have been widely applied in 
biochemistry and biophysics. Chou and his professor, Talalay introduced a scientific term 
“combination index (CI) to quantitatively defined synergism (CI <1), additive effect (CI=1) 
and antagonism (CI>1) in drug combinations. This theory was further applied to provides 
algorithms for automated computer simulations for both synergism and antagonism at 
respective dose level and can be illustrated as CI plot and isobologram, respectively.
141
  
 A few points are worthwhile to take note while carrying out synergistic studies in 
vitro. Firstly, dose range and dose density has to be determined several data points above IC50 
and several below IC50 as this increase the accuracy of the assay. Secondly, constant-ratio 
drug combinations are a pre-requisite for generating Fa-CI plot (Chou-Talalay plot), Fa-DRI 
plot (dose-reduction index plot) and the class isobologram.   In non-constant ratio design, no 
“computer simulated” CI plot will be generated and rather substitute with a conservative, 
normalized isobologram.
142
    
 
3.9 Combination studies of Peroxygenin and Temozolomide in both B and T cells. 
 Molecular mechanism of conventional chemotherapeutic drugs is often associated 
with oxidative DNA damage giving rise to cell death executed by apoptosis and necrosis.  
Inevitably, compounds that induce oxidative DNA stress will trigger DNA damage response, 
eventually lead to tumor cell death. Here, we apply an in house substance, Peroxygenin that 
give rise to reactive oxygen species (ROS) which may lead to oxidative DNA damage and 
cytotoxic activity in cancer cells.
143,144
 On the other hand, Temozolomide (TMZ) is a gold 
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standard in glioblastoma treatment and acts as an oral alkylating agent since 1987.  
Surprisingly, molecular mechanism of TMZ involved DNA interference forming cytotoxic 
methylguanine and methyladenine which are cytotoxic.
145
  In addition, these mismatched 
lethal base pairs result in DNA breakage inducing cell cycle arrest at G2/M phase causing 
apoptosis and necrosis. On the downside, TMZ is treated at high dose (up to 400 µM) in 
glioblastoma patient and leads to undesirable side effect, thus it is worth to carry out drug 
combination studies to seek possible synergism with peroxygenin.  
 
Figure 3.47: Chemical structures of Peroxygenin and Temozolomide. 
 We carried out the drug combination studies in two different namely BaF3/FLT3: ITD 
and Jurkat T cell. Treatment with TMZ alone in both cell lines required high working 
concentration ranging from 400-800 µM). The combination of Peroxygenine (IC50 = 0.5 µM) 
and TMZ reduced the IC50 from 300 µM to 113 µM in Jurkat T cell whereas in BaF3 FLT3: 
ITD cells the IC50 reduced from 725 to 478 µM (Figure 3.48-3.51). However, this drug 
combination does not confidently demonstrate synergistic effect in Chou-Talalay 
combination index (CI). At certain drug combination ratio, antagonism effects were observed 
in both cell lines.  
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3.10 Synergistic effect of 16 and PKC412 on STAT5 inhibition in leukemic cell lines. 
The synergistic effect of STAT5 inhibitor 16 with the staurosporine-derived FLT3-
inhibitor PKC412 was investigated.
146,147
 STAT5 is a transcription factor that critically 
contributing to the transforming effects of FLT3-ITD and previous studies have shown that 
FLT3 ligand and mutated FLT3 (internal tandem duplication) enhance STAT5 
overactivation. PKC412 is a staurosporine-derived, potent inhibitor of the kinase domain of 
the receptor tyrosine kinase FLT3, which is responsible for the phosphorylation and over-
activation of STAT5 leading to cellular hyperproliferation in those cases of AML carrying 
the FLT3-ITD mutation. Therefore, the combinatorial targeting of STAT5 and FLT3 with 
both a STAT5 and an FLT3 inhibitor should be a valuable strategy for AML treatment in 
these cells. To test this hypothesis, we investigated the functional synergism of the two 
inhibitors PKC412 and compound 16 acting on the two targets, FLT3 and STAT5, within the 
same signal transduction pathway. Therefore, combination treatment of leukemic cells with 
two inhibitors targeting the same signal transduction pathway (FLT3-ITD-STAT5 signaling) 
can be a promising strategy to overcome or prevent resistance toward kinase inhibitors.  
PKC412, a staurosporine-derived potent inhibitor of the kinase FLT3 exhibits 
therapeutic effect on AML patients bearing the FLT3 mutation. Treatment with PKC412 
alone, however, often leads to major drawbacks such as incomplete target inhibition and 
short-lived responses. Here, we explored the synergistic possibility of targetting the FLT3 
and its downstream mediator, STAT5 to deliver drug combinatorial approach for improved 
treatment efficacy
134,146
 and better patient outcomes. MV-411 leukemic cells were treated 
with concentrations of inhibitors resulting in 20% of cell apoptosis individually as well as in 
combination. The combination of 16 and PKC412 resulted in a 3-fold increase in annexin-V-
staining corresponding to 60% apoptotic cells, in decreased reporter gene expression, and in 
reduced STAT5 phosphorylation (Figure 3.52b). Our experiments revealed the synergistic 
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inhibition of STAT5 phosphorylation and the induction of apoptosis at significantly lower 
doses of the two inhibitors (IC20) when compared to the use of the single substances. (Figure 
3.52a) Both compounds impaired synergistically the cell proliferation after 48 h of treatment 
as demonstrated by a Chou-Talalay
141
 combination index (CI) plot (Figure 3.52c). For 
example, the IC50 of compound 16 reduced 3-fold in the presence of 1.25 nM (IC10) of 
PKC412. (Figure 3.52c) 
 
 
Figure 3.48: Synergistic effect of drug combination using Peroxygenine and Temozolomide 
in Jurkat E6.1 cells. Effect of drug treatment using Peroxygenine (a) and Temozolomide (b) 
alone and in combination (c) on Jurkat E6.1 cell viability as shown by Alamar blue assays. 
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Figure 3.49: Combination index (CI) plot showing the synergistic effect of Peroxygenine and 
Temozolomide in Jurkat E6.1 cells. (a) CI values were generated using CalcuSyn software 
(Conservion, Ferguson, MO) and plotted as a function of fractional growth inhibition (Fa) 
where Fa = (A570 control − A570 treated)/A570control. CI values of < 1, =1, and >1 indicate 
synergism, additivity and antagonism, respectively (b) Analysis of the synergistic effect of 
the combination of Peroxigenine and Temozolomide in Jurkat E6.1 cells The calculated EC90 
values for the combination were plotted as the fractional concentration (Fc) of Peroxygenine 
and Temozolomide on the x and y axes. 
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Figure 3.50: Synergistic effect of drug combination using Peroxigenine and Temozolomide 
in BaF3/FLT3-ITD cells. Effect of drug treatment using Peroxygenine (a) and Temozolomide 








Figure 3.51: Combination index (CI) plot showing the synergistic effect of Peroxygenine and 
Temozolomide in BaF3/FLT3-ITD cells. (a) CI values were generated using CalcuSyn 
software (Conservion, Ferguson, MO) and plotted as a function of fractional growth 
inhibition (Fa) where Fa = (A570 control − A570 treated)/A570control. CI values of < 1, =1, and 
>1 indicate synergism, additivity and antagonism, respectively (b) Analysis of the synergistic 
effect of the combination of Peroxygenine and Temozolomide in BaF3/FLT3-ITD cells. The 
calculated EC90 values for the combination were plotted as the fractional concentration (Fc) 
of Peroxygenine and Temozolomide on the x and y axes. 
 




Figure 3.52: Synergy of STAT5 inhibitor 16 with kinase inhibitor midostaurin (PKC412) in MV-411 cells; dose-finding study and activity in a murine 
cancer model. (a) MV-411 cells were treated with PKC412 (10 nM) or compound 16 (10 µM) alone or in combination and incubated for 24 h followed by 
annexin V/ propidium iodide staining and flow cytometry. Apoptosis was quantitated for three independent experiments. (b) Cell viability assays were 
carried out by treating MV-411 cells with compound 16 (10 µM) and PKC412 (10 nM) alone or in combination. The number of viable cells was 
distinguished using an ATP-dependent bioluminescence assay (CellTiter-Glo, Promega). (c) Effect of drug combination (16and PKC412) on cell viability 
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Figure 3.53: (a) MV-4-11 cells were treated with 16 or PKC412 alone or in combination and 
incubated for 6 h and immunobloted with pSTAT5 to study synergistic effect of both 
compounds on STAT5 phosphorylation reduction. (b) Relative STAT5 phosphorylation levels 
were plotted based on the raw data from Western blotting chemiluminescence readings to 
study the synergistic effect of both compounds on STAT5 phosphorylation reduction. MV-
411 cells were treated with compound 16 or PKC412 alone or in combination and incubated 
for 6 h. (c) Analysis of the synergistic effect of the combination of 16 with PKC412. The 
calculated EC90 values for the combination were plotted as the fractional concentration (Fc) 
of 16 and PKC412 on the x and y axes. (d) Combination index (CI) plot showing the 
synergistic effect of compound 16 and PKC412 in MV-411 cells. CI values were generated 
using CalcuSyn software (Conservion, Ferguson, MO) and plotted as a function of fractional 
- 118 - 
 
growth inhibition (Fa) where Fa = (A570 control − A570 treated)/A570control. CI values of < 1, 
=1, and >1 indicate synergism, additivity and antagonism, respectively.  
 
Figure 3.54: Dose-finding study and activity in a murine cancer model. (a) The corresponding 
body weight changes in non-xenografted mice during compound 16 treatments. (b) 
Compound 16 significantly inhibits tumor growth in BaF3/FLT3-ITD xenograft tumor model. 
Time course of tumor growth suppressed by compound 16 (200 mg/kg) in mice bearing 
BaF3/FLT3-ITD tumor.(c) Significant reduction in tumor volume was observed in compound 
16- treated groups, compared with vehicle treated group. Tumor volume change in 
BaF3/FLT3-ITD xenografts treated with 16 (200mg/kg) and vehicle respectively. (d) Treated 
group shows reduction in activated STAT5 and has lower STAT5-DNA binding activity in 
the nuclear extract from tumor schock compared to non treated vehicle group.  
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Finally, the inhibitory effect of 16 was examined in a murine xenograft model of 
leukemia. Treatment of nude mice with 16 was tolerated well and had no significant effect on 
mice body weight (Figure 4.42a). Nude mice were inoculated subcutaneously with 
BaF3/FLT3-ITD cells. The control group displayed rapid tumor growth, while tumor growth 
in the group treated s.c. with compound 16 (200 mg/kg) was delayed and became first 
apparent on day 11 (Figure 4.42b). Tumor growth in the treated group was reduced to 6% T/C 
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In this contribution, protein-induced Mannich ligations have been discovered and 
characterized as protein-catalyzed, non-enzymatic reactions following a fundamental 
mechanism for the formation and identification of protein ligands. The reactions delivered 
potent, specific and cellularly active inhibitors of the transcription factor STAT5. The starting 
point, phosphate-mimetic fragment 3 was activated by the protein STAT5b-SH2 enabling 
three-component reactions with FA and various 1H-tetrazoles in aqueous physiological buffer 
yielding low-micromolar and sub-micromolar inhibitors of the protein-protein-interaction site. 
The progress of the observed Mannich ligations depended on the pH of the solution and on 
the presence of the protein. At pH 7.4 the reaction occurred only in the presence of the 
protein, while at pH 5.0 it was switched to an entirely protein-independent reaction. Protein-
induced reactions were analyzed using FP and TS assays; products formed were quantified by 
HPLC-MS and protein-induced product was saturated at 432 nM (average of 3 independent 
experiments) with 250 nM protein. Product saturation is typical for protein-dependent 
reactions and resulted from auto-inhibition by the products formed. The reaction was also 
inhibited competitively by alternative ligands of the SH2 domain confirming that the 
phosphotyrosine recognition site constituted the catalytic center. 
Remarkably, all initial 1H-tetrazole fragments like compound 25 did not bind to the 
STAT5b-SH2 protein at all (KI > 10 mM) while for example the ligation product of 3, FA, 
and 25, namely 5-tetrazolyl-1-methylamino-furazane-3-carboxylate 10, displayed super-
additive binding with an affinity of 1.4 µM and the enhanced ligand efficiency of 2.23 kJ mol
-
1
 per non-hydrogen atom. These findings excluded the mechanism of a protein-templated 
reaction, which requires the binding of both fragments to the protein template in order to 
initiate the reaction. Instead, an alternative mechanism of protein-dependent reactions was 
observed, in which only one of the starting molecules, here fragment 3, binds to the protein. 
Molecular modeling suggested that H-bonding by the side chain amide of Asn642 induced the 
reaction of fragment 3 with FA, that of the intermediary formiminium ion with tetrazoles, and 
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the high selectivity of the reactions.
117
 This hypothesis was challenged by investigating the 
protein-dependent reaction of 3, FA, and 1H-tetrazole with the phosphotyrosine binding site 
of STAT3-SH2, which is structurally closely related containing Arg618 and Ser622 but lacks 
Asn642. Indeed STAT3-SH2 did not catalyze the Mannich ligation reaction and no product 
was identified in HPLC-MS. In agreement with this result, STAT3, STAT1, and the protein 
tyrosine phosphatase SHP2, all lacking the Asn-residue in the phosphotyrosine recognition 
sites, did not bind the STAT5-inhibitors 10 and 16, although cross-reactivity has been 
reported for other STAT-inhibitors.
148,149
 The importance of Asn642 was further confirmed by 
the mutant STAT5b N642A, which was generated by site-directed mutagenesis. The mutant 
protein displayed strongly reduced binding affinity to peptide 1 and to inhibitor 10 and did not 
catalyze a Mannich ligation reaction as shown for the wild-type protein. In conclusion, the 
observed protein-dependent reaction constitutes indeed a protein-induced reaction in which 
the protein catalytically activates the bound fragment 3 by specific binding interactions 
without templating the reacting fragments priorly.  
Specificity of the formed inhibitors for STAT5 was also confirmed in complex cellular 
systems. Binding of inhibitors 10 and 16 to STAT5a,b in cell lysates was determined by 
cellular thermal shift experiments (CETSA). This experiment was carried out by incubating 
cell lysates with 10 and 16 for 1 hr respectively, the compound-lysate mixtures were then 
aliquoted and heated at temperatures ranging from 43-73 ºC. The melting temperature of 
STAT5 shown an obvious shift, indicating both compounds exert thermal stabilization on 
STAT5 protein in complex cell lysates. The high selectivity of the protein-ligand interaction 
was demonstrated by the fact that inhibitor 10 in cell lysates suppressed photocrosslinking of 
the biotinylated STAT5 ligand 27 with STAT5 but not with other proteins. In addition, the 
selectivity of compound 16 in living cells was proven by isothermal dose-response 
fingerprints (ITDRF). It was found that 50% of the target proteins STAT5a and b were 
occupied in living cells with 16 at concentrations (OC50 values) being in the same range as the 
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IC50 values observed for the inhibition of STAT5 phosphorylation and cell proliferation, 
indicating that the interaction of 16 with the target STAT5 alone was sufficient to generate 
and explain the observed biological effects. Likewise, compound 16 was able to block STAT5 
transcription and to inhibit cellular proliferation of cancer cells in a mouse model. Another 
proof for the cellular selectivity of 16 for STAT5 was that the proliferation of all tested cell 
lines which proliferate independently from STAT5 activation was not inhibited by 16 and 
these cells showed no sign of toxicity. 
Our work demonstrates the growing power of protein-dependent fragment ligations in 
fragment based drug discovery. Protein-induced multicomponent reactions such as Mannich 
ligations enlarge the chemical diversity of protein ligands accessible by the method 
considerably. Protein-induced fragment ligations seem to be especially advantageous for the 
formation of potent and specific ligands as molecular interactions responsible for binding 
catalyze the ligation reaction. Considering the omnipresence of formaldehyde in living cells 
and the versatility of reactions this and other aldehydes can undergo, the mechanism should 
find broad application on numerous protein targets and many bioactive fragments should be 
expandable to chemically diverse and potent protein ligands, possibly even in living 
cells.
149,150
 Thus, protein-induced reactions seem to constitute an additional, non-enzymatic 
mechanism exerted by proteins enabling the molecular evolution of ligands and modulating 
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STAT5 activation is often associated with leukemia initiation and maintenance, 
qualifying it as a promising therapeutic target for blood cancer treatment and also tackling the 
rising rate of secondary resistance. Priorly, this thesis explored the therapeutic potential of 
STAT5 by assembling potent inhibitors via protein-induced Mannich Ligation which provides 
an additional avenue for protein templated ligand formation. In these studies, STAT5 protein 
was employed as target protein and served as the template that catalyzes three component 
reactions of a highly potential phosphate mimetic, 3, formaldehyde, and 1H-tetrazoles to 
generate ligands with binding affinity for the protein. The above-mentioned Mannich ligation 
are proven to be very specifically catalyzed by STAT5 active site and can be carried out in 
physiological condition; no product was formed and detected when the same reactions were 
carried out with closely related protein such as STAT3, mutated STAT5N642A , SHP2 and 
PTP1B. Nonetheless, we also include proper control namely bovine serum albumin (BSA) 
and isolation tag, maltose binding protein (MBP) to test the reaction feasibility. As predicted, 
no product was detected validating the protein induced Mannich ligation is target selective 
and specific.  
 The reaction product, 10 that binds and serves to inhibit STAT5 activity was detected 
in mass spectrometry, fluorescence polarization assay and thermal shift assay. Molecular 
modelling and docking was carried out to study structure-activity relationship and the key 
binding residues involved in protein-ligand binding. Based on the molecular docking results, 
we deduced residue Asn642 plays an important role in initiating the fragment 3 binding at the 
STAT5 active site in protein-induced Mannich ligation. To prove our hypothesis, we have 
prepared the mutant STAT5N642A by site directed mutagenesis and confirmed the sequence of 
the mutant gene construct. Coherently, the mutant protein shown to bind to compound 16 with 
reduced affinity (30 µM) while the protein induced Mannich ligation reactions with fragment 
3, formaldehyde and 1H-tetrazol conduced at physiological condition in the presence of 
STAT5 protein yield no products. These finding support our hypothesis on the functional 
- 126 - 
 
relevance of the residue Asn642 in initiating the Mannich ligation reaction via prior binding 
of fragment 3 and latter the binding of the formed inhibitors.  
By studying the binding pocket of STAT5-SH2 domain, we designed compound 16 
from ligation product 10 for better cellular permeability thus higher cellular potency. As 
planned, the poor physiochemical properties of compound 10 is well tackled as compound 16 
portrayed 10 fold higher in cellular efficacy. We then proceed to characterize the activities 
and the properties of both of the leading compounds in regard to the STAT5 inhibition using 
functional biochemical assays. Firstly, we employed BaF3/FLT3: ITD as cellular model to 
test out the in cellulo efficacy of the compounds in a mimicked acute myeloid leukemia model. 
Compound 16 reduced STAT5 phosphorylation and disrupts STAT2: DNA binding, 
significantly affect cell survival and proliferation. Consequently, the expression of STAT5 
downstream target was drastically reduced upon STAT5 inhibition by compound 16 as shown 
in both RT-PCR and luciferase reporter assay experiments.  
Furthermore, we also examined the drug selectivity and specificity of both compound 
10 and 16 in complex cell lysates by recruiting dual labelled peptide, 27 for photo-cross 
linking experiment. To our surprise, both compounds competitively displaced peptide 27 
leading to lower STAT5 yield in the eluent of Neutravidin pull down assays. This strongly 
indicates that these compounds selectively bind to STAT5 even in complex cellular 
environment which further supports and validates our observation in the functional 
biochemical assay. Nonetheless, we also proved the binding of the inhibitors to STAT5 
protein in whole cell lysates using cellular thermal shift assays (CETSA). CETSA indicated 
that the binding of inhibitors to STAT5 still occur in the lysates, suggesting that there was no 
significant competition presence for the ligand by other proteins. On the same page, the 
photo-cross linking of peptide 27 with STAT5 but not other proteins was inhibited by 
compound 10.  
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Besides that, the selectivity of STAT5 inhibitors was investigated in living cells using 
isothermal dose response finger prints (ITDRF). The cellular occupancy of STAT5a protein 
(OC50= 25 µM) in cells was comparable and close to the observed IC50 of cellular 
proliferation assay (28 µM), thus indicating our inhibitors are STAT5 specific and no other 
nonspecific binding is responsible for the observed phenotype. To exclude any off-target 
effect, we carried out siRNA experiment and the results suggested that the effect of inhibitors 
on cell viability is solely due to STAT5 inhibition. We also examined the effect of both 
compounds in cell lines known to be driven by STAT5, including K562 (human CML cell 
line) and MV-4-11 (human AML cell line) and observed reduction in cell proliferation and 
increase in apoptotic cells. On the other hand, our inhibitors do not exhibit cytotoxicity 
towards normal epithelial cell and other types of cancers that are not driven by STAT5.   
 As we have observed STAT inhibition in animal cell lines with constitutively active 
STAT5, i.e. BaF3/FLT3: ITD, K562 and MV-411, we conclude that compound 16 inhibits 
STAT5 not only in mouse model (BaF3/ FLT3: ITD) but also human leukemic cell lines 
(MV-411 and K562) that are known to be driven by constitutively active STAT5. This 
positive finding has encouraged us to proceed with treating xenograft mouse model with 
compound 16.  We have observed slower tumor growth in mice group treated with compound 
16 (200mg/kg). Tumor growth in the treated group was reduced to 28% confirming that 
compound 16 is equally potent in vivo and exhibit desired anti tumor efficacy. 
 Given that drug combination is an alternative to achieve synergistic therapeutic effect 
for dose and toxicity reduction as well as minimize drug resistancy. We intended to apply 
combination studies of compound 16 with a known FLT3 inhibitor, PKC412.  Briefly, 
PKC412 is a staurosporine, derived potent inhibitor of receptor tyrosine kinase FLT3, which 
is responsible for the phosphorylation and over-activation of STAT5 leading to cellular 
hyperproliferation in those cases of AML carrying FLT3-ITD mutation. We deduced that by 
combinatorial targeting both STAT3 and its upstream, FLT3 with a STAT5 inhibitor and an 
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FLT3 inhibitor could be a valuable strategy for AML treatment. We tested out our hypothesis 
by investigating the functional synergism of the two inhibitors PKC412 and compound 17 
acting on the two targets, FLT3 and STAT5 with the same signal transduction pathway. Our 
findings revealed synergistic inhibition of STAT5 phosphorylation and the induction of 
apoptosis at significantly lower doses of the two inhibitors (IC20) when compared to the use of 
the single substances. Current findings provide alternative in applying lower dose of STAT5 
specific inhibitor, compound 16 but still able to achieve desired effect in leukemic cell lines. 
Drug toxicity and resistancy can be avoided as an outcome of synergism.  
 Our studies have illustrated the development of specific STAT5 inhibitor via protein-
induced Mannich ligation. We have also employed different biophysical and biochemical 
assay to characterize the effect and activities of our inhibitors in vitro using leukemic cellular 
model as well as in vivo using xenograft mouse model. We have also examined the selectivity 
and specificity of our inhibitors using photo cross linking experiment and their synergism 
with receptor tyrosine kinase inhibitor, PKC412 has been well examined.  Most interestingly, 
we have revealed the residues Asn642 plays vital role in initiating the protein templated 
reaction as well as protein-ligand binding. The importance of the residues Asn642 was then 
proven using site directed mutagenesis.  
 Undeniably, the reaction condition of protein induced mannich ligation mimics the 
physiological conditions in living cells. Experiments have been conducted with increasing 
concentration of formaldehyde finding that a concentration of 250 µM yielded optimal results 
of the ligation reactions without affecting the protein and the protein assays. This 
concentration of formaldehyde is in fact a physiologically relevant concentration, increasing 
the feasibility of reaction in mammalian cells. This intriguing observation serves as a platform 
to study the possibility in cellulo assembly of potent ligand.  
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6.1 Fluorescence Polarization assay and screening.   
Ca. 17000 compounds and fragments from the ChemBioNet library were tested in a 
fluorescence polarization (FP) assay to investigate their ability to bind to STAT5b-SH2 
domain by displacing the fluorophore-labeled peptide 5-carboxyfluorescein-
GY(PO3H2)LSLPPW-NH2 1. Purified compounds were tested in the same assay. The peptide 
purity was >95% and the assays were performed at room temperature. The final concentration 
of buffer components used was 10 mM HEPES (pH 7.5), 1 mM EDTA, 0.1% Igepal CA-630, 
50 mM NaCl, and 5% DMSO and the final concentration of protein used was at 125 nM. The 
protein was first added to the black 384-well plate (Corning 3676) followed by test 
compounds and fluorophore-labeled peptide. The plates were centrifuged, and measured using 
Safire
24
 well plate reader (Tecan, Crailsheim, Germany) after 15 min incubation at room 
temperature. For testing secondary site binding of primary hit fragments, the same assay was 
conducted in the presence of 4-formylphenyl phosphate 2 as described earlier. For specificity 
analysis, FP assay was conducted with 100 nM GST-tagged, full length human STAT3 
protein (SignalChem, Richmond, BC, Canada) and 10 nM fluorophore-labeled peptides (5-
carboxyfluorescein-GY (PO3H2) LPQTV-NH2). The assay buffer contains 50 mM NaCl, 10 
mM HEPES (pH 7.5), 1 mM EDTA, 0.01% Triton-X100 and 2 mM dithiothreitol). The test 
compounds were serially diluted and incubated with STAT3 protein at room temperature for 1 
h followed by 10 nM of fluorophore-labeled peptide. The mixture was centrifuged and 
incubated for 30 min at room temperature before FP was recorded using the MTP reader. For 
analysis of the data GraphPad Prism 5
129
 was used. Ligand efficiencies (LE) were calculated 
using the equation LE = -ΔGº/HA with ΔGº being the standard free energy of binding in kJM-
1
 and HA the number of heavy, non-hydrogen atoms. 
6.2 Detection of protein-induced ligand formation via FP assay.  
All FP assays were conducted in a total volume of 20 μl in 50mM of MOPS buffer (pH 7.4) at 
room temperature. For investigating the tolerance of the assay for FA, serial dilutions of 
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FA (concentration range: 0–1mM) were prepared and incubated with 250 nM of MBP-
STAT5b in buffer. For the protein-induced reaction, 250 nM of MBP-STAT5b protein were 
added to a mixture of 250 μM of 3 and one heteraryl nucleophile per microtiter plate well 
with increasing concentration of FA up to the concentration of 250 μM. Reaction mixtures 
were incubated for 12 h with mild shaking. Plates were centrifuged and 10 nM of FP probe 1 
were added and incubated for 1 h with mild shaking before measurement with Safire
24
 well 
plate reader (Tecan, Crailsheim, Germany). 
 
6.3 Detection of ligand formation via mass spectrometry 
Extracted ion chromatography was performed with reaction mixtures containing 250 nM of 
MBP-STAT5b protein, 250 µM (IC20) 4-amino-furazane-3-carboxylic acid 3, equimolar 
amount (250 µM) of one heteraryl nucleophile and FA with a total volume of 100 µl. The 
reaction mixtures were vortexed to mix thoroughly and incubated overnight at room 
temperature and was analyzed using a HPLC/QTOF-MS instrument by Agilent, consisting of 
an Infinity 1290 UHPLC coupled to a 6550 iFunnel QTOF. After 12 h each sample was 
analyzed in triplicate by injecting (10 μl) into the LC/MS instrument and the ligation products 
were identified by their molecular weights and by comparison of the retention times of 
synthetic reference. Calibration curve for hit compounds 9, 10 and 16 is given in Appendix 
Figure 10. Eluents were mixtures of water and acetonitrile (with 0.1% formic acid). Injection 
volume was set to 10 µL. Samples were eluted using gradient elution of started off with 97:3 
(water/acetonitrile) for 1 min followed by 95:5 to 5:95 over 5 min. Flow rate was set to 0.3 
ml/min. The QTOF is equipped with an electrospray ionisation-source used with the 
following parameters: negative ion mode, fragmentor voltage 175 V, capillary voltage 4000 
V, nozzle voltage 1000 V, gas temperature 200 ºC, gas flow 14 l/min, stealth gas temperature 
350 ºC, stealth gas flow 11 1/min. The reference masses 121.050873 m/z and 922.009798 m/z 
were used for reference ion correction. The mass range was set to 100-1000 and a scan rate of 
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1 spectrum/s was chosen. Due to the low complexity of sample matrix, the instrument was run 
in full-scan mode (ms-only) with sufficient selectivity and sensitivity. In order to have a clear 
separation and lower interference from the buffer salts, HPLC-flow from 1.3 to 5 min was 
directed to the mass detector. Data processing and integration were performed using the 
MassHunter software by Agilent Technologies with mass window set to 10 ppm. All control 
experiments were run consecutively and carried out as described below. 
Lane 1: Blank reaction, negative control 
For a negative control, 4-amino-furazane-3-carboxylic acid 3 (250 µM, IC20), equimolar 
amounts (250 µM) of a hetaryl nucleophile, e.g. 5-benzyl-1H-tetrazol 26, and formaldehyde 
were incubated for 24 h at room temperature in MOPS buffer (50 mM) at pH 7.4 in the 
absence of the protein template (MBP-STAT5b-SH2). The reaction mixture was analyzed 
using the method described above. 
Lane 2: Protein-induced ligation 
4-Amino-furazane-3-carboxylic acid 3 (250 µM, IC20) and equimolar amounts (250 µM) of a 
hetaryl nucleophile, e.g. 5-benzyl-1H-tetrazol 26 or and formaldehyde were incubated for 24h 
at room temperature in MOPS buffer (50 mM) at pH 7.4 in the presence of the protein 
template (MBP-STAT5b-SH2). The reaction mixture was analyzed using the method 
described above. 
Lane 3 and 4: Protein-induced reaction in the presence of high affinity FP probe 1 
Ligations were carried out after pre-incubating MBP-STAT5b-SH2 in MOPS buffer (50 mM) 
at pH 7.4 with 100 nM and 300 nM of 1, respectively, for 1 h at room temperature followed 
by the addition of 4-amino-furazane-3-carboxylic acid 3 (250 µM), an equimolar amount (250 
µM) of a 1H-tetrazole, and of FA in total assay volume of 100 µl. The reaction mixture was 
incubated for 24 h at room temperature and was analyzed using method as described above. 
Lane 5 and 6: Protein-induced ligation in the presence of competitive inhibitor 10 
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Ligations were carried out by pre-incubating MBP-STAT5b (final concentration 250 nM) 
with 1 and 5 µM of 10 for 1 h at room temperature followed by addition of 250 µM (IC20) 4-
amino-furazane-3-carboxylic acid 3, equimolar amounts (250 µM) of one hetaryl nucleophile 
and FA. The reaction mixtures were incubated for 24 h at room temperature and was analyzed 
using method as described above. 
Lane 7: Protein-induced Mannich ligation experiments with maltose binding protein 
(MBP) in place of MBP-STAT5-SH2 protein 
Ligations were carried out by mixing 1 µM (in excess) of MBP protein, 250 µM (IC20) 4-
amino-furazane-3-carboxylic acid 3, equimolar amount (250 µM) of one heteraryl nucleophile 
and FA The reaction mixtures were incubated for 24 h at room temperature and was analyzed 
using method as described below. 
 
6.4 Detection of protein-induced ligand formation via TSA.  
The possibility of using TSA48 assay to determine protein-induced ligand formation. The 
compatibility of FA with the TSA
109,118
 was investigated using MBP-STAT5b-SH2 protein 
(500 nM) mixed with increasing concentrations of FA up to the concentration of 250 μM and 
incubated at room temperature with mild shaking in a sealed 384 PCR plate. To determine the 
formation of ligand via a protein-induced reaction, MBP-STAT5b-SH2 protein 500 nM was 
added to 250 μM (IC20) 4-aminofurazane-3-carboxylic acid 3, equimolar amount (250 μM) 
of one heterarylnucleophile per PCR plate well with increasing concentration of FA up to the 
concentration of 250 μM. Reaction mixtures were incubated for 12 h with mild shaking at 
room temperature, respectively. After 12 h, the plates were centrifuged and 1 μl of 400X 
Sypro Orange solution (Thermo Scientific) was added, resulting in a total assay volume of 20 
μl, with a final protein concentration of 475 nM. The PCR plates were again sealed with 
optical seal, shaken for 15 min, and centrifuged. Thermal scanning (20–95 °C at 1 °C min−1) 
was performed using a real-time PCR setup LightCycler (Roche Diagnostics, Mannheim, 
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Germany) and fluorescence intensity was measured after every 0.3 s. Curve fitting, melting 





6.5 Molecular modelling and docking  
 
6.5.1 Homology modelling of STAT5B 
Template was adopted from the C-terminal region (Trp589 to Ser680, 92 amino acids) of 
crystal structure, 1Y1U
64
. The alignment was taken from Lin et al. Seven side chains were 
mutated to turn the SH2-domain of mouse STAT5A to human STAT5B using Sybyl8.1. The 
side chain conformation of Arg618 from the template structure of 1Y1U was manually 
adjusted so that it may interact in a bidentate coordination with the acidic group of the 
substrate like observed in other SH2 domains (e.g. 1BKM or 1O46). 
 
6.5.2 Preparation of STAT5 conformations 
The software AutoDockTools was used to convert homology modeled STAT5 and ligands to 
PDBQT from the PDB files. Polar hydrogens were assigned and Gasteiger charges were 
added and finally structures were saved in the PDBQT file format for docking. 
 
 
6.5.3 Molecular docking  
6.5.3.1 Sybyl 8.1 (Surflex-Dock) 
In order to rationalize the binding of the synthesized compounds in the active site of 
HuSTAT5B model, docking calculations were performed using Surflex-Dock interfaced 
within Sybyl8.1. The surflex-dock scoring function was used to score the docking 
interaction. The surflex-dock score considers several factors related to ligand-receptor 
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interaction, hydrophobicity, polarity, repulsiveness, entropy, and solvation. The docking 
parameters included ligand flexibility and rigid protein structure, and all other parameters 
were set to their default values. The resulting compounds were minimized using 
the Powell module with the standard Tripos force field within the pocket while the receptor 
was fixed. 
 
6.5.3.2  AutoDock Vina docking 
 The AutoGrid and AutoDock Vina
122
 procedures were used to conduct the grid point energy 
calculations of the receptor and the binding pose scoring of the ligands, respectively. The binding 
conformations of the ligands were optimized using the Lamarckian Genetic Algorithm 
(LGA), where the initial population size for each ligand was set to 2 500 000 and the grid was set 
at 30x 30x 30 Å, centered around the phosphotyrosines binding site in the SH2 domain of 
STAT5. The exhaustiveness was set to 100 for a better global minimum search. 
 
6.5.3.3  BINding ANAlyzer 
Docking conformation with minimum EFreeBind was loaded into BINANA for descriptors 
calculations. BINANA
124
 is a python implemented algorithm that assist in characterizing 
binding of inhibitor-receptor complex. Receptor and ligand files were prepared by 
MGLTools
123
 1.5.6 in PDBQT format. BINANA descriptors consist of (i) close contacts, (ii) 
electrostatic interactions; (iii) hydrophobic contacts, (iv) hydrogen bonds, (v) salt bridges and 
(vi) π interactions. 
 
6.6 Biochemical Assays  
 
6.6.1 Expression of MBP-STAT5b protein 
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Expression of the truncated version of STAT5b (aa 136-703) cloned into a modified pQE70, 
with N-terminal MBP-tag and C-terminal His-tag was conducted on autoinduction medium 
(overnight express / Novagen). Cells were grown to an optical density (O.D.) of 0.3 at 37 °C, 
then the temperature was reduced to 20 °C for further 48 h of expression. Comparable soluble 
expression levels were obtained with Rosetta2 (DE3) and BL21 (DE3) pLysS (both 
Novagen). The protein was purified by Ni-chelating chromatography followed by gel 
filtration (Superdex 200 / 10 mM HEPES pH 7.8, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 
10% glycerol). A yield of 15 mg MBP-STAT5b-His per liter of culture was obtained and 
aliquots (200 µl of 3.2 mg/ml) were quick-frozen and stored at –80 °C, ready for use. 
 
6.6.2  Thermal shift assays  
Thermal shift assays were performed with fragments 3, 25, and 26 as described previously
118 
 
in 96-well PCR plates (catalog no: HSL9901 Bio-Rad Laboratories, Richmond, CA). Assays 
were carried out using 500 nM of MBP-STAT5b protein mixed with serial concentration of 
fragments in the presence of 20x Sypro Orange (Thermo Scientific). Assay buffer contains 
300 mM HEPES, pH 7.4, 175 mM NaCl and 1% DMSO. The PCR plates were sealed with 
optical seal, shaken for 15 min, and centrifuged. Thermal scanning (20 to 95°C at 1°C/min) 
was performed using a real-time PCR setup (Light Cycler, Roche Diagnostics, Mannheim, 
Germany and fluorescence intensity was measured after every 0.3 s. Curve fitting, melting 






6.6.3  Activity measurement of SHP-2 using a DiFMUP assay. 
An enzyme assay using (DiFMUP) as a substrate was employed for the determination of 
SHP-2
151
 activity. Test compounds were dissolved in dimethyl sulfoxide (DMSO) at a 
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concentration of 100 mM and the assay was carried out at a final DMSO concentration < 1 %. 
The phosphatase reactions were performed at room temperature in 384-well black plate, clear 
flat bottom, low flange, non-binding surface (Corning, Cat# 3766) using a final volume of 
20 μL and the DiFMUP assay buffer contained a final concentration of 50 mM MOPS 
(pH = 6.5), 200 mM NaCl, 0.03 % Tween-20, 1 mM DTT (freshly added prior to each 
measurement) and 2.5 nM SHP-2 (final concentration). SHP-2 and tested compound in buffer 
solution were incubated for 30 min at r.t. The reaction was started by adding DiFMUP 
(Invitrogen, cat# D6567, 10 μM, correspond to the experimentally determined KM values of 
the enzymes) and the measurements were performed on microplate reader (infinite M1000 
Pro, Tecan) using excitation and emission wavelengths of 360 nm and 460 nm. Measurements 
were performed in triplicate and the IC50 values were calculated with GraphPad Prism 5
129
. 
Determinated IC50 values were converted into the corresponding KI values applying the 
Cheng Prusoff equation KI = IC50 / (1 + [S]/KM ). 
 
6.6.4 Photo-crosslinking and competitive displacement of 27 with recombinant MBP-
STAT5 SH2 protein.   
Peptide probe 27 (100 µM) was incubated with 200 µL of recombinant MBP-STAT5 SH2 
protein in the binding buffer (50 mM HEPES, pH 7.5, 200 mM NaCl, 2 mM MgCl2 , 0.1% 
tween-20, 20% glycerol, 2 mM PMSF, Roche Complete EDTA-free protease inhibitor 
cocktail) for 1 h at 4 ºC. The samples were then irradiated at 365 nM using a UV 
transilluminator for 15 min at 4 ºC. For competitive displacement studies, non fluorescent; 
phosphotyrosines containing control peptide (0-100 µM)  was added together with peptide 
probe 27 and incubated with recombinant MBP-STAT5 SH2 protein  for 1 h at 4 ºC prior to 
UV photo-crosslinking for 15 min at 4 ºC. SDS sample buffer (final concentration 1x) were 
added to the buffer and boiled before running on SDS PAGE followed by western blotting. 
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6.6.5  Neutravidin pull-down  
A total amount of 1mg/mL of heavy and light cell lysates were added with 100 µM of peptide 
27 and allowed to incubate for 1 h at 4 ºC. The samples were then irradiated at 365 nM using 
a UV transilluminator for 15 min at 4 ºC. For competitive displacement studies, non 
fluorescent; phosphotyrosines containing control peptide (0-100 µM) or compound 10 was 
added together with peptide probe 27 and incubated with for 1 h at 4 ºC prior to UV photo-
crosslinking for 15 min at 4 ºC. Then, 10 mg of Neutravidin agarose beads 
(Thermoscientific), which trapped biotinylated proteins was added to the cell lysates and 
mxed well at 4 ºC overnight. Next, neutravidin beads were extensively washed for five times 
with 1X PBS before boiling with 1x SDS-PAGE sample loading buffer (Sigma) for 5 min. 
The eluate was subjected to Western blot and the cytosolic β-acin serves as the loading 




6.6.6  LC-MS/MS Data Acquisition and Data Analysis.  
In-solution digestion and MS analysis was performed. Peptides were desalted on Stage Tips 
and analyzed using LTQ-Orbitrap XL (Thermo Electron). Peptides were separated on a C18-
reversed-phase column packed with Reprosil and directly mounted on the electrospray ion 
source on an LTQ-Orbitrap XL. We used a 140-min gradient from 2% to 60% acetonitrile in 
0.5% acetic acid at a flow of 200 nL/min. The raw files were processed with MaxQuant 
(version 1.0.11.5) and searched with the Mascot search engine (MatrixScience) against a 
IPIhuman v3.37 protein database concatenated with a decoy of the reversed sequences. 
Carbamidomethylation was set as fixed modification while methionine oxidation and protein 
Nacetylation were considered as variable modifications.The search was performed with an 
initial mass tolerance of 7 ppm mass accuracy for the precursor ion and 0.5 Da for the MS/MS 
spectra. Search results were processed with MaxQuant filtered with a false discovery rate of 
0.01. Before statistical analysis, known contaminants and reverse hits were removed. Only 
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proteins identified with at least 2 unique peptides and 2 quantitation events were considered 





6. 7 Cellular Assays 
6.7.1 Nuclear and cytoplasmic extracts preparation 
Nuclear extracts and cytoplasmic extracts were prepared from BaF3/FLT3-ITD cells using the 
Nuclear Extraction kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer’s 
protocol. 
 
6.7.2 Whole cell lysate preparation 
BaF3/FLT3-ITD cells were grown in suspension at 37 ºC in a humidified atmosphere with 5% 
CO2 in RPMI medium containing 10% dialyzed FBS. After harvesting, cell pellets were 
washed twice with PBS and frozen with liquid N2. To prepare whole cell lysates, the cell 
pellets were resuspended in a hypotonic buffer (10 mM HEPES, pH 7.5, 2 mM MgCl2, 0.1% 
tween-20, 20% glycerol, 2 mM PMSF, and Roche Complete EDTA-free protease inhibitors) 
and incubated for 10 min at 4 ºC. The suspension was centrifuged at 16000 xg for 15 min at 4 
ºC and the supernatant was kept for use later. The pellets were resuspended in a high-salt 
buffer (50 mM HEPES, pH 7.5, 420 mM NaCl, 2 mM MgCl2, 0.1% tween-20, 20% glycerol, 
2 mM PMSF, and Roche Complete EDTA-free protease inhibitors) and incubated for 30 min 
at 4 ºC . The suspension was then centrifuged at 16000 xg for 15 min at 4 ºC and the 
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6.7.3  SILAC BaF3/FLT3: ITD cell extract.  
BaF3/FLT3:ITD cells were SILAC-labelled in RPMI 1640 medium containing 10% FBS and 









(SIGMA ALRICH) or the corresponding non labelled (light) amino acids, respectively. Five 
consecutive batches of cells were independently harvested, and cell extracts were prepared as 
described below (6.7.2 whole cell lysate preparation).  
 
6.7.4 Cellular Thermal Shift Assay (CETSA) 
Cellular thermal shift assays
127
 were performed to monitor the target engagement of 10 and 16 
for STAT5a and STAT5b protein in BaF3/FLT3-ITD cells. Briefly, cell lysate from a total of 
2 × 106 BaF3/FLT3-ITD cells was collected, diluted in PBS and separated in identical 
aliquots. Lysates were divided into 45 μL in each of PCR tubes and heated individually at 
different temperatures with Thermocycler (Biometra, Göttingen, Germany). The heated 
lysates were centrifuged and the supernatants were analyzed by SDS-PAGE followed by 
immunoblotting analysis by probing with anti-STAT5a (C-6) sc271542 and STAT5b (G-2) 
sc-1656 (Santa Cruz Biotechnology) antibody, respectively. 
 
6.7.5 Isothermal dose response fingerprint experiments (ITDRF 
139
) 
BaF3/FLT3-ITD cells were grown in suspension at 37 ºC in a humidified atmosphere with 5% 
CO2 in RPMI medium containing 10% dialyzed FBS. Approximately 2 × 10
6
 cells were 
collected, washed with PBS buffer and replaced with fresh RPMI with 10% FBS. Cells were 
then separated in identical aliquots before treated with compound 16 at a final concentration 
between 0 and 100 µM (0.1% DMSO) and incubated under standard tissue culture conditions 
for 6 h. Cells were re-suspended in PBS supplemented with Complete EDTA-free protease 
inhibitors (Roche), aliquots (100 μl) containing equal cell numbers in PCR tubes were 
prepared. Tubes were incubated at approximately the Tm of the proteins of interest as 
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determined by CETSA melting curve experiments, 60 °C (Tm for actin) for 3 min, followed by 
room temperature for 3 min. The tubes were centrifuged (300 g, 3 min, 4 °C). The supernatant 
was removed and cells suspended in lysis buffer (100 mM HEPES, 300 mM NaCl, 2% NP-40 
and 10 mM EDTA, pH 7.4), supplemented with protease inhibitors. The tubes were incubated 
at 4 °C for 1 h, with vortexing every 20 min. Samples were centrifuged for 30 min at 16,000 
x g at 4 °C to pellet cell debris and precipitated proteins. The supernatants were analyzed by 
SDS-PAGE followed by immunoblotting analysis by probing with anti-STAT5a (C-6) 
sc271542 and STAT5b (G-2) sc-1656 (Santa Cruz Biotechnology) antibody, respectively. 
 
6.7.6 Western blot analysis and immunoprecipitation 
Cells were seeded at 0.5x10
6
 and allowed to grow overnight followed by 6 h incubation with 
test compounds (0.1% DMSO) before protein extraction with M-PER
TM
 Mammalian Protein 
Extraction Reagent (Pierce) containing 1% (vol/vol) complete protease inhibitor cocktail 
(Roche Molecular Biochemicals) and 1% (vol/vol) phosphate inhibitor cocktail (Sigma). For 
Western blotting, 15 μg of protein from each sample were then separated on a 10% SDS-
PAGE and transferred to a PVDF membrane. The blots were blocked with TBST buffer (20 
mM Tris-HCl [pH 7.4], 140 mM sodium chloride, and 0.05% Tween 20) containing 5% BSA 
at room temperature for 1 h, washed 3 times in TBST buffer, and incubated with primary 
antibody overnight at 4°C. The membranes were then incubated with HRP-conjugated 
secondary antibody at room temperature for 1 h. The reaction products were detected using 




6.7.7 STAT5 luciferase reporter assay 
BaF3/FLT3-ITD cells (5x10
6
 cells in 0.3 ml) were co-transfected with a ratio of 10:1 pGL-
STAT5 and pRL-TK as a transfection efficiency control in Opti-MEM medium via 
electroporation. (ECM 830 electroporator, BTX Instruments, Holliston, MA). The transfected 
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cells were then seeded in a 24-well plate and treated with serial dilution of compounds for 6  
h. The cells were collected 48 h after transfection, and the luciferase activities in the cell 
lysates were determined using the dual luciferase reporter assay system (Promega, WI, USA). 
Each transfection was performed in triplicate and repeated twice. 
 
6.7.8 RNA isolation and real-time PCR 
RNA was harvested using NucleoSpin RNA kit (Macherey-Nagel). cDNA was generated 
using the SuperScript™ II Reverse Transcriptase (Thermo Scientific) and Real-Time 
quantitative RT-PCR was performed using Transcriptor High Fidelity cDNA Synthesis and 
Light-Cycler 480 SYBR Green I Master Kits on a Light-Cycler 480 Real-Time PCR System 
according to instructions given by the manufacturer (Roche). Data were evaluated using the 
Light-Cycler 480 software (1.5). Quantitative reverse transcription polymerase chain reaction 
(RT-PCR) was performed using primers as described. Data are expressed as mean fold change 
± SE of 3 replicates and S9 expression was used as an internal control. The sequences of the 
oligo-primers used are shown in Appendix Table 1. 
 
6.7.9 Transient transfection of STAT5 siRNA  
Transient transfection for knockdown of endogenous STAT5 proteins was prepared by using 
STAT5 siRNA (STAT5 siRNA (h), sc-29495) from Santa Cruz Biotechnology (Santa Cruz, 
CA) and Control siRNA (control siRNA-A, sc-37007)  was used a negative control. Cell were 
transfected with STAT5 siRNA using siRNA transfection reagent (sc-29528, Santa Cruz, CA) 
according to the manufacturer’s instructions. Selective silencing of STAT5 was confirmed by 
western blot analysis. To assay the effect of STAT5 knockdown on cell viability, cells were 
first transfected with STAT5 siRNA or control siRNA and incubated for 24 h before treated 
with compound 16 (50 µM) or DMSO for 48 h. Viable cells was distinguished using an ATP-
dependent bioluminescence assay (CellTiter-Glo, Promega). 
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6.7.10 Cell proliferation assay 
The effect of compounds on cell lines was evaluated by In Vitro Toxicology Assay Kit, 
Resazurin based with indicator dye Alamar Blue (Sigma). Adherent and suspension cells were 
plated at 5 × 10
3
 per well and 1x10
4 
per well respectively in triplicate in 96-well plates and 
incubated in medium containing 10% FBS. For adherent cells, the complete medium was 
replaced after 24 h and incubated with test medium containing vehicle control or serial 
concentration of compounds for 48 h at 37 °C. The remaining unused wells in the periphery 
of microtiter well plate were added with PBS to avoid evaporation effects. Alamar Blue was 
then added, and all plates were incubated at 37 °C, and a colorimetric change was measured 
according to the manufacturer’s protocol. 
 
6.7.11 Phospho-specific flow cytometry of intracellular protein  
BaF3/ FLT3-ITD or K562 cells were seeded at 0.2 x10
6
 cells/ml per well in 6-well plates 
overnight and incubated with serial concentration of tested compounds for 6 h. A total amount 
of 10
6
 cells were collected and washed twice in 1xPBS and resuspended in 100 μl 
cytofix/cytoperm solution (BD Biosciences) at 4 ºC. After 20 min, cells were washed twice 
with BD Perm/Wash buffer solution and incubated with 20 μl of specific fluorochrome (PE) 
conjugated monoclonal antibody anti-p-STAT5 (Phosflow™ PE-Cy™7 mouse anti-Stat5 
(pY694) (BD Biosciences) at 4 ºC. After 30 min, the cells were washed twice and analyzed by 
flow cytometry. For isotype control, the cells were incubated with 2 μL of PE conjugated rat 
anti-mouse IgG1 monoclonal antibody (BD Biosciences) at 4 ºC for 30 min and washed twice 
in before being analyzed on a FACScan Flow Cytometer (Becton-Dickinson, San Jose, CA). 
Data interpretation was done using the Flowjo software
152




- 144 - 
 
6.7.12 Cell viability assay 
The effect of compounds on cell viability was evaluated using Cell Titer-Glo Luminescent 
Cell Viability assay kit (Promega). Cells were plated at 5 × 10
3
 per well and 1x10
4 
per well 
respectively in triplicate in white-walled, clear-bottom 96-well plates (3903, Corning Costar) 
and incubated in medium containing 10% FBS overnight. Cells were treated with or without 
compounds at 37 ºC for 48 h before carrying out the viability assay. The number of viable 
cells was measured using the CellTiter-Glo ATP-dependent luminescent assay (Promega, 
Madison, WI) following the manufacturer instruction. Luminescence reading was measured 
using Tecan Infinite M1000 plate reader (Tecan, Männedorf, Switzerland). The graphically 
represented values are means ± s.d. for three independent samples.  
 
6.7.13 Cell apoptosis analysis 
Cell apoptosis was determined using Annexin V staining. BaF3/FLT3-ITD or K562 
suspension cells were plated at 0.2x10
6
 per well in 6-well plates and incubated with serial 
concentration of tested compounds for 48 h. Cells were washed twice in ice-cold PBS 
resuspended in 1x binding buffer (10 mM Hepes (pH 7.4), 140 mM NaCl and 2.5 mM CaCl2) 
to a final concentration of 1x 10
6
 cells/ml. Subsequently, FITC Annexin V solution (5 μl) was 
added to 100 μl of the cell suspension. The mixture was incubated for 30 min at room 
temperature and washed in 1x Binding Buffer and again resuspended in 200 μl of 1x Binding 
buffer. Propidium iodide staining solution (5 μl, Sigma) was added shortly before analysis on 
a FACScan Flow Cytometer (Becton-Dickinson, San Jose, CA). Data interpretation was done 
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6.7.14 Electrophoretic mobility shift assay (EMSA) 
Gel shift assay was conducted using a double-stranded, biotin-labeled oligonucleotide probe 
containing the consensus binding site for STAT5 (sense strand, 
5′AGATTTCTAGGAATTCAATCC -3′), using the Gelshift Chemiluminescent EMSA kit 
(Active Motif) according to the manufacturer’s protocol. Protein-DNA complexes were 
resolved on a nondenaturing polyacrylamide gel, transferred to a positively charged nylon 
membrane, and cross-linked to a membrane using the UV-light cross-linker. After blocking, 
the membrane was incubated with blocking buffer containing streptavidin conjugated to HRP. 





6.7.15 Quantitative evaluation and inhibition of DNA-binding of activated STATs by 
ELISA 
STAT1, STAT3 and STAT5a and b activity were determined in nuclear protein extracts (20 
µg) by the TransAM STATs family kits from Active Motif (Carlsbad, CA). All assays were 
performed following the manufactory instruction after the nuclear protein extraction. 
 
6.7.16 Statistical analysis 
Statistical calculations were performed using GraphPad Prism 5
129
 software and reported as 
mean ± SEM. Experiments were performed in triplicates and/or repeated at least three times 
unless indicated otherwise. Two-tailed Student’s t-tests and one-way ANOVA were used to 
identify statistically significant data. p-values are considered as follows: * p-value < 0.05; ** 
p-value < 0.01; and *** p-value < 0.001. Synergy in cell viability assays was determined by 
plotting isobolograms and calculating the combination index (CI) using CalcuSyn software 
(Calcusyn software, Biosoft, San Diego, CA, USA) (Conservion, Ferguson, MO) using the 
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Chou–Talalay141 method to ascertain if the effects of drug combinations were synergistic (CI 
< 1), additive (CI = 1), or antagonistic (CI > 1).  
 
6.7.17 Animal experiments 
NSG mice (NOD/Shi-scid/IL-2Rγnull) from obtained from The Jackson Laboratory aged 6 
weeks with an average body weight of 22 grams. Studies were conducted at EPO GmbH, 
Berlin, in accordance with the United Kingdom Coordinating Committee on Cancer Research 
Regulations for the Welfare of Animals and in accordance with the German Animal 
Protection Law approved by the local responsible authorities, Berlin, Germany. BaF3/FLT3-
ITD cells were injected into mice subcutanously (106 cells per mouse). Inoculated and control 
mice (6 in each group) were treated for 16 d once daily s.c. with either the vehicle (10% (v/v) 
DMSO / 0.25% Tween 80) or compound 16 (200 mg kg-1) dissolved in vehicle, starting 
shortly after tumor cell inoculation. Former studies had shown that this concentration of test 
compound is well tolerated by the mice. Tumor volumes and body weights were recorded 
daily and expressed as mean ± standard deviation. 
 
6.8 Chemical Synthesis (This part is carried out by Dr. Eric Nawrotzky and Thomas 
Rudolf) 
 
General synthetic methods 
Method A: To a solution of 4-amino-furazan-3-carboxylic acid or methylester (1.0 mmol) 
and tetrazole (1.2 mmol) in 2.7 mL of acetonitrile (hipersolv chromanorm) and 0.3 mL of 
acetic acid, formaldehyde (37 % solution in water, 2.0 mmol) was added and this reaction 
mixture was stirred at r.t. for 16 h. Afterwards the mixture was lyophilizated and residue was 
purified by flash column chromatograph. 
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Method B: A solution of 4-amino-furazan-3-carboxylic acid (1.2 mmol), tetrazole (1.0 
mmol), and formaldehyde (37 % aqueous solution, 10.0 mmol) in 2.7 mL of acetonitrile and 
0.3 mL of concentrated hydrochloric acid was stirred in a sealed microwave reaction vial at 
105 °C in a microwave reactor for 5 h. After cooling the reaction, solids were filtrated off, 
washed with a small amount of water and dried under reduced pressure. The residue was 
purified by flash column chromatography. 
Method C: 
 
A suspension of the nitrile component (1.0 mmol), NaN3 (2 mmol), and NH4Cl (1.1 mmol) in 
DMF (5 mL) was stirred in a sealed microwave reaction vial at 140 °C in a microwave reactor 
for 1 h. After the mixture was evaporated in vacuum, the residue was poured into water and 
acidified with concentrated HCl to pH = 2 and cooled to 5 °C. Then the precipitate was 








Diethylchlorophosphate (1.18 mL, 8.19 mmol, 1 eq.) was added dropwise to a cooled (0°C) 
solution of 4-hydroxybenzaldehyde ( 1.0 g, 8.19 mmol, 1 eq.) and triethylamine (1.36 mL, 
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9.83 mmol, 1.2 eq.) in dry DCM (5 mL) under inert atmosphere. The reaction mixture was 
warmed to room temperature and stirred furthermore for 3 h. Afterwards the organic phase 
was extracted with 1 M HCl, saturated NaHCO3, dried over sodium sulfate and after filtration 
the filtrate was evaporated in vacuum. 
The protected phosphate (0.5 g, 1.94 mmol, 1 eq.) and trimethylsilylbromide (0.51 mL, 
3.88 mmol, 2 eq.) was stirred in MeCN ( 5 mL) at room temperature for 6 h. Subsequently the 
reaction mixture was quenched with 10 mL of H2O/MeOH (1:10), Amberlite® IR120 in 
protonated form (4 g) was added and the mixture was stirred at room temperature for 12 h. 
After filtration and purification by flash column chromatography the product was obtained as 
white solid (0.254 g, 1.26 mmol, 64 %). 
1
H-NMR (500 MHz, DMSO-d6): δ = 9.94 (s, 1H, H-6), 7.92 (d, J = 8.3 Hz, 2H, H-3), 7.37 (d, 
J = 8.3 Hz, 2H, H-2) ppm. 
13
C-NMR (101 MHz, DMSO-d6): δ = 192.32 (C-5), 156.36 (C-1), 
132.23 (C-4), 132.09(C-3), 120.94 (C-2) ppm. 
31
P-NMR (162 MHz, DMSO-d6):δ = 21.3 (m, 






4-Amino-1,2,5-oxadiazole-3-carboxylic acid [3] 
 
To a stirred suspension of ethyl cyanoacetate (28.3 g, 0.25 mol, 1 eq.) and sodium nitrite (17.3 
g, 0.25 mol, 1.0 eq.) in a mixture of EtOH (17 mL) and water (200 mL) was added dropwise 
85% H3PO4 (10 mL) at 10-15 °C and stirred for 12 h. Afterwards the reaction mixture was 
treated with NaOH (4×10 g, 1 mol, 4 eq.) and KOH (2×14 g, 0.5 mol, 2.0 eq.). To the 
resulting solution NH2OH∙HCl (69.5 g, 1.0 mol, 4.0 eq.) was slowly added at room 
temperature and heated upto 95 °C, stirred for 2 h, cooled to ambient temperature and 
quenched with conc. HCl to pH 1. Precipitation occurred on cooling to 0 °C for 12 h and the 
precipitate was collected by filtration and dried. The filtrate was extracted with diethyl ether 
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(3×30 mL). The combined organic extracts were evaporated under reduced pressure. The 
residue was combined with the precipitate and recrystallized from hot water to givecompound 
1 (21.3 g, 0.165 mol, 66 %) as white solid. 
1
H-NMR (300 MHz, DMSO-d6): δ = 9.69 (br s, 1H, H-1), 6.24 (s, 2H, H-5) ppm. 
13
C-NMR 
(75 MHz, DMSO-d6): δ = 162.5 (C-2), 157.1 (C-3), 144.9 (C-4) ppm. HRMS: (ESI): 
C3H3N3O3 [M], 129.0174 Da. calcd m/z 128.0096 [M-H]
-




4-Amino-1,2,5-oxadiazole-3-carboxylic acid methylester [X1] 
 
To a solution of 4-amino-1,2,5-oxadiazole-3-carboxylic acid 3 (2 g, 15.5 mmol, 1.0 eq.) in 
MeOH (20mL) was added dropwise a catalytic amount of conc. H2SO4 and heated up to 
60 °C and stirred for 3 h. Afterwards the reaction mixturewas evaporated in vacuum, the 
residue was dissolved in DCM (50 mL), washed with water, saturated solution of NaOH and 
Brine. Subsequently the mixtures was evaporated and recrystallized from hot CHCl3to give 
compound 2 (2.11 g, 14.73 mmol, 95 %) as white solid. 
1
H-NMR (300 MHz, DMSO-d6): δ = 6.24 (s, 2H, H-5), 3,76 (s, 3H, H-1) ppm. 
13
C-NMR 
(75 MHz, DMSO-d6): δ = 159.4 (C-2), 156.5 (C-3), 139.9 (C-4), 53.5 (C-1) ppm. 











4-Acetamido-1,2,5-oxadiazole-3-carboxylic acid [4] 
 
Commercial available at Sigma-Aldrich (#CDS002372) 
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Methyl 4-(2-bromoacetamido)-1,2,5-oxadiazole-3-carboxylate [X2] 
 
To a solution of 4-amino-1,2,5-oxadiazole-3-carboxylic acid methylester X1 (143 mg, 
1 mmol, 1 eq.) and 4-DMAP (369.3 mg, 1.0 mmol, 1.0 eq.) in dried DCM (15 mL) 2-
bromoacetyl bromide (242.2 mg, 1.2 mmol, 1.2 eq.) was slowly added under inert 
atmosphere. The reaction mixture was stirred at 0 °C for 2 h, evaporated in vacuum and was 
purified by flash column chromatography to give the product (339.7 mg, 0.92 mmol) in 92 % 
yield as a white solid. 
1
H NMR (300 MHz, CDCl3): δ = 9.92 (s, 1H, H-5), 4.13 (s, 2H, H-7), 4.11 (s, 3H, H-1) ppm. 
13
C-NMR (75 MHz, CDCl3): δ = 160.02 (C-6), 159.85 (C-2), 153.56 (C-3), 138.71 (C-4), 
54.06 (C-1), 28.01 (C-7) ppm. HRMS: C6H6BrN3O4 [M], 262.9542 Da. calcd m/z 285.9439 
[M+Na]
+
, found m/z 285.9289 [M+Na]
+
. 
Methyl 4-(2-(1H-tetrazol-1-yl)acetamido)-1,2,5-oxadiazole-3-carboxylate [X3] 
 
To a solution of Methyl 4-(2-bromoacetamido)-1,2,5-oxadiazole-3-carboxylate X2 (264.2 mg, 
1.5 mmol, 1.0 eq.) and 1H-tetrazol (9.1 mL (0.45M solution), 1.65 mmol, 1.1 eq.) in 
acetonitrile (5 mL) was added Et3N (0.15 mL, 1.5 mmol, 1.0 eq.) and stirred at 90 °C for 5 h. 
After the mixture was evaporated in vacuum, the residue was dissolved in DCM (20 mL) and 
washed with H2O (5 mL). The organic phase was dried over Na2SO4 and after filtration the 
filtrate was evaporated in vacuum. The residue was purified by flash column chromatography 
to give the product (229.1 mg, 0.65 mmol) in 43 % yield as a white solid. 
1
H NMR (300 MHz, CD3CN): δ = 9.41 (s, 1H, H-5), 8.72 (s, 1H, H-8), 5.79 (s, 2H, H-7), 
4.00 (s, 3H, H-1) ppm. 
13
C-NMR (75 MHz, CD3CN): δ = 163.78 (C-6), 159.67 (C-2), 154.51 
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(C-3), 150.25 (C-8), 142.29 (C-4), 56.11 (C-1), 54.50 (C-7) ppm. HRMS: (ESI): C7H7N7O4 
[M], 253.0560 Da. calcd m/z 276.0457 [M+Na]
+




4-(2-(1H-tetrazol-1-yl)acetamido)-1,2,5-oxadiazole-3-carboxylic acid [5] 
 
To a stirred solution of Methyl 4-(2-(1H-tetrazol-1-yl)acetamido)-1,2,5-oxadiazole-3-
carboxylate X3 (50.0 mg, 0.2 mmol, 1.0 eq.) in THF (1.0 mL) was added 0.1 M LiOH 
(0.1 mL) and Water (0.4 mL) and the reaction mixture was stirred at r.t. for 30 min. 
Afterwards the reaction mixture was neutralized with Amberlite
®
 IR-120 hydrogen form, 
filtrated and washed with H2O/THF (2.0 mL, 1:1 (v/v)). The mixture was evaporated to give 
compound 5 (43.9 mg, 0.18 mmol, 92 %) as white solid. 
1
H NMR (300 MHz, CD3CN): δ = 9.31 (s, 1H, H-4), 8.82 (s, 1H, H-7), 5.43 (s, 2H, H-6) ppm. 
13
C-NMR (75 MHz, CD3CN): δ = 164.28 (C-5), 160.61 (C-1), 155.11 (C-2), 151.3 (C-7), 
142.89 (C-3), 54.62 (C-6) ppm. HRMS: (ESI): C6H5N7O4 [M], 239.0403 Da. calcd m/z 
262.0301[M+Na]
+




4-((1H-1,2,3-Triazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylic acid [6] 
 
Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (129 mg, 1 mmol, 1.0 eq.), 1H-1,2,3-triazolezole (103.6, 1.5 mmol, 1.5 eq.) 
and formaldehyde (0.2 mL, 2.0 mmol, 2.0 eq.) to give the product (165.9 mg, 0.79 mmol) in 
79 % yield as a white solid. 
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1
H NMR (300 MHz, DMSO-d6): δ = 8.16 (m, 1H, H-6), 7.81 (t, J = 7.0 Hz, 1H, H-7), 7.71 
(m, 1H, H-5), 5.82 (d, J = 6.9 Hz, 2H, H-7) ppm. 
13
C-NMR (75 MHz, DMSO-d6): δ = 160.1 
(C-1), 155.4 (C-2), 140.2 (C-3), 133.2 (C-6), 124.6 (C-5), 57.8 (C-4) ppm. HRMS: (ESI): 
C6H6N6O3 [M], 210.1530 Da. calcd m/z 209.1450 [M-H]
-
, found m/z 209.0470 [M-H]
-
. 
4-((1H-Benzo[d][1,2,3]triazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylic acid [7] 
 
Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (129 mg, 1.0 mmol, 1.0 eq.), 1H-benzotriazole (179 mg, 1.5 mmol, 1.5 eq.) 
and formaldehyde (0.2 mL, 2.0 mmol, 2.0 eq.) to give the product (93.8 mg, 0.36 mmol) in 
36 % yield as a white solid. 
1
H NMR (300 MHz, DMSO-d6): δ = 8.09 (d, J = 8.4 Hz, 1H, H-9), 8.05 (t,J = 7.0 Hz 1H, H-
11), 8.03 (d, J = 8.3 Hz 1H, H-6), 7.57 (t, J = 7.6 Hz, 1H, H-8), 7.39 (t, J = 7.5 Hz, 1H, H-7), 
6.17 (d, J = 6.9 Hz, 2H, H-4) ppm. 
13
C-NMR (75 MHz, DMSO-d6): δ = 160.2 (C-1), 156.1 
(C-2), 145.8 (C-10), 143.5 (C-3), 132.9 (C-5), 127.9 (C-8), 124.6 (C-7), 119.6(C-9), 111.9(C-
6), 57.2(C-4) ppm. HRMS: (ESI): C10H8N6O3 [M], 260.0658 Da. calcd m/z 259.0580 [M-H]
-
, 




4-((1H-Pyrazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylic acid [8] 
 
Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (129 mg, 1.0 mmol, 1.0 eq.), 1H-pyrazole (102.1, 1.5 mmol, 1,5 eq.) and 
formaldehyde (0.2 mL, 2.0 mmol, 2.0 eq.) to give the product (198.8 mg, 0.95 mmol) in 95 % 
yield as a white solid. 
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1
H NMR (300 MHz, DMSO-d6): δ = 7.82 (d, J = 2.2 Hz, 1H, H-7), 7.61 (t, J = 6.9 Hz, 1H, H-
8), 7.45 (d, J = 2.1 Hz, 1H, H-5), 6.23 (t, J = 2.1 Hz, 1H, H-6), 5.52 (d, J = 6.8 Hz, 3H, H-4) 
ppm. 
13
C-NMR (75 MHz, DMSO-d6): δ = 159.7 (C-1), 155.6 (C-2), 139.1 (C-3), 130.1 (C-7), 
129.5 (C-5), 105.3 (C-6), 59.2 (C-4) ppm. HRMS: (ESI): C7H7N5O3 [M], 209.0549 Da. calcd 
m/z 208.0471 [M-H]
-




4-((1H-1,2,4-Triazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylic acid [9] 
 
Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (129 mg, 1.0 mmol, 1.0 eq.), 1H-1,2,4-triazolezole (103.6, 1.5 mmol, 
1.5 eq.) and formaldehyde (0.2 mL, 2.0 mmol, 2.0 eq.) to give the product (138.7 mg, 
0.66 mmol) in 66 % yield as a white solid. 
1
H NMR (300 MHz, DMSO-d6): δ = 8.59 (s, 1H, H-6), 7.97 (s, 1H, H-5), 7.69 (t, J = 6.9 Hz, 
1H, H-7), 5.61 (d, J = 6.8 Hz, 2H, H-4) ppm. 
13
C-NMR (75 MHz, DMSO-d6): δ = 159.6 (C-
1), 155.3 (C-2), 151.5 (C-3), 144.5 (C-5), 140.2 (C-6), 57.3 (C-4) ppm. HRMS: (ESI): 
C6H6N6O3 [M], 210.1530 Da. calcd m/z 209.1450 [M-H]
-




4-((1H-Tetrazol-1-yl)-methylamino)-1,2,5-oxadiazole-3-carboxylic acid [10] 
 
Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (129 mg, 1.0 mmol, 1.0 eq.), 1H-tetrazol (3.3 mL (0.45M solution), 
1.5 mmol, 1.5 eq.) and formaldehyde (0.2 mL, 2.0 mmol, 2.0 eq.) to give the product 
(184.8 mg, 0.88 mmol) in 88 % yield as a white solid. 
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1
H NMR (300 MHz, DMSO-d6):δ = 9.43 (s, 1H, H-6), 7.90 (t, J = 6.9 Hz, 1H, H-4), 5.91 (d, 
J = 6.9 Hz, 2H, H-5) ppm. 
13
C-NMR (75 MHz, DMSO-d6): δ = 160.2 (C-1), 155.8 (C-2), 
144.6 (C-3), 140.7 (C-6), 57.2 (C-5) ppm. HRMS:(ESI): C5H5N7O3 [M], 211.0454 Da. calcd  
m/z 210.0376 [M-H]
-
, found m/z 210.0397 [M-H]
-
. Anal: calcd for C5H5N7O3: C, 28.44; H, 
2.39; N, 46.44; found C, 28.12; H, 2.26; N, 46.82.  
 
4-((5-Phenyl-1H-tetrazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylic acid [11] 
 
Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (129 mg, 1.0 mmol, 1.0 eq.), 5-phenyl-1H-tetrazole (219 mg, 1.5 mmol, 
1.5 eq.) and formaldehyde (0.2 mL, 2.0 mmol, 2.0 eq.) to give the product (252.6 mg, 
0.88 mmol) in 88 % yield as a white solid. 
1
H NMR (300 MHz, DMSO-d6): δ = 8.10 (t, J = 7.0 Hz, 1H, H-10), 8.04 (d, J = 7.8 Hz, 2H, 
H-7), 7.58 – 7.52 (m, 3H, H-8, H-9), 6.14 (d, J = 7.0 Hz, 2H, H-4) ppm. 13C-NMR (75 MHz, 
DMSO-d6): δ = 164.7 (C-5), 160.2 (C-1), 155.8 (C-2), 140.7 (C-3), 131.2 (C-6), 129.9 (C-7), 
127.4 (C-9), 126.9 (C-8), 62.1 (C-4) ppm. HRMS: (ESI): C11H9N7O3 [M], 287.2390 Da. 
calcd m/z 286.2310 [M-H]
-





carboxylic acid [12] 
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Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (83.9 mg, 0.7 mmol, 1.3 eq.), 5-(4-(trifluoromethyl)phenyl)-1H-tetrazole 
(147.2 mg, 0.5 mmol, 1.0 eq.) and formaldehyde (0.1 mL, 2.0 mmol, 2.0 eq.) to give the 
product (159.9 mg, 0.45 mmol) in 90 % yield as a white solid. 
1
H NMR (300 MHz, CDCl3): 
δ = 8.40 (s, 1H, H-12), 8.32 (d, J = 7.8 Hz, 1H, H-7), 7.72 (d, J = 7.9 Hz, 1H, H-9), 7.60 (t, 
J = 7.8 Hz, 1H, H-8), 6.88 (t, J = 7.5 Hz, 1H, H-13), 6.20 (d, J = 7.6 Hz, 2H, H-4) ppm. 
13
C-
NMR (75 MHz, CDCl3): δ =
 
163.6 (C-5), 160.90 (C-1), 155.20 (C-2), 138.94 (C-3), 
131.68(C-10), 130.16 (C-7), 129.47 (C-8), 127.83 (C-6), 127.06 (C-9), 125.54 (C-11), 123.87 
(C-12), 60.72 (C-4) ppm. HRMS: (ESI): C12H8F3N7O3 [M], 355.0641 Da. calcd m/z 394.0278 
[M+K]
+







Prepared according to general procedure Method B using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (167.7 mg, 0.7 mmol, 1.3 eq.), 5-(3-fluorophenyl)-1H-tetrazole (164.2 mg, 
1.0 mmol, 1.0 eq.) and formaldehyde (0.15 mL, 2.0 mmol, 2.0 eq.) to give the product 
(250.3 mg, 0.82 mmol) in 82 % yield as a white solid. 
1
H NMR (300 MHz, CDCl3): δ = 7.94 (d, J = 7.8 Hz, 1H, H-7), 7.84 (dd, J = 9.5, 2.2 Hz, 1H, 
H-11), 7.46 (ddd, J = 8.3, 7.8, 5.8 Hz, 1H, H-8), 7.17 (t, J = 8.4 Hz, 1H, H-9), 6.85 (t, J = 7.6 
Hz, 1H, H-12), 6.20 (d, J = 7.6 Hz, 2H, H-4) ppm. 
13
C-NMR(75 MHz, DMSO-d6): 
δ = 163.72 (C-5), 159.56 (C-1), 155.83 (C-2), 140.95 (C-3), 134.28 (C-6), 131.65 (C-10), 
129.16 (C-8), 123.72 (C-7), 121.85 (C-11), 118.93 (C-9), 61.85 (C-4) ppm. HRMS: (ESI): 
C11H8FN7O3 [M], 305.0673 Da. calcd m/z 304.0594 [M-H]
-
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4-((5-(3-(Trifluoromethoxy)phenyl)-1H-tetrazol-1-yl)methylamino)-1,2,5-oxadiazole-3-
carboxylic acid [14] 
 
Prepared according to general procedure Method B using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (83.9 mg, 0.7 mmol, 1.3 eq.), 3-(1H-tetrazol-5-yl)phenyl hypofluorite 
(115.1 mg, 1.0 mmol, 1.0 eq.) and formaldehyde (0.1 mL, 2.0 mmol, 2.0 eq.) to give the 
product (252.4 mg, 0.82 mmol) in 68 % yield as a white solid. 
1
H NMR (300 MHz, CDCl3): δ = 8.09 (d, J = 8.0 Hz, 1H, H-7), 8.00 (s, 1H, H-12), 7.52 (dd, 
J = 7.8 Hz, 1H, H-8), 7.32 (d, J = 8.0 Hz, 1H, H-9), 6.85 (t, J = 7.6 Hz, 1H, H-13), 6.20 (d, 
J = 7.6 Hz, 2H, H-4) ppm. 
13
C-NMR (75 MHz, DMSO-d6): δ = 163.20 (C-5), 159.82 (C-1), 
155.54 (C-2), 149.11 (C-10), 140.82 (C-3), 132.03 (C-8), 129.21 (C-6), 126.32 (C-7), 125.76 
(C-9), 123.44 (C-11), 118.73 (C-12), 62.04 (C-4) ppm. HRMS: (ESI): C12H8F3N7O4 [M], 
371.2362 Da. calcd m/z 370.2282 [M-H]
-







Prepared according to general procedure Method B using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (167.7 mg, 0.7 mmol, 1.3 eq.), 5-(4-fluorophenyl)-1H-tetrazole (164.2 mg, 
1.0 mmol, 1.0 eq.) and formaldehyde (0.15 mL, 2.0 mmol, 2.0 eq.) to give the product 
(213.7 mg, 0.7 mmol) in 70 % yield as a white solid. 
1
H NMR (300 MHz, CDCl3): δ = 8.14 
(dd, J = 8.7, 5.5 Hz, 2H, H-7), 7.17 (t, J = 8.7 Hz, 2H, H-8), 6.81 (t, J = 7.6 Hz, 1H, H-11), 
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6.19 (d, J = 7.6 Hz, 2H, H-4) ppm. 
13
C-NMR (75 MHz, DMSO-d6): δ = 163.68 (C-5), 159.83 
(C-1), 155.56 (C-2), 140.61 (C-3), 134.08 (C-6), 129.85 (C-7), 129.16 (C-8), 123.72 (C-9), 
116.85 (C-10), 61.85 (C-4) ppm. HRMS: (ESI): C11H8FN7O3 [M], 305.0673 Da. calcd m/z 
304.0594 [M-H]
-





4-((5-Benzyl-1H-tetrazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylic acid [16] 
 
Prepared according to general procedure Method B using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (80.2 mg, 0.62 mmol, 1.2 eq.), 5-benzyl-1H-tetrazole (100.0 mg, 
0.52 mmol, 1.0 eq.) and formaldehyde (0.47 mL, 5.2 mmol, 10.0 eq.) to give the product 
(81.3 mg, 0.27 mmol) in 52 % yield as a off white solid. 
1
H NMR (500 MHz, DMSO-d6): δ = 7.9 (t, J = 6.6 Hz, 2H, H-11), 7.27 (d, J = 7.0 Hz, H-8), 
7.25 - 7.22 (m, 3H, H-9, H-10), 5.89 (d, J = 6.6 Hz, 2H, H-4), 4.48 (s, 2H, H-6) ppm. 
13
C-
NMR (126 MHz, DMSO-d6): δ = 159.99 (C-1), 155.42 (C-2), 154.9 (C-5), 140.28 (C-3), 
135.65 (C-7), 129.17 (C-8), 128.93 (C-9), 127.34 (C-10), 56.36 (C-4), 28.57 (C-6) ppm. 
HRMS: (ESI): C12H11N7O3 [M], 301.0923 Da. calcd m/z 300.0845 [M-H]
-
, found m/z 
300.0805 [M-H]
-
. Anal: calcd for C12H11N7O3: C, 47.84; H, 3.68; N, 32.55; found C, 48.11; 











Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (143 mg, 1.0 mmol, 1.0 eq.), 5-([1,1'-biphenyl]-4-yl)-1H-tetrazole (266 mg, 
1.2 mmol, 1.2 eq.) and formaldehyde (0.1 mL, 2.0 mmol, 2 eq.) to give the product (221.5mg, 
0.61 mmol) in 61 % yield as a white solid. 
1
H NMR (300 MHz, CDCl3): δ = 8.14 (d, J = 8.2 Hz, 2H, H-7), 8.11 (t, J = 7.0 Hz, 1H, H-
14), 7.86 (d, J = 8.4 Hz, 2H, H-8), 7.74 (d, J = 7.2 Hz, 2H, H-11), 7.50 (t, J = 7.6 Hz, 2H, H-
12), 7.41 (t, J = 7.2 Hz, 1H, H-13), 6.17 (d, J = 7.0 Hz, 2H, H-4) ppm. 
13
C-NMR (75 MHz, 
CDCl3): δ = 164.41 (C-5), 160.09 (C-1), 155.78 (C-2), 142.59 (C-9), 140.69 (C-10), 139.58 
(C-3), 129.54 (C-12), 128.52 (C-13), 127.95 (C-6), 127.45 (C-7), 127.20 (C-8), 126.27 (C-
11), 62.03 (C-4) ppm. HRMS: (ESI): C17H13N7O3 [M], 363.1080 Da. calcd m/z 386.0978 
[M+Na]
+




Methyl 4-((1H-tetrazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylate [18] 
 
Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid methylester X1 (143 mg, 1.0 mmol, 1.0 eq.), 1H-tetrazol (3.3 mL 
(0.45M solution), 1.5 mmol, 1.5 eq.) and formaldehyde (0.2 mL, 2.0 mmol, 2.0 eq.) to give 
the product (184.8 mg, 0.88 mmol) in 88 % yield as a white solid. 
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1
H NMR (300 MHz, DMSO-d6): δ = 9.44 (s, 1H, H-6), 8.01 (t, J = 6.9 Hz, 1H, H-7), 5.92 (d, 
J = 6.9 Hz, 2H, H-5) ppm. 
13
C-NMR (75 MHz, DMSO-d6): δ = 159.5 (C-2), 155.6 (C-3), 
144.6 (C-4), 126.2 (C-6), 53.9 (C-5), 53.8 (C-1) ppm. HRMS: (ESI): C6H7N7O3 [M], 
225.0610 Da. calcd m/z 248.0508 [M+Na]
+








To a stirred solution of acetylbromide (0.85 mL, 11.35 mmol, 3.0 eq.) and cat. amount of 
zinc(II) chloride (5 mg) in dry DCM (2.5 mL) was added paraldehyde (0.51 mL, 3.78 mmol, 
1 eq.) under inert atmosphere and the reaction stirred for 45 min at 0 °C. The reaction mixture 
was quenched with water and the organic phase was washed two times with water. After 
evaporation of methylene chloride the product was obtained as colourless oil (467.8 mg, 
2.82 mmol) in 75 %. 
1
H NMR (400 MHz, DMSO-d6): δ = 6.67 (q, J = 5.9 Hz, 1H, H-3), 2.09 (s, 3H, H-1)), 1.97 
(d, J = 5.9 Hz, 3H, H-4) ppm. 
13
C-NMR (101 MHz, DMSO-d6): δ = 168.45 (C-2), 71.76 (C-
3), 26.82 (C-1), 21.06 (C-4) ppm. HRMS: (ESI): C4H7BrO2 [M], 165.9629 Da. calcd m/z 
166.9708 [M+H]
+




1-Acetoxyethyl 4-((1H-tetrazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylate [19] 
 
To a stirred solution of4-((1H-tetrazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylic acid 
16 (100 mg, 0.47 mmol, 1.0 eq.) and DIPEA (0.16 mL, 0.94 mmol, 2 eq.) in DMF (2 mL) was 
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added 1-bromoethyl-acetate X4 (156 mg, 0.94 mmol, 2 eq.) and the reaction was stirred for 
18 h at room temperature. The reaction mixture was evaporated in vacuum and purified by 
flash column chromatography to give the product (63.7 mg, 0.21 mmol) in 45 % yield as a 
brownish oil. 
1
H NMR (500 MHz, DMSO-d6): δ = 9.44 (s, 1H, H-10), 8.02 (t, J = 6.9 Hz, 1H, H-8), 7.04 (q, 
J = 5.5 Hz, 1H, H-3), 5.93 (d, J = 6.9 Hz, 2H, H-9), 2.09 (s, 3H, H-1), 1.57 (d, J = 5.5 Hz, 3H, 
H-4) ppm. 
13
C-NMR (126 MHz, DMSO-d6): δ = 169.03 (C-5), 156.90 (C-2), 155.76 (C-7), 
144.48 (C-6), 139.22 (C-10), 89.85 (C-3), 56.97 (C-9), 20.98 (C-4), 20.75 (C-1) ppm. HRMS: 












carboxylic acid [20] 
 
Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid 3 (143 mg, 1.0 mmol, 1.0 eq.), 5-(3-benzyloxyphenyl)-1H-tetrazole (302 mg, 
1.2 mmol, 1.2 eq.) and formaldehyde (0.1 mL, 2.0 mmol, 2 eq.) to give the product 
(204.24mg, 0.52 mmol) in 52 % yield as a white solid. 
1
H NMR (300 MHz, CDCl3): δ = 8.12 (t, J = 7.0 Hz, 1H, H-16), 7.67 – 7.62 (m, 2H, H-9, H-
10), 7.49 (m, 1H, H-11), 7.48 (m, 2H, H-14), 7.40 (m, 2H, H-13), 7.34 (s, 1H, H-7), 7.19 (d, 
J = 8.4 Hz, 1H, H-15), 6.15 (d, J = 7.1 Hz, 2H, H-4), 5.20 (s, 2H, H-12) ppm. 
13
C-NMR 
(75 MHz, CDCl3): δ = 164.47 (C-5), 160.06 (C-1), 159.27 (C-2), 155.78 (C-8), 137.27 (C-3), 
131.06 (C-10), 128.93 (C-14), 128.58 (C-15), 128.35 (C-6), 128.23 (C-11), 128.15 (C-13), 
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119.41 (C-9), 117.83 (C-7), 69.82 (C-12), 58.60 (C-4) ppm. HRMS: (ESI): C18H15N7O4 [M], 
393.1186 Da. calcd m/z 392.1107 [M-H]
-




Methyl 4-((5-phenyl-1H-tetrazol-1-yl)methylamino)-1,2,5-oxadiazole-3-carboxylate [21] 
 
Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid methylester X1 (143 mg, 1.0 mmol, 1.0 eq.), 5-phenyl-1H-tetrazole (219 mg, 
1.5 mmol, 1.5 eq.) and formaldehyde (0.2 mL, 2.0 mmol, 2 eq.) to give the product 
(183.7 mg, 0.61 mmol) in 61 % yield as a white solid. 
1
H NMR (300 MHz, CDCl3): δ = 8.13 (dd, J = 6.7, 2.9 Hz, 2H, H-9), 7.49 (m, 1H, H-10), 
7.47 (d, J = 2.7 Hz, 2H, H-8), 6.69 (t, J = 7.5 Hz, 1H, H-11), 6.19 (d, J = 7.5 Hz, 2H, H-5), 
4.03 (s, 3H, H-1) ppm. 
13
C-NMR (75 MHz, CDCl3): δ = 165.7 (C-6), 159.9 (C-2), 155.2 (C-
3), 137.9 (C-4) 130.6 (C-10), 128.9 (C-9), 126.9 (C-8), 126.9 (C-7), 60.4 (C-1), 53.6 (C-5) 














Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid methylester X1  (72.6 mg, 0.5 mmol, 1.0 eq.), 3-(1H-tetrazol-5-yl)phenol 
(97.3 mg, 0.6 mmol, 1.2 eq.) and formaldehyde (0.1 mL, 1.0 mmol, 2.0 eq.) to give the 
product (236.2 mg, 0.64 mmol) in 64 % yield as a white solid. 
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1
H NMR (300 MHz, DMSO-d6): δ = 9.82 (s, 1H, H-12), 8.18 (t, J = 6.9 Hz, 1H, H-14), 7.48 
(m, 1H, H-10), 7.46 (s, 1H, H-13), 7.34 (t, J = 7.8 Hz, 1H, H-9), 6.91 (d, J = 8.1 Hz, 1H, H-8), 
6.13 (d, J = 6.9 Hz, 2H, H-5), 3.94 (s, 3H, H-1). 
13
C-NMR (75 MHz, DMSO-d6): δ = 164.79 
(C-6), 158.81 (C-2), 158.6 (C-11), 155.61 (C-3), 140.03 (C-4), 131.05 (C-7), 128.44 (C-9), 
118.25 (C-8), 117.61 (C-13), 113.47 (C-10), 61.93 (C-1), 53.81 (C-5). HRMS: (ESI): 
C12H11N7O4 [M], 317.0873 Da. calcd m/z 340.0770 [M+Na]
+






Prepared according to general procedure Method B using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid methylester (83.9 mg, 0.7 mmol, 1.3 eq.), 3-(1H-tetrazol-5-yl)phenyl 
hypofluorite (115.1 mg, 1.0 mmol, 1.0 eq.) and formaldehyde (0.1 mL, 2.0 mmol, 2.0 eq.) to 
give the product (252.4 mg, 0.82 mmol) in 68 % yield as a yellowish solid. 
1
H NMR (300 MHz, CDCl3): δ = 8.22 (t, J = 7.8 Hz, 1H, H-8), 8.08 (d, J = 7.8 Hz, 1H, H-7), 
7.91 (s, 1H, H-12), 7.72 (t, J = 7.5 Hz, 1H, H-13), 7.56 (d, J = 7.8 Hz, 1H), 6.17 (d, J = 7.3 Hz, 
2H, H-4), 3.94 (s, 3H, H-14) ppm. 
13
C-NMR (75 MHz, DMSO-d6): δ = 
13
C NMR (126 MHz, 
DMSO-D6) δ 163.49 (C-5), 158.80 (C-1), 155.58 (C-2), 149.41 (C-10), 140.03 (C-3), 132.34 
(C-8), 129.45 (C-6), 126.03 (C-7), 123.75 (C-9), 122.39 (C-11), 118.98 (C-12), 62.23 (C-4), 

















Prepared according to general procedure Method A using 4-amino-1,2,5-oxadiazole-3-
carboxylic acid methylester X1 (72.6 mg, 0.5 mmol, 1.0 eq.), 3-(1H-tetrazol-5-yl)phenol 
(97.3 mg, 0.6 mmol, 1.2 eq.) and formaldehyde (0.1 mL, 1.0 mmol, 2.0 eq.) to give the 
product (236.2 mg, 0.64 mmol) in 64 % yield as a white solid. 
1
H NMR (300 MHz, CD3CN): δ = 7.98 (s, 1H, H-13), 7.89 (d, J = 7.6 Hz, 1, H-8), 7.70 (s, 
1H, H-14), 7.51 (t, J = 7.9 Hz, 1H, H-9), 7.38 (d, J = 7.7 Hz, 1H, H-10), 7.09 (t, J = 7.3 Hz, 
1H, H-16), 6.14 (d, J = 7.3 Hz, 2H, H-5), 3.98 (s, 3H, H-1), 2.97 (s, 3H, H-15) ppm. 
13
C-
NMR (75 MHz, CD3CN): δ =
 
165.48 (C-6), 160.10 (C-2), 156.44 (C-3), 140.38 (C-11), 
139.80 (C-4), 131.41 (C-9), 129.58 (C-7), 123.76 (C-10), 123.18 (C-8), 119.10 (C-13), 61.98 
(C-7), 54.13 (C-8), 39.78 (C-15) ppm. HRMS: (ESI): C13H14N8O5S [M], 394.0808 Da. calcd 
m/z 417.0706 [M+Na]
+






Commercial available at Sigma-Aldrich (#88185), lyophilization of 0.45 M solution give 1H-










Prepared according to general procedure Method C using phenylacetonitrile (1.15 mL, 
10.0 mmol, 1.0 eq.), NaN3 (1.3 g, 20.0 mmol, 2.0 eq.), and NH4Cl (535 mg, 10.0 mmol, 
1.0 eq.) to give the product 26 (1039.7 mg, 0.64 mmol) in 65 % yield as an off white solid. 
1
H NMR (500 MHz, DMSO-d6): δ = 7.39 - 7.29 (m, 2H, H-5), 7.33 - 7.27 (m, 2H, H-4), 7.26 
- 7.22 (m, 1H, H6), 4.29 (s, 2H, H-2). ppm. 
13
C-NMR (126 MHz, DMSO-d6): δ = 145.09 (C-
1), 138.20 (C-3), 129.28 (C-5), 129.21 (C-4), 127.57 (C-6), 33.87 (C-2) ppm. HRMS: (ESI): 
C8H8N4 [M], 160.0749 Da. calcd m/z 183.0647 [M+Na]
+




5-CF -K(biotin)GpcFLSLPPW-NH2 [27] (synthesized by Dr. Stefan Wagner) 
The dual labelled peptide was synthesized according to previously published work. The 
photoactive building blocks sodium-(N-fluorenyl-9-methyloxycarbonyl-4-(O-benzyl-
sodiumphosphonocarbonyl))-phenylalanine and was furnished after multistep. For evaluations 
of affinity experiments utilizing avidin-biotin analysis N-Fluorenyl-9-methoxycarbonyl-N
6
-
(biotin)-lysine was synthesized.  Coupling of N-Fmoc-protected amino acids and consequent 
basic deprotection that followed the photoactive building block were performed under 
modified protocols described in literature.
153
 Acylation with 5,6-carboxyfluorescein, NH-
4HCO3 buffered HPLC purification and ion-exchange towards the sodium salt furnished 
peptide 27 in 12 % yield. 





























Appendix Figure 1: Uncropped pictures of western blots from the corresponding cropped 
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Appendix Figure 2: Gating strategies used for flow cytometry stainings. a, Gating strategy 
used for flow cytometry staining to determine apoptosis using fluorescein isothiocyanate 
(FITC)-conjugated annexin-V and dual stainied with phycoerythrin (PE)-conjugated 
propidium iodide to exclude necrotic cells. Debris were excluded using a forward scatter area 
(FSC-A) versus side scatter area (SSC-A) gate. Single cells (singlets) were then selected on a 
FSC-A versus FSC-W plot to exclude signaling data from doublets. b, Phospho-flow 
cytometry gating strategy used for the analysis of STAT5 phosphorylation using PE Mouse 











Appendix Figure 3: Reaction scheme for the synthesis of tetrazole derivatives. 
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Appendix Figure 4: Fluorescence polarization binding assays of STAT5 inhibitors. Dose-
response fluorescence polarization (FP) curves for the competitive binding of compounds 2-
13 refer to Appendix Table 2 to recombinant STAT5-SH2 domain (n=3). Error bars denote 
mean ± SEM. 
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Appendix Figure 5: Dose-response fluorescence polarization (FP) curves for the competitive 
binding of compounds 14-20 refer to Appendix Table 2 to recombinant STAT5-SH2 domain 
(n=3). Error bars denote mean ± SEM. 
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Appendix Figure 6: Dose-response fluorescence polarization (FP) curves for the competitive 
binding of compounds 21-26 refer to (Appendix table 3) to recombinant STAT5-SH2 domain 













C-NMR spectrum of 10 








C-NMR spectrum of 16 
 








C-NMR spectrum of 19 




Appendix Figure 10: (a-c) Standard calibration curves of 6 different concentrations of 
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Appendix Table 1: List of primers used in this study.  
Genes  Forward Primer Reverse Primer 
Pim-1(m) TCTTCTGGCAGGTGCTG GGTAGCGAATCCACTCTG 
Bcl-xL(m) ATGGCAGCAGTGAAGCAAGC ACGATGCGACCCCAGTTTACTC 
Cis(m) CTGGACTCTAACTGCTTGTC TAGGCAGCACCGAGTCAC 
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Appendix Table 2: STAT5 inhibitors and their respective KI values and ligand efficiencies 
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Conversion of IC50 values into KI values was  
carried out as described and ligand efficiency was 
calculated using the equation derived.
1
  
n.a. = not applicable, NA = number of non-hydrogen 
atoms 
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Appendix Table 4:  Identification of peptide 27 interaction partners in BaF3/FLT3-ITD cell lines using Neutravidin pull down in SILAC experiments. 
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* Interaction partner of peptide 27 is highlighted yellow, having the higher SILAC ratio in the forward but small in the cross-over experiment.  
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Appendix Table 5:  Identification of peptide 27 interaction partners in mouse BaF3 cell spiked with MBP-STAT5b followed by Neutravidin pull 
down in SILAC experiments. 
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* Interaction partner of peptide 27 is highlighted yellow, having the higher SILAC ratio in the forward but small in the cross-over experiment. 
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Appendix Table 6:  Identification of STAT5b in mouse BaF3 cells and competitive displacement of peptide 27 by STAT5 inhibitor, 10 followed by 
Neutravidin pull down.  
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Appendix Table 7: Determination of maximum tolerated dose (MTD) and toxicity of compound 16 in non-xenografted mice. 
 




Appendix Table 8: Raw data tabulated for the corresponding body weight changes in non-xenografted mice and 
the tumor volume reduction upon treatment using compound 16.  
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